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Summary of Thesis 
 
Cytochrome P450 (CYP) 2D6 is an important enzyme, since it can metabolize about 25% of 
clinical drugs and is subject to inhibition and polymorphism with significant clinical 
consequences. The elucidation of its crystal structure has provided very useful information on 
how ligands (e.g., substrates or inhibitors) interact with this enzyme and how CYP2D6 
determine its substrate specificity and inhibitor selectivity. However, the resolved structure of 
CYP2D6 (Protein database (PDB) Code: 2F9Q) is ligand-free, and thus how and whether 
ligand binding induces conformational changes of the active site are unknown. Although there 
are reports on the binding of ligands to CYP2D6 using pharmacophore, homology and 
quantitative structure-activity relationship (QSAR) approaches, the molecular factors affecting 
the binding of synthetic or herbal compounds to CYP2D6 are not fully elucidated. 
Herbal medicines are becoming popular all over the world, which may result in adverse effects 
or potential adverse herb-drug interactions when used in combination with conventional drugs. 
However, because of their complicated chemical composition and limited in vivo and in vitro 
approaches, there are limited data on the binding affinities and binding mechanisms of herbal 
compounds with CYP2D6. 
In this regard, we hypothesize that a number of physicochemical factors determine the binding 
of compounds to human CYP2D6, and that a number of compounds share similar structural 
features, and therefore binding features as CYP2D6 substrates/inhibitors. Thus, the objectives 
of the current project are: (1) to further explore the molecular factors determining the binding 
of a compound to native and mutated CYP2D6; (2) to develop a QSAR model for the 
prediction of binding strength of existing or new compounds to CYP2D6; and (3) to examine 
the binding of Chinese herbal compounds from Huangqin (S. baicalensis) & Fangjifuling 
decoction with CYP2D6. 
In this project, the following work has been done: (1)  a set of libraries of CYP2D6 
substrates/inhibitors, and identified compounds from a single herb (S. baicalensis) and a herbal 
formula (Fangjifuling decoction) have been generated; (2) an array of pharmacophore and 
QSAR models of CYP2D6 substrates/inhibitor have been constructed and validated for the 
prediction of interaction between compounds and CYP2D6 via in silico approaches; (3) a large 
number of CYP2D6 substrates and inhibitors have been successfully subject to docking study 
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to explore their binding mechanisms to CYP2D6 with/without mutation; and (4) the resultant 
models have been successfully applied to predict the interaction between herbal compounds 
and CYP2D6 with/without mutation. 
In this study, we have developed and validated pharmacophore models for the CYP2D6 
substrates/inhibitors. The model for 2D6 substrates consisted of two hydrophobic features and 
one hydrogen bond acceptor (HBA) feature, giving a relevance ratio (RR) of 76% when a 
validation set of substrates was tested. Similarly, the pharmacophore model for CYP2D6 
inhibitors also consisted of two hydrophobic features and one HBA, with an RR of 78.8%. 
There were longer distances between feature groups in the model for inhibitors than those of 
the model for substrates.   
We also have constructed and validated QSAR models for the prediction of binding affinity of 
existing or new compounds to CYP2D6. Unfortunately, when the training set was randomly 
chosen, models generated from 24 CYP2D6 substrates/inhibitors gave regressive equation of 
y=0.085x+82.824 with R
2
=0.085 for substrates and y=0.320x+9.879 with R
2
=0.320 for 
inhibitors, which all showed poor prediction accuracy. However, two QSAR models from 
selected 6 substrates and 9 inhibitors presented relatively high R
2
, in which equation of 
y=0.980x+2.829 with R
2
=0.980 was for substrates and y=0.948x+1.051 with R
2
=0.948 for 
inhibitors. The relatively high R
2
 values gave rise to a linear relationship and a better 
prediction. 
We have further validated and applied CDOCKER to explore the molecular factors 
determining the binding of a compound to native and mutated CYP2D6. A large number of 
CYP2D6 substrates (n=120) and inhibitors (n=33) were subject to molecular docking to the 
active site of wild-type CYP2D6. Our docking study demonstrated that 117 out of 120 
substrates (97.50%) and 30 out of 33 inhibitors (90.91%) could be docked into the active site 
of CYP2D6. We have demonstrated that 11 residues for substrates and 8 residues for inhibitors 
played an important role in their binding and consequently determining the metabolic activity 
towards the substrate and inhibitor selectivity.  
In present study, the CDOCKER algorithm was also applied to study the impact of mutations 
of 28 active site residues (mostly non-conserved) in CYP2D6 on substrate/inhibitor binding 
modes using five probe substrates (bufuralol, debrisoquine, dextromethorphan, sparteine, and 
tramadol) and four known inhibitors (quinidine, pimozide, fluoxetine, and halofantrine). 
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Apparent changes of the binding modes have been observed with Phe120Ile, Glu216Asp, 
Asp301Glu mutations for these substrates and inhibitors. 
To examine the binding of active components from Chinese herbal medicines with CYP2D6, 
libraries of compounds from Huangqin & Fangjifuling decoction were constructed and 
subsequently subject to the docking. Overall, 18 out of 40 compounds from Huangqin and 60 
out of 130 compounds from Fangjifuling decoction were mapped with our optimized 
pharmacophore models. Among them, 100% compounds from Huangqin and 90% from 
Fangjifuling decoction could be docked into the active site of the wild-type CYP2D6, which 
suggested that they may be substrates and/or inhibitors of CYP2D6. The role of Phe120, 
Glu216, Asp301, Ser304 for herbal compound binding to CYP2D6 has been further supported 
by our docking studies. 
In conclusion, our project has documented the main molecular factors determining the binding 
of a compound to native and mutated CYP2D6, which allow us to predict and understand the 
interaction between molecules and CYP2D6. Our study has demonstrated the use of an 
effective and efficient computational approach to studying the molecular mechanisms of 
interaction of herbal compounds and functionally important proteins.  
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CHAPTER 1        GENERAL INTRODUCTION  
1.1 Introduction to Human Cytochrome P450s 
The cytochrome P450 (CYP), an enzyme superfamily, has been found across all 
organisms in every kind of life forms with diverse presents in prokaryotic and eukaryotic 
worlds. In prokaryotes, CYPs present as soluble proteins whereas in eukaryotes they are 
bound to the membranes of either mitochondrion or the endoplasmic reticulum [1]. The 
name of CYP derived from its unique character, namely all the enzymes are bound to cell 
(cyto) membranes and compass a heme pigment (chrome and P) that absorbs light at a 
wavelength of 450 nm when exposed to carbon monoxide [2].  
Nowdays, more than 9,000 named sequences in the CYP superfamily have been reported 
in animals, plants, bacteria and fungi (http://drnelson.utmem.edu/CytochromeP450.html. 
Access date: 25 May. 2011). There are 57 functional CYP genes in humans and 58 
pseudogenes which are grouped into different classes or families. The nomenclature of 
CYPs employs a three-tiered classification based on amino acid sequence similarity 
determined through gene sequencing, indicated by an Arabic numeral (family, e.g. 
CYP1, > 40% similarity), a capital letter (subfamily, e.g. CYP1A, > 55% similarity) and 
another Arabic numeral (gene, e.g. CYP1A2, > 97% identity comprise alleles) [3].  
In common, CYPs are responsible for a vast number of oxidations including 
hydroxylation, N-, O- and S-dealkylation, sulphoxidation, epoxidation, deamination, 
desulphuration, dehalogenation, peroxidation, and N-oxide reduction in nature, which 
resulted in biotransformation of endogenous (e.g. fatty acids and retinoic acid) and 
exogenous (e.g. drugs and carcinogens) compounds in living bodies [4] . Through these 
reactions, CYPs process a Phase 1 metabolism for a number of therapeutic drugs, from 
hydrophobic forms to hydrophilic forms that are generally less toxic or much more toxic 
in few cases [5].  
A typical CYPs reaction is catalysed a reductive scission of molecular dioxygen (bound 
to the heme iron at the core of the CYP), and then introducing a single atom from oxygen 
into a hydrocarbon substrate (RH) to generate a hydroxylated metabolite (ROH) and a 
molecule of water [6]. During the reaction, two electrons are transferred from 
nicotinamide adenine dinucleotide phosphate (NADPH) to CYP via electron transfer 
proteins. CYPs are divided into four classes according to the methods of electron delivery 
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from NADPH to catalytic site [6]: class I CYPs need both a flavin adenine dinucleotide 
(FAD)-containing reductase and an iron sulphur redoxin, comprised by most prokaryotic 
bacterial CYPs and eukaryotic mitochondrial CYPs [7]; class II CYPs require only a 
FAD/FMN-containing CYP reductase for electron transferring, including endoplasmic 
CYPs (microsomal CYPs) [8]; class III CYPs require no electron donor and are 
self-sufficient; and class IV CYPs receive electrons directly from NADPH, which merely 
exist in fungal CYPs. In mammals, the mitochondrial CYPs (class I) are essential for the 
biosynthesis of vitamin D, bile acids and cholesterol-derived steroid hormones, whereas 
the functions of microsomal CYPs (class II) are extremely diverse, from biosynthesis of 
steroid hormones to metabolism of therapeutic drugs. Meanwhile, class III CYPs catalyse 
the rearrangement or dehydration of alkylhydroperoxides or alkylperoxides initially 
generated by dioxygenases in both mammals and plants and class IV CYPs reduce nitric 
oxide (NO) generated by denitrigication nitrous oxide (N2O) in fungi [9]. 
Most of the human CYPs with much narrow substrate specificity are devoted mainly to 
the metabolism of endogenous substrates, such as sterols, fatty acids, eicosanoids, and 
vitamins while fifteen individual CYP enzymes in families 1 (1A1 and 1A2), 2 (2A6, 
2A13, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1 and 2F1) and 3 (3A4, 3A5 and 3A7) with a 
wide-substrate binding profile are heavily involved in xenobiotics metabolism(including 
a number of therapeutic drugs) [10]. Among them, CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 
and 3A4/5 are essential for most therapeutic drug oxidations and CYP3A4 is responsible 
for metabolizing more than 50% of drugs that are CYP substrates [11]. A typical feature 
of these drug-metabolizing CYPs is that they exhibit broad and overlapping substrate 
specificity [12].  
Human CYP enzymes are the most important heme-thiolate enzyme system and are 
predominantly expressed in the liver, although they are found in practically all tissues, 
such as small intestinal mucosa, lung, kidney, brain, placenta, olfactory
 
mucosa, and skin, 
with the intestinal mucosa probably being the most important extrahepatic
 
site of drug 
biotransformation [12]. In human liver, all CYPs comprise approximately 2% of total 
microsomal proteins (0.3–0.6 nmol/mg, CYPs/microsomal protein). The relative 
abundance of individual CYPs in liver has been determined as CYP1A2 (>10%), 2A6 
(~10%), 2B6 (<5%), 2C8 (~5%), 2C9 (>15%), 2C19 (<5%), 2D6 (~2-4%), 2E1 (~15%), 
and 3A4/5/7 (35%) [10, 13]. The significance of the individual CYP enzyme in human 
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drug metabolism varies, with CYP3A, CYP2D, and CYP2C being responsible for the 
metabolism of 50, 25, and 20% respectively of the currently known drugs [10].  
A large interindividual variation in the activity of human CYPs is observed, ranging from 
20- (CYP2E1 and 3A4) to >1,000-fold (CYP2D6) [14]. The expression and activities of 
CYPs are impacted by a large number of factors, including genetic (e.g., genetic 
mutation), host (e.g., diseases), and environmental factors (e.g., inducers and inhibitors), 
making drug metabolism highly variable [15-18]. Genetic mutations, such as deletion, 
insertion and copy number variants (CNVs), the most common type of which is single 
nucleotide polymorphisms (SNPs) occurring at a frequency of ≥1% in a given 
population, have often been observed [19]. Genetic mutations may lead to polymorphism, 
where two phenotypes, poor metabolisers (PMs) and extensive metabolisers (EMs), exist 
in the population. Poor metabolisers lack detectable activity of a certain enzyme as a 
result of an autosomal-recessively transmitted defect in its expression, which may lead to 
greater bioavailability, higher plasma concentrations, prolonged elimination half-life and 
possibly increased pharmacological response from standard doses of drugs [11, 19]. A 
number of allelic variants have been identified in most human CYP genes 
(http://www.cypalleles.ki.se). The polymorphisms within CYP enzymes mainly affect the 
pharmacokinetics of drugs that are metabolized by those enzymes. The genotype-induced 
pharmacokinetic changes might have certain important influence on drugs that have 
narrow therapeutic windows and also develop adverse drug reactions [19]. Environmental 
factors, such as applying two or more drugs/herbs simultaneously, may have significant 
influence on the CYP expression or activity through enzyme induction or inhibition, and 
thus influence pharmacokinetics of the drugs, leading to clinically significant drug-drug 
or herb-drug interactions [20, 21].  
Overall, almost 50% of the overall elimination of commonly used drugs can be attributed 
to one or more of the various CYP enzymes in humans [22]. CYP activity differs among 
individuals of a given population. Variability in CYP content and activities have 
profound influence on  response in vivo of humans to drugs [23]. Most CYPs are subject 
to induction and inhibition, and genetic mutations play an important or dominant role in 
the enzyme activity variation of many CYPs, in particular CYP2A6, 2C9, 2C19, and 2D6 
[11, 19].  
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1.2 Introduction to Human CYP2D6 
The CYP2D6 enzyme is responsible for the clearance of at least 20% of the compounds 
in present clinical applications, including antiarrhythmics, antidepressants, antipsychotics, 
-blockers and analgesics [24]. It attracts arising interests by displaying a genetic 
polymorphism, the consequence of which is largely different in individuals and ethnics 
differences in CYP2D6-mediated metabolism of drugs, known as debrisoquine/sparteine 
polymorphism [25, 26]. The polymorphism affects a significant proportion of the 
Caucasian population and results in the defective metabolism of a number of clinical 
drugs, and inheritance of the ‗poor-metabolizer‘ phenotype has been linked with an 
increased susceptibility to Parkinson‘s disease and certain types of cancer [27-29]. 
Understanding the structure of CYP2D6 and potential protein–ligand interactions would 
be helpful in rational design of potential drug candidates for the pharmaceutical 
companies.  
1.2.1 Distribution of CYP2D6 
CYP2D6 has been identified in human kidney [30], intestine [30-32], breast [33], lung 
[34, 35], placenta [36] and brain [37-39] at low to moderate levels. CYP2D6 metabolises 
25% of all medications in the human liver with a small percentage of all hepatic CYPs 
(<2%) [19, 40-43], while CYP2D6 mRNA was undetectable in fetal liver [44]. The 
protein and enzyme activity toward bufuralol have been detected at low levels in human 
intestine which are expressed differentially along the gastrointestinal tract with the 
highest in jejunum and decreased distally to the colon [1, 31, 32]. Human CYP2D6 RNA 
and protein [38, 39, 45], rat CYP2D RNA and proteins [37], and mouse Cyp2d mRNA 
and protein [46] are expressed at moderate to high levels in cerebellum. CYP2D6 protein 
was primarily found in large principal neurons such as pyramidal cells of the cortex, 
pyramidal cells of the hippocampus, and Purkinje cells of the cerebellum while was 
absent in glial cells [38]. Higher expression of CYP2D6 was detected in brain regions of 
alcoholics compared to nonalcoholics [45]. The expression level of CYP2D6 was 3-fold 
lower in bronchial mucosa and 6-fold lower in lung parenchyma compared to that in the 
liver [34].  
Among the rat CYP2D subfamily, the mRNA level of CYP2D3 increased with 
development [47], whereas no similar change was observed in the mRNA levels of 
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CYP2D1 and 2D2 [48]. Neville et al. showed that the CYP2D3-mediated diazepam 
p-hydroxylation was more active in young adult male rats (>5 weeks) than in neonates 
[49]. However, CYP3A4/5 is the most expressed CYP enzyme in human small intestine 
[50], whereas CYP2D6 and 2C19 are less expressed isoforms. In human breast tissue, 
alternatively spliced forms of CYP2D mRNA from the region of exon 5 to 8 of CYP2D6 
or 2D7P have been identified [33], which may play a part in the regulation of the 
expression of CYP2D6 in local tissues. 
1.2.2 Polymorphism of CYP2D6 
In 1969, Alexanderson et al. provided the first direct evidence from a twin study that the 
metabolic clearance of nortriptyline was influenced by genetic factors [51]. Mahgoub et 
al. and Eichelbaum et al. independently discovered that the metabolism of debrisoquine 
and sparteine, respectively, is polymorphic, and it was later shown that these drugs are 
metabolized by a common enzyme, i.e. CYP2D6 [25, 26]. The pattern of CYP2D6 
polymorphisms and phenotypes are considered to be dramatically variable among 
different ethnic groups, due to different CYP2D6 allele distribution, resulting in different 
percentages of PMs, inter-mediate metabolizers (IMs), EMs and ultrarapid metabolizers 
(UMs) [52, 53]. Phenotypically, the CYP2D6 UMs, EMs, IMs and PMs compose 
approximately 3–5%, 70–80%, 10–17% and 5–10% of Caucasians, respectively [54]. 
Generally Whites have the highest frequency of the PM phenotype, with British and 
Swiss Whites having the highest incidences (8.9% and 10%, respectively) [55]. In 
contrast, the frequency of PMs in Asians is relatively low, particularly among Chinese, 
Korean and Japanese populations (0–1.2%) [56-58]. The prevalence of the PM phenotype 
is slightly higher among Indians than in the populations of Southeastern and Eastern Asia, 
with frequencies of 1.8–4.8% [59]. Data on the frequency of PMs in Africans differ 
widely, varying in the range of 0–19% [60, 61]. There is also a wide range in the 
incidence of PMs in African Americans (1.9–7.3%) [62-64]. However, the 
genotype-phenotype relationship of most CYP2D6 alleles is not well established till now.   
The prevalence of the CYP2D6 allele differs indifferent populations. For example, the 
CYP2D6*4 is by far the most frequent null allele in Caucasians. It occurs with a 
frequency of 20–25% and is responsible for 70–90 % of all PMs [54]. No functional 
alleles are present in about 6% of Caucasians [54]. However, the CYP2D6*4 allele occurs 
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with a very low frequency of ~1% in Asians. Its frequency is 6–7% in Africans and 
African Americans [65].  
The most common CYP2D6 allele in the Asian population is CYP2D6*10, occurring with 
a frequency of 35–55% in Chinese, Japanese and Koreans [66]. However, it occurs at a 
low frequency of ~2% in Caucasians; but it accounts for 10–20% of individuals with the 
IM phenotype [67]. CYP2D6*17 is virtually absent from European Caucasians and of 
low frequency in Asians, but it occurs with a high frequency in the African 
American/Black population. This variant appears to explain why Black Africans have a 
higher median metabolic ratio (MR) [65]. Thus, there are three alleles with significantly 
biased distribution in different ethnic groups: CYP2D6*4, *10, and *17 being prevalent 
in Caucasians, Asians and Africans, respectively.  
The CYP2D6 polymorphism may altere drug response or influence occurrence of adverse 
drug reactions due to changes in the substantial metabolic pathway either in the activation 
to form active metabolites or clearance of the agent. For example, encainide metabolites 
are more potent than the parent drug and thus QRS prolongation is more apparent in EMs 
than in PMs [68]. In contrast, propafenone is a more potent –blocker than its metabolites 
and the –blocking activity during propafenone therapy is more prominent in PMs than 
EMs [69], as the parent drug accumulates in PMs. Since flecainide is mainly eliminated 
through renal excretion, and both R- and S-flecainide possess equivlent potency for 
sodium channel inhibition, the CYP2D6 phenotype has a minor impact on the response to 
flecainide. Since the contribution of CYP2D6 is greater for metoprolol than for carvedilol, 
propranolol and timolol, a stronger gene-dose effect is seen with this –blocker, while 
such an effect is lesser or marginal in other –blockers [70]. 
1.2.3 Structural Features and Functional Relevance of CYP2D6 
The crystal structure of human CYP2D6, which showed the characteristic CYP fold as 
observed in other members of the CYP superfamily, with the lengths and orientations of 
the individual secondary structural elements being very similar to those seen in CYP2C9, 
has been determined and refined to a 3.0 Å resolution [71].  There are six main areas 
with remarkable differences even though there are significant similarities between 
CYP2D6 and 2C9, with the most notable involving the F helix, F-G loop, B‘ helix,  
sheet 4, and part of  sheet 1, all of which are situated on the distal face of the protein  
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[71]. The F helix in CYP2D6 has two additional turns and arcs down much more closely 
over the heme pocket toward the N-terminal end of strand 2 of  sheet 1. The B‘ helix in 
CYP2D6 is pushed out away from the heme pocket, and there are an additional three 
residues in the loop immediately following it (i.e. residues 101-118). On the opposite side 
of the F helix from the B‘ helix,  sheet 4 consisting of residues 468-487 adopts a shift in 
conformation in the same direction as the F helix shift. The 2D6 structure has a well 
defined active site cavity above the heme group with a volume of 540 Å3 (Figure 1-1). 
1.2.3.1 Active Site Cavity 
There is a well defined cavity above the heme in CYP2D6 structure, described as a shape 
of "right foot" with volume of about 540 Å
3
 determined by VOIDOO and bordered by the 
heme group and residues from the B' helix (side chain of Ile106), the B'-C loop (side 
chains of Leu110, Phe112, Phe120, and Leu121 and main chain atoms of Gln117, 
Gly118, Val119, and Ala122), the F helix (side chains of Leu213, Glu216, Ser217, and 
Leu220), the G helix (side chains of Gln244, Phe247, and Leu248), the I helix (side 
chains of Ile297, Ala300, Asp301, Ser304, Ala305, Val308, and Thr309), the loop 
between helix K and -sheet 1 strand 4 (side chains of Val370 and Met374 and main 
chain atoms of Gly373), and residues from the loop between the strands of -sheet 4 (side 
chains of Phe-483 and Leu484) [71]. 
The "heel" of the foot-shaped cavity lies above the heme, offset toward the propionate 
side and the "arch" is formed by the side chain of Phe120 [71]. The "ball" of the foot is 
bordered by residues from the B'-C loop and the N-terminal end of the I helix. Additional 
residues in the I helix line the whole length of the right side of the foot. The "toe" area is 
bordered by residues from the B' and G helices. The upper part of the foot is bordered by 
residues in the F helix, which is perpendicular to the foot axis while the back of the heel 
is shaped by residues in the loop following the K helix. The "ankle" region narrows and 
marks the entrance of the cavity which leads up to the outside. It is bordered by residues 
of the F helix at the front and residues of the I helix on the right, with the back of the 
ankle being defined entirely by residues from the loop between the strands of -sheet 4. 
The back, left side, and toe areas of the cavity are strongly hydrophobic in character. The 
upper part and right side of the foot has several important hydrophilic side chains 
(Glu216 in helix F, Gln244 in helix G, and Ser304 in helix I). Under the ball of the foot 
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lies Asp301 (helix I). Above the ankle region, the cavity entrance is bordered by a 
number of long charged/hydrophilic side chains from the F helix (Gln210, Glu211, 
Lys214, and Arg221) and residues from the region between the two strands of sheet 4 
(side chains of Ala482 and Ser486 and main chain atoms of Val485), with the side chains 
of Asp179 (helix E) and Thr312 (helix I) also in the vicinity (Figure 1-2). 
1.2.3.2 Heme Binding Site 
The heme is anchored in the binding site by hydrogen bonding interactions with the side 
chains of Arg101, Trp128, Arg132, His376, Ser437, and Arg441 in a close 
approximation to the situation seen in CYP2C9 [72]. The heme iron is pentacoordinated 
with Cys443, where no visible sign of a water molecule in the sixth coordination position 
in the electron density maps. There is a small area of residual electron density about 5-6 
Å above the heme group, which could not be identified nearest to the side chain of 
Phe120 even not particularly close to any other active site residues. It is unlikely to be a 
water molecule for hydrogen bonding residues nearby. It may be significant  since a 
peak is present in all four CYP2D6 molecules, which has also been seen with CYP2C9. 
The highly conserved Thr309 in the I helix is in an ideal position to hydrogen-bond to the 
water molecule formed from the cleavage of the dioxygen bond of the heme-hydroperoxy 
intermediate during the CYP cycle [73]. 
1.2.3.3 Role of Some Key Residues (Glu216 and Asp301 as Cases) 
The cavity contains the two negatively charged residues, Asp301, in the I helix at the 
base of the cavity, and Glu216, on the underside of the F helix and points down into the 
cavity space (Figure 1-3). The carboxylate oxygens of the two residues are about 6 Å 
apart. It is showed that Asp301 played a key role in the binding of substrates to CYP2D6 
using site-directed mutagenesis (SDM) studies [74]. The positioning of Asp301 in the 
various models studied showed that it could readily explain the so-called 5-7-Å 
pharmacophore model [75] (i.e. that the primary binding nitrogen was 5-7 Å distant from 
the site of metabolism). However, the existence of numerous substrates, such as 
metoprolol, which are metabolized at sites further from this nitrogen, gave rise to a 
different 10-Å pharmacophore [76] and suggest that Glu216 was the primary binding 
residue [77]. It is  carried out some automated docking of various ligands using the 
GOLD program and came to the conclusion that Glu216 was the more likely binding 
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residue [78]. They and, independently, Hanna et al. [79] concluded that Asp301 played a 
structural role in hydrogen bonding to a backbone NH of the B'-C loop. The crystal 
structure clearly shows that Asp301 does indeed form two hydrogen bonds with the 
backbone NH groups of Val119 and Phe120 (Figure 1-3).  
Rowland et al. [71] proposed that both Asp301 and Glu216 act as binding residues for 
substrates and inhibitors of 2D6. However, the two rotameric states, trans and gauche-, of 
the aspartate can account for all the various pharmacophoric models, and therefore 
Glu216, which sits at the top of the active site cavity, is more likely to act as a 
recognition residue that attracts basic ligands to the pocket and forms an intermediate 
binding site prior to the substrate migrating to a "reactive" position within the cavity.It is 
noted that whereas mutation of either Glu216 or Asp301 to Asp and Glu, respectively, 
can alter the rate and regioselectivity of hydroxylation of debrisoquine, mutation of either 
residue to a neutral amino acid results in loss of activity. 
The mutation of Glu216 altered the substrate specificity in an extreme approach that the 
mutant protein catalyzed testosterone 6-hydroxylation typically mediated by CYP3A4. 
Besides, the Glu216Ala/Lys and Asp301Gln mutants with removal of the negative charge
 
from either 216 or 301 catalyzed the metabolism atypical CYP2D6 substrates, including 
anionic compounds such as diclofenac and tolbutamide that lack a basic nitrogen atom 
and are model substrates of CYP2C9 [80]. Mutants Glu216Gln, Glu216Phe, and 
Asp301Asn produced rates ~5-,
 
10-, and 22-fold higher than the wild-type enzyme in 
diclofenac 4‘-hydroxylation, respectively, while the turnover rates of the Glu216Ala, 
Glu216Lys, and Asp301Gln derivatives
 
were increased 50- to 75-fold. The catalytic 
activity was increased still further (>1000-fold of the wild-type enzyme)
 
upon 
neutralization of both residues with double Glu216Gln/Asp301Gln mutations, but its 
testosterone
 
6-hydroxylase activity was increased only 2-fold over wild-type. This 
suggests that the binding site of CYP2D6 is thus intrinsically rather promiscuous, with 
Glu216 and Asp301 favouring the binding of basic substrates and discriminating against 
acidic substrates. The rate of formation of 4‘-hydroxy diclofenac was not significantly 
greater with the Glu216Lys mutant than with Glu216Ala, suggesting that the carboxylate 
group of the substrate is not positioned near this residue. 
Both Glu216 and Asp301 play critical roles in the action of quinidine, which is a potent 
competitive inhibitor but not a substrate of CYP2D6 as an inhibitor of CYP2D6 [81-83]. 
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A classical type I binding spectrum with CYP2D6 and quinidine was observed [84], 
which is usually associated with substrate-enzyme binding [85]. Quinidine possesses a 
number of structural features seen in most typical CYP2D6 substrates, including a basic 
nitrogen atom, a flat hydrophobic
 
region, and a negative molecular electrostatic potential 
[86]. Stereoisomer quinine have been reported about the relationship between structure 
and inhibitory activity for quinidine and its less potent [87], and substantial decreases in 
inhibitory potency were observed for the N-methyl, N-ethyl, and N-benzyl quininium 
salts. It is suggested that the quaternary nitrogen of this antipode interacts with a distinct 
region of the CYP2D6 active site as compared to the corresponding nitrogen of quinidine. 
It is notable that  esterification of quinidine resulted in a substantial loss of inhibitory 
potency, likely due to disruption of a hydrogen-bonding interaction of the hydroxyl group, 
suggesting that hydrogen bonding contributes more to the tight binding of quinidine than 
does the charge-pair interaction of the positively charged nitrogen [87]. The conservative
 
substitutions Glu216Asp and Asp301Glu showed similar inhibition to that
 
of the 
wild-type enzyme by 1 µM
 
quinidine comparing to enzymes with non-conservative 
replacements which were at least 50% active at 10 µM quinidine [81]. The double
 
mutant 
Glu216Gln/Asp301Gln, with complete removal of the charge but
 
not the polarity, was 
found to be insensitive to
 
inhibition by quinidine, retaining 80% of its bufuralol 
1‘-hydroxylase activity and 85% of its dextromethorphan O-demethylase activity in the 
presence of 100 µM quinidine [81]. However, alanine
 
substitution of the aromatic side 
chain of Phe120, Phe481, or Phe483 showed only a minor effect on the enzyme inhibition 
by quinidine [81]. These findings suggest that the negative charges at Glu216 and 
Asp301, but not the aromatic rings of the three phenylalanine residues, are important for 
the binding of quinidine.  
In contrast to the wild-type enzyme, the mutant Glu216Phe formed O-demethylated 
quinidine, and the mutant proteins with double Glu216Gln/Asp301Gln mutations or 
Phe120Ala resulted in both O-demethylated quinidine and 3-hydroxyquinidine [81]. 
Quinidine 3-hydroxylation turnover rates for Glu216Gln/Asp301Gln and Phe120Ala 
were estimated to be 0.14 and 0.07 min-1, respectively, which are slower than the typical 
rates of 1–5 min-1 observed for the wild-type enzyme for standard substrates such as 
bufuralol and dextromethorphan [80]. As a major metabolite of quinidine formed by 
CYP3A4, 3-Hydroxyquinidine reacted as a specific marker for phenotyping CYP3A4 in 
vitro [82, 88]. The mutated CYP2D6 with double Glu216Gln/Asp301Gln substitutions 
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was able to catalyze nifedipine N-oxidation [80]. Substitution of Asp301 alone is not 
sufficient to enable CYP2D6 to metabolize quinidine, and Glu216 clearly plays an 
important role in determining the mode of binding; substitution of Glu216 with a bulky 
side chain in the Glu216Phe mutant confers on CYP2D6 the ability to catalyze the 
O-demethylation of quinidine and 6-hydroxylation of testosterone [80], another marker 
reaction catalyzed by CYP3A4. It is indicated that both Glu216 and Asp301 determined 
the substrate specificity of CYP2D6 as a critical role. 
Computational docking studies showed that quinidine could bind tightly to CYP2D6 but 
not in an orientation favourable for catalysis. The binding of quinidine to the wild-type 
CYP2D6 enzyme appears to be governed by interactions between the aromatic rings of 
quinidine and Phe120 and Phe483 and by a hydrogen bond between the hydroxyl group 
of quinidine and the carboxyl group of Glu216 [81]. Tethered docking studies 
demonstrated unfavorable contacts of quinidine with Phe120 and Ala305 in the 
orientation consistent with generation of 3-hydroxyquinidine and with Phe120, Leu121, 
and Glu216 in the orientation consistent with formation of O-demethylquinidine[81]. It 
suggests that these residues played significant role in preventing
 
metabolism of quinidine 
in wild-type CYP2D6. In contracts, the orientation of quinidine in the Glu216Phe mutant 
suggests an interaction between the aromatic rings of quinidine and Phe216 and Phe120 
and a hydrogen bond between the basic nitrogen atom of quinidine and the side chain of 
Ser304, facilitating the formation of O-demethylquinidine [81]. However, similar 
docking studies on the Glu216Gln/Asp301Gln mutant produced only solutions in which 
the quinidine molecule was positioned away from the heme.  
Ellis et al. [74] reported that replacement of Asp301 with neutral residues (Asn, Ala or 
Gly) in yeast recombinant P450 2D6 almost abolished (1-2% of the wild-type) catalytic 
activity toward debrisoquine and racemic metoprolol, two classical substrates of 
CYP2D6. The Asp301Glu mutant retained rates of activity comparable with that of the 
wild-type [74]. However, the regioselective oxidation of metoprolol, as assessed by the 
ratio of formation of O-desmethyl and -OH metabolites, was significantly different with 
microsomes prepared from the Asp301Glu mutant compared with the wild-type (8.5:1 
and 3.8:1, respectively). A change in the regioselective oxidation of metoprolol was also 
apparent with the R- and S-enantiomers [74]. In contrast, enantio-selective oxidation of 
metoprolol was not altered by the substitution of Asp301 with Glu (Asp301Glu). The 
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attenuation of enzyme activity had been proposed to be due to the disruption of an 
electrostatic bond between Asp301 and the substrate. The level of expression of a 
Asp301Als mutant (holoprotein) was only 20% of the level of the other mutants [74]. 
Mutation of Asp301 to neutral residues resulted in a 10-fold lower affinity of CYP2D6 
for the amine ligand quinidine [74]. Asn or Gln replaced Asp301 and thus led to a 130- to 
145-fold increase in Km values for bufuralol; the increase was 80-fold with the 
Asp301Gln mutant but as much as 1400-fold for Asp301Asn for dextromethorphan [80]. 
These findings demonstrate that substitution of Asp301 with neutral amino acids (e.g. 
Asn, Ala, or Gly), differing in size and polarity, resulted in marked reductions in enzyme 
catalytic activity; while substitution of the Asp301 carboxylate residue with a similar 
functional moiety (Glu) did not affect the catalytic competence of the enzyme 
significantly, although a subtle change in the regio-selective oxidation of metoprolol and 
a 10-fold reduction in quinidine binding were noted. It is also observed perturbed 
structural integrity of the active site to varying degrees when Asp301 was replaced with a 
neutral residue (Asn, Ala, or Gly) [74]. The study has initially provided evidence that 
Asp301 may serve as a point anionic charge to dock the basic nitrogen atom of ligands of 
CYP2D6 and/or to maintain the integrity of the active site and that in its absence the 
topography of the active site is altered [74]. 
Little effect of Asp301 mutations with Asn, Ser, or Gly on the binding to 
spirosulfonamide and its analogs, all high affinity substrates of CYP2D6 lacking basic 
nitrogen atoms had been found [89]. The sulfonamide moiety is not basicly due to the 
strong electron-withdrawing properties of the sulfone group. This raises further concerns 
about the reliability of CYP2D6 models based on a critical electrostatic interaction with 
Asp301. The Asp301Asn mutant failed to bind bufuralol and quinidine. Neutral Asp301 
mutants (Asn, Ser, and Gly) showed relatively high affinity for spirosulfonamide (Kd 
10-6 M) [89]. The oxidation rate of spirosulfonamide in Asp301Asn was decreased 
about 10-fold, as in the case of bufuralol [79], although the rate of formation of 
anti-OH-spirosulfonamide was increased in the Asp301Gly and Asp301Ser mutants. 
These results argue that loss of catalytic activity of the Asp301 neutral mutants cannot be 
attributed to a loss of binding affinity for a cationic substrate, for the same pattern being 
observed with an uncharged substrate; attenuated electrostatic interaction of substrate did 
not provide an explanation of the role of Asp301 in susbtrate binding [89]. Asp301 may 
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interact with spirosulfonamide through hydrogen bonding to the sulfonamide group, as 
opposed to electrostatic interactions. Removal of the moiety (and the fluorine on the 
adjacent phenyl ring) produced a compound that was both a reasonable tightly bound 
ligand (Kd=4 µM) and a substrate; the presence of a carboxylate leads to a loss of 
apparent binding and oxidation [89]. Spirosulfonamide yielded strong classic type I heme 
perturbation spectra with recombinant CYP2D6 with a Ks of 1.6 µM. CYP2D6 also 
bound and oxidized most analogues of spirosulfonamide with substitutions of the 
sulfonamide group. Based on these results with non-amine substrates,  it has been 
proposed that Asp301 played an important structural role in CYP2D6 integrity and that 
mutations of Asp301 caused more extensive changes in CYP2D6 than can be interpreted 
in the context of electrostatic interaction with ligands [89]. 
However, Hanna et al. found that substitution of Asp301 with Glu, Asn, Ser or Gly 
significantly decreased CYP2D6-mediated bufuralol 1‘-hydroxylation with enzyme 
activity remaining of 61.9%, 11.4%, 9.0% and 9.0%, respectively, compared to the 
wild-type enzyme [79]. This suggests that positively charged residues are particularly 
disruptive in bacterial (E. coli) and in insect cells (baculovirus) expression systems. 
Similar reduction of 6-hydroxylation of bufuralol was observed with these mutants. With 
the exception of the Asp301 mutant which had comparable expression level to the 
wild-type, Asp301Gly, Asp301Ala, Asp301Leu, Asp301Ser, Asp301His, Asp301Lys, 
Asp301Arg, and Asp301Cys (replaced with neutral or negatively or positively changes 
residues) all resulted in significantly reduced yields of the CYP2D6 holoprotein when 
expressed in the bacterial system [79], suggesting an additional role of Asp301 in protein 
folding and heme incorporation. Indeed, initial efforts to reverse the putative 
Asp301-basic substrate interaction with a Lys/Arg301-acidic substrate pair were 
unsuccessful due to failure of mutants substituted with basic residues at codon 301 to 
incorporate heme [79]. It proves that Asp301 is important for proper heme insertion and 
presumably protein folding; neutral and particularly basic residues were highly 
disruptive. 
1.2.4 Substrates of CYP2D6 
Typical substrates for CYP2D6 are largely lipophilic bases and include some 
antidepressants, antipsychotics, antiarrhythmics, antiemetics, -adrenoceptor antagonists 
(β-blockers) and opioids.  Most CYP2D6 substrates are bases containing a basic 
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nitrogen atom 5–10 Å from the site of metabolism and appears to have high affinity and 
low capacity from CYP2D6 [90]. 
1.2.4.1 Probe Substrates of CYP2D6 
Several compounds, including dextromethorphan, sparteine, debrisoquine, bufuralol, and 
tramadol, have been used as probe substrates of CYP2D6 [91]. Dextromethorphan, a 
synthetic analog of narcotic analgesics, is also a commonly used CYP2D6 probe in vitro 
and in vivo [91]. In humans, it is primarily excreted as the unchanged parent drug and 
dextrorphan [92], which is pharmacologically active [93]. The formation of dextrorphan 
is primarily catalyzed by CYP2D6 (Figure 2) [91]. Dextrorphan is further metabolized by 
CYP2D6 to 3-hydroxymorphinan [94]. Sparteine and debrisoquine are two prototypical 
substrates of CYP2D6, but are not available now [91]. Sparteine is primarily metabolized 
by CYP2D6 to an N-oxide via N
1
-oxidation [95]. The N-oxide rearranges with loss of 
water to 2-dehydrosparteine (i.e., 2,3-didehydrosparteine) [91]. Debrisoquine was used as 
an antihypertensive agent, and its 4-hydroxylation (so CYP2D6 is called debrisoquine 
4-hydroxylase) is primarily mediated by the polymorphic CYP2D6 [96]. In addition, 
bufuralol, a β-adrenoceptor blocker, has been extensively used as a probe substrate for 
the in vitro study of CYP2D6 activity. Bufuralol was metabolized to three metabolites, 
namely, 1‘-hydroxybufuralol, 1‘-oxobufuralol, and 1‘2‘-ethenylbufuralol (Figure 1-4) 
[97]. The level of 1‘-hydroxybufuralol, a major metabolite of bufuralol, is often measured 
as an index of CYP2D6 activity and/or levels, and the amount of 1‘-hydroxybufuralol 
formed from bufuralol is known to be small in CYP2D6-deficient metabolizers [98].  
1.2.4.2 Therapeutic Drugs 
CYP2D6 metabolize a number of drugs that target the cardiovascular and central nervous 
system (>100) [41, 42], and among these are many drugs with a narrow therapeutic index. 
The drugs include tricyclic antidepressants (e.g. clomipramine, imipramine, doxepin, 
desipramine, and nortriptyline), SSRIs (fluoxetine, fluvoxamine, and paroxetine), other 
non-tricyclic antidepressants (atomoxetine, maprotiline, mianserin, and venlafaxine), 
neuroleptics (e.g. chlorpromazine, perphenazine, thioridazine, zuclopenthixol, mianserin, 
olanzapine, risperidone, sertindole, and haloperidol), -blockers (e.g. atenolol, bufuralol, 
carvedilol, metoprolol, bisoprolol, propranolol, bunitrolol, bupranolol, timolol and 
alprenol), opioids (e.g. codeine, dihydrocodeine and tramadol), antiemetics (tropisetron, 
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ondansetron, dolasetron, and metoclopramid), antihistamines (e.g. terfenadine, oxatomide, 
loratadine, promethazine, mequitazine, azelastine, diphenhydramine and 
chlorpheniramine), and antiarrhythmics (e.g. sparteine, propafenone, encainide, 
flecainide, cibenzoline, aprindine, lidocaine, procainamide and mexiletine) [41, 42, 99]. 
CYP2D6 played a role in the metabolism of several anti-HIV agents, including ritonavir 
with a Km of 10 µM, nevirapine, and delavirdine [100-102]. It is also a major contributor 
to the oxidation of several antihistamines including loratadine, promethazine, astemizole, 
mequitazine, terfenadine, azelastine, oxatomide, epinastine, diphenhydramine, and 
chlorpheniramine [103-116]. 
1.2.4.3 Toxicants and Environmental Compounds 
CYP2D6 is largely responsible for the metabolism of ibogaine to its O-desmethyl active 
metabolite 12-hydroxyibogamine (noribogaine) [113], a psychoactive alkaloid isolated 
from the root of Tabernanthe iboga, a rain forest shrub native to Africa. Study using 
human liver microsomes indicated that CYP2D6 and 3A4 were able to metabolize 
emetine to cephaeline (both are alkaloids from ipecac) and 9-O-demethylemetine, and 
CYP3A4 also participated in metabolizing emetine to 10-O-demethylemetine [117]. The 
CYP2D6 enzyme also has high affinity for toxic plant alkaloids such as lasiocarpine and 
monocrotaline, both pyrrolizidine alkaloids, which found in plants have long been known 
to be a health hazard for livestock, wildlife, and humans [118-120]. The major metabolic 
pathways of unsaturated pyrrolizidine alkaloids such as lasiocarpine in animals are [121, 
122]: a) hydrolysis of the ester groups; b) N-oxidation; and c) dehydrogenation of the 
pyrrolizidine nucleus to dehydro-alkaloids (pyrrolic derivatives). Routes a and b are 
believed to be detoxification mechanisms, while route c leads to toxic metabolites 
capable of binding DNA and proteins and appears to be the major activation mechanism 
[122, 123]. CYP2D6 has also been shown to metabolize procarcinogens and neurotoxins 
such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [124-127], 1,2,3,4- 
tetrahydroquinoline [128], and indolealkylamines [129].  
1.2.5 Inhibitors of CYP2D6 
It is of importance to identify drugs as CYP2D6 inhibitors which expect to increase the 
plasma concentration of these drugs extensively metabolized by CYP2D6. A number of 
compounds have been found to inhibit CYP2D6, including ritonavir [130, 131], indinavir, 
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saquinavir, nelfinavir, and delavirdine [130, 132]. In addition, both bupropion and 
hydroxybupropion inhibited CYP2D6-mediated dextromethorphan O-demethylation, 
with IC50 values of 58 and 74 µM, respectively [133]. 
Pimozide,a potent neuroleptic used extensively in Europe for the treatment of 
schizophrenia and other psychiatric diseases, was also an inactivator of CYP2D6[134]. 
Quinidine and fluoxetine are competitive inhibitors of CYP2D6, which did not exhibit a 
preincubation-dependent increase in inhibitory potency. Quinidine, pimozide, and 
halofantrine compete for the substrate-binding site of CYP2D6 but are not metabolized 
by it [83]. 
Quinidine, which has been applied in clical application for more than 200 years and is 
still important for the treatment of atrial flutter and fibrillation, is a selective inhibitor of 
CYP2D6. The major metabolic pathways for quinidine are 3-hydroxylation, N-oxidation 
and vinylic hydroxylation in humans [135, 136] (Figure 1-5). It is metabolized to the 
main metabolite (3S)-3-hydroxy-quinidine, quinidine N-oxide, and a few other minor 
metabolites including oxo-2‘-quinidine, O-desmethylquinidine and quinidine 
10,11-dihydrodiols resulting from vinylic hydroxylation. Metabolic clearance in vivo is 
15 times faster for the 3-hydroxylation pathway than for the N-oxidation pathway and 
was not associated with sparteine oxidation polymorphism [137]. In vitro, an 
anti-CYP3A4 antibody has been shown to inhibit more than 95% and 85% of the 
formations of 3-OH-quinidine and quinidine N-oxide, respectively [82]. It is likely that 
quinidine is more specific for CYP3A4 activity than drugs like nifedipine, cortisol, and 
others, because these drugs were shown to be substrates for both CYP3A4 and CYP3A5 
in the same study [138]. Studies with yeast-expressed isozymes revealed that only 
CYP3A4 actively catalyzed the (3S)-3-hydroxylation; CYP3A4 was the most active 
enzyme in quinidine N-oxide formation, but CYP2C9 and 2E1 also catalyzed minor 
proportions of the N-oxidation [88]. An in vivo pharmacokinetic interaction between 
quinidine and erythromycin [139], cimetidine [140], and amiodarone [141] in humans has 
been reported (Figure 1-5). 
Many compounds from plants have been proved to be inhibitors of CYP2D6. Both 
cephaeline and emetine, two natural alkaloids, were potent inhibitors of CYP2D6 and 
CYP3A4 as indicated by the inhibition of probe substrate metabolism [117]. The Ki 
values were 54 and 355 M for cephaeline and 43 and 232 M for emetine for CYP2D6 
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and CYP3A4, respectively [117]. Hyperforin, a major active component from St John‘s 
wort, was a potent noncompetitive inhibitor of CYP2D6-dependent bufuralol 
1'-hydroxylation in recombinant enzyme with a Ki of 1.5 µM [142]. In the elderly, Panax 
ginseng, but not St John's wort, garlic oil, and Ginkgo biloba, inhibited 
CYP2D6-mediated debrisoquine metabolism [143].  
1.3 In Silico Approaches to Studying CYP2D6 
1.3.1 Pharmacophore Study 
The first substrate models for CYP2D6 were constructed by manual alignments based on 
a set of substrates containing a basic nitrogen atom at either 5 Å [118] or 7 Å [144]  from 
the site of oxidation, and on aromatic rings near the site of oxidation which were fitted 
coplanar [118, 144]. In the space-filling 5-Å model, no substrates were fitted onto each 
other [118]. Neither of the models could rationalize the binding of other types of 
substrates.  
An extended model by Islam et. al. with incorporation of the heme moiety from the 
crystal structure of P450cam (CYP101), which also indicated a distance between a basic 
nitrogen atom and the site of oxidation between 5 and 7 Å and debrisoquine was 
positioned arbitrarily, was derived in a similar approach to the orientation of camphor in 
the CYP101 crystal structure [145]. Camphor, a substrate molecule, was buried in an 
internal pocket just above the heme distal surface adjacent to the oxygen binding site of 
CYP101 [145]. The model also included the iron-oxygen complex involved in the 
hydroxylation, and a set of 15 compounds was fitted onto debrisoquine. However, this 
model was limited to accomodate tamoxifen which was later proposed not to be 
metabolized by CYP2D6 [146], while later studies indicate that tamoxifen is a good 
substrate of CYP2D6 [147-150]. 
The positioning of Asp301 in the various models showed that it could readily explain the 
5-7-Å pharmacophore model [75, 146]. In the small-molecule model for CYP2D6 by 
Koymans et al., debrisoquine and dextromethorphan were used as templates for the 
5- and 7-Å compounds, respectively, and it suggested that a hypothetical carboxylate 
group within the protein was responsible for a well defined distance of either 5 or 
7 Å between basic nitrogen atom and the site of oxidation within the substrate [75]. The 
oxidation sites of the two templates were superimposed and the areas adjacent to the sites 
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of oxidation were fitted coplanar, while the basic nitrogen atoms were placed 
2.5 Å distant which interacted with different oxygen atoms of the postulated carboxylate 
group in the protein [75]. The model was constructed based on 16 substrates, accounting 
for 23 metabolic reactions with their sites of oxidation and basic nitrogen atoms fitted 
onto the site of oxidation of the templates, and one of the basic nitrogen atoms of the 
template molecules, respectively. It predicted the metabolism of four compounds giving 
14 possible CYP-dependent metabolites.  
An inhibitor molecule-based model constructed by Strobl et al. had the similar overall 
criteria to the substrate-based models of CYP2D6 constructed by Koymans et al. [75]. 
The template of this model was derived by fitting six potent competitive reversible 
inhibitors of CYP2D6 onto each other and ajmalicine, the most potent inhibitor for 
CYP2D6 with a Ki of 3.3 nM was selected as a starting template because of its rigid 
structure. Other strong inhibitors used for model construction included chinidin, 
chlorpromazine, trifluperidol, prodipin and lobelin, with Ki values of 0.06, 7.0, 0.17, 
0.0048 and 0.12 M, respectively. The basic nitrogen atoms of all inhibitors tested were 
superimposed and the aromatic planes of these inhibitors were fitted coplanar. The 
derived preliminary pharmacophore model was characteristic of a tertiary nitrogen atom 
which was protonated to a high degree at physiological pH and a flat hydrophobic region, 
and the plane of which was almost perpendicular to the N-H axis and maximally 
extended up to a distance of 7.5 Å from the nitrogen atom [75]. The pharmacophore 
model also contained region B in which additional functional groups with lone pairs 
enhanced inhibitory potency, and region C in which hydrophobic groups were allowed 
but did not increase binding affinity and inhibitory effect [75]. Compounds with 
enhanced inhibitory potency contained additional functional groups with negative 
molecular electrostatic potential and hydrogen bond acceptor properties in region B on 
the opposite side at distances of 4.8-5.5 Å and 6.6-7.5 Å from the nitrogen atom, 
respectively [75]. Compounds (e.g. reserpine) that took additional space were not 
inhibitors. Consecutively, other inhibitors were fitted onto the derived template. These 
included derivatives of ajmalicine such as tetrahydroalstonine (Ki=5.0 M) and 
19-epiajmalicine (Ki=17 nM), yohimbine derivatives such as corynanthine (Ki=0.080 M) 
and -yohimbine (Ki=0.031 M), harmine (Ki=50 M) and its analogs such as harmalol 
(Ki =65 M) and harman (Ki =86 M), and cinchona alkaloids including quinidine (Ki=60 
nM), quinine (Ki=4.6 M), cinchonine (Ki=3.5 M), 10, 11-dihydroquinidine (Ki=0.066 
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M) and quininone (Ki=0.72 M). Serpentine, cathenamine and sempervirine all 
possessed an iminium atom instead of a basic nitrogen atom, but they were still 
competitive inhibitors of CYP2D6 with Ki values of 2.2, 3.2, and 9.7 M, respectively, 
suggesting a demand for a modification of the pharmacophore.  
Other pharmacophore modelling studies have demonstrated that typical CYP2D6 
substrates were lipophilic bases with a planar hydrophobic aromatic ring and a nitrogen 
atom which can be protonated at physiological Ph [76, 151-153]. These compounds 
usually have a negative molecular electrostatic potential above the planar part of the 
molecule and are found in a large number of drugs acting on central nervous and 
cardiovascular system particularly. The nitrogen atom is considered to be essential for 
electrostatic interactions with the carboxylate group of Asp301, a candidate residue in the 
active site of CYP2D6 [76, 151-153]. Pharmacophore modelling studies suggested that 
binding of substrate was generally followed by oxidation 5 to 7 Å from this proposed 
nitrogen-Asp301 interaction [75, 118, 144, 154, 155]. Lipophilicity and amine basicity 
are thus considered critical determinants of substrate binding to CYP2D6. 
1.3.2 QSAR Study 
A set of 3D/4D-QSAR pharmacophore models has also been derived for competitive 
inhibitors of CYP2D6 by Ekins et al. [102]. The first model for 20 inhibitors of 
CYP2D6-mediated bufuralol 1‘-hydroxylation produced a positive correlation between 
observed and predicted Ki values, while a second model using 31 literature-derived Ki 
values provided a better correlation between observed and predicted Ki values with a 
R value of 0.91. Both pharmacophores were capable of predicting Ki values for 9 to 10 of 
15 CYP2D6 inhibitors within 1 log residual [102].  
A QSAR analysis identified a correlation between IC50 values and lipophilicities in a 
series of close analogs of MAMC which has been designed as specific CYP2D6 
substrates [156]. It is also found that elongation of the alkyl chain dramatically increased 
the affinity of the compounds toward CYP2D6, as indicated by an up to 100-fold 
decrease in Km values. The Vmax values displayed a much less pronounced decrease with 
an increasing N-alkyl chain, resulting in as much as a 30-fold increase in the Vmax/Km 
value [156]. In contrast to CYP2D6, N-alkylation of MAMC did not significantly affect 
the Km values of O-dealkylation by CYP1A2, but it resulted in higher Vmax values. 
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1.3.3 Homology Modelling and Docking Study 
De Groot et al. [157] derived a homology model of CYP2D6 and proposed that the site of 
oxidation above the heme moiety was one of the two possible sites of oxidation, located 
above pyrrole ring B of the heme moiety. In a further refined model, they pointed out the 
actual positions of the heme moiety and the I-helix containing Asp301, thereby 
incorporating some steric restrictions and orientational preferences into this model [158]. 
In this refined small-molecule model, an Asp residue was coupled to the basic nitrogen 
atoms, thus enhancing the model with the direction of the hydrogen bond between Asp in 
the protein and the protonated basic nitrogen atom. The site of oxidation for substrates 
was fitted onto the defined oxidation site above pyrrole ring B of the heme moiety, while 
the C and C atoms of the attached Asp moiety were fitted onto the C and C atoms 
of Asp301, respectively [158]. A variety of substrates fitted in the original substrate 
model for CYP2D6 [75, 158, 159] were properly fitted into the refined substrate model, 
indicating that the refined substrate model for CYP2D6 accommodates the same variety 
in molecular structures as the original substrate model. This refined model has been used 
to design a novel and selective CYP2D6 substrate, MAMC, suitable for high-throughput 
screening [160] and to investigate the hydroxylation of debrisoquine [161]. 
Homology modeling has been used to develop structures of CYPs for which sequence 
information was available when X-ray structures were lack. These models have to be 
verified by either crystallization or site-directed mutagenesis experiments. Prior to the 
availability of crystal structures of mammalian CYPs, models of human CYPs were 
based on the structures of more distantly related bacterial CYPs including P450cam 
(CYP101), P450BM3 (CYP102), P450eryF (CYP107A), and P450terp (CYP108) that 
share less than 25% sequence identity with human CYP2D6, but the incorporation of 
rabbit CYP2C5 structure as a template provided more accurate information on ligand 
binding to CYP2D6 as rabbit CYP2C5 and CYP2D6 share about 40% sequence  
identity. Among bacterial CYPs, P450102 is considered to provide the most useful 
structural information for homology studies on eukaryotic P450s, since this 
well-characterized and crystallized bacterial enzyme belongs to the so-called class II 
P450s [162] to which many eukaryotic P450s belong, as well. Class II P450s are bound 
to the endoplasmic reticulum and interact directly with a cytochrome P450 reductase, 
containing flavin adenine dinucleotide and flavin mononucleotide, while class I P450s are 
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found in the mitochondrial membranes of eukaryotes and in most bacteria and require an 
FAD-containing reductase and an iron-sulfur protein (putidaredoxin) [162]. Docking 
studies are usually carried out on known CYP2D6 substrates for these homology models.  
Homology models also suggest a role for aromatic residues in the active site to undergo 
Vander Waals interactions with aromatic moieties of the substrates. Three aromatic 
phenylalanine residues, namely Phe120, Phe481 and Phe483, have been proposed as 
important active-site residues. The aromatic moiety of Phe120 has a steric effect on the 
orientation of molecules in the active site of CYP2D6, and thus plays a role in controlling 
the regioselectivity of substrate oxidation [78]. Phe120 is positioned close to the haem 
iron and is a key factor in controlling substrate access to the haem. This has been 
confirmed by site-directed mutageneiss experiments and recently determined crystal 
structure of CYP2D6 [71].  
More recently, Ito et al. [163] have derived a homology model based on rabbit CYP2C5 
crystal structure and docked 11 substrates/inhibitors into the active site of the model. 
These included propranolol, metoprolol, thioridazine, R-bufuralol, MPTP, debrisoquine, 
dextromethorphan, nortriptyline, codaine, quinidine and yohimbine. They found that 
Glu216, Asp301, Phe120 and Phe483 as well were ligand binding residues by docking 
and molecular dynamics simulation studies, which is in agreement with previously 
reported site-directed mutagenesis data and the crystal structure of CYP2D6 [71]. 
Many early models of the active site of CYP2D6 suggested the involvement of a 
negatively charged carboxylate group in the enzyme forming a salt bridge with the basic 
nitrogen atom of the substrate [75-77, 126, 144, 146, 152, 154, 157, 164, 165]. A number 
of structural models have pointed to Asp301 being the important residue in the I-helix 
responsible for substrate recognition [74, 75, 146, 154]. The central region of the I-helix 
is one of the most spatially conserved areas of the P450 core, which is located close to the 
heme moiety and runs across the distal face of the heme, completely or partially covering 
pyrrole ring B [166, 167]. 
It was proposed that Asp100 or Asp301 was an alternative carboxylate residue for the 
interaction with the basic nitrogen of CYP2D6 ligands [8]. However, this residue is 
located in the peripheral region and it may not involve substrate binding. A site-directed 
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mutagensis study has confirmed that the substitution of this residue with neutral amino 
acids such as Asn or Ala did not alter the catalytic activity of the enzyme [146]. 
In a homology model, codeine docked in the active site of CYP2D6 in an orientation 
consistent with O-demethylation [78]. It is surprised that the docking did not position the 
basic nitrogen atom of the substrate close to Asp301. Instead, the basic nitrogen was 
observed to interact with Glu216, a second acidic residue in the active site. Early 
modelling studies suggested that Asp301 was not involved directly in substrate binding 
but plays a structural role positioning the B-C loop, including Phe120 [168], and this 
hypothesis has been subsequently verified when the crystal structure of CYP2D6 was 
determined [71]. The docking results for MPTP [78] and dextromethorphan [169] also 
positioned the basic nitrogen atoms of the substrates close to Glu216 and away from 
Asp301. 
A three-dimensional protein model for CYP2D6 based on the structures of CYP101, 
CYP102 and CYP108 with incorporation of a wide variety of site-directed mutagenesis 
data concerning P450s of the CYP2 family has been derived by De Groot et al. The final 
model consisted of four segments: a) the B-, B‘-, and C-helices and the 1-sheet 
(Gly66-Lys146); b) the F- and G-helices (Leu205-Asp263); c) the I-, J-, J‘-, K-, and 
L-helices, the 2-, 3-, 4-, and 5-sheets, and the heme binding domain 
(Pro286-Arg497); and d) the heme moiety [157]. Three classical CYP2D6 substrates 
including debrisoquine, dextromethorphan, and GBR12909 and one potent inhibitor 
ajmalicine were consecutively docked into the active site of the protein model. Amino 
acids responsible for binding and/or orientation of the various CYP2D6 substrates and 
inhibitor were identified: Pro102 and Gln108 (strand leading to B'-helix, SRS1), Arg115, 
Ser116, Gln117, Leu121, and Ala122 (strand running from B'-helix, SRS1), Leu213 
(F-helix, SRS2), Asp301, Ser304, Ala305, and Thr309 (I-helix, SRS4), Val370 (K-helix, 
SRS5), Pro371 (3-sheet, SRS5), and Leu484 (5-sheet, SRS6) [157]. The basic nitrogen 
atoms of the compounds were orientated within hydrogen bonding distance from Asp301, 
which was proven to be important in the catalytic activity of CYP2D6, and the site of 
oxidation of the substrates was orientated above the heme moiety in a similar way as the 
site of oxidation of camphor in the CYP101 crystal [145]. In particular, Asp301 was 
found to be a crucial amino acid responsible for forming an ionic hydrogen bond with a 
basic nitrogen atom from the substrate or inhibitor [157]. The energy optimized positions 
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of the substrates in the protein agreed well with the original relative positions of the 
substrates within the substrate model [159]. The substrate model incorporates only one 
oxidation site and two possible positions for a basic nitrogen atom of the substrates 
guided by the presence of two oxygen atoms within a carboxylate (Asp301) [159]. 
However, the protein model for CYP2D6 suggests the presence of two possible sites of 
oxidation and only one position for the basic nitrogen atom [157]. The derived protein 
model indicates new leads for experimental validation and extension of the substrate 
model regardless of its impossibility to predict CYP2D6 metabolism.In further modelling 
studies with incorporation of information on rabbit CYP2C5 structure proposed by Kirton 
et al. suggested that Asp301 played a structural role through the formation of a hydrogen 
bond with a residue in the flexible B‘-C loop and a second acidic residue, Glu216, is in a 
position where it may play a role in the binding of the basic nitrogen of CYP2D6 
substrates [78]. 
The existence of numerous substrates, such as metoprolol, which are metabolized at sites 
further from this nitrogen, gave rise to a different 10-Å pharmacophore [170] and Lewis 
has thus suggested that Glu216 is the primary recognition residue that attracts basic 
ligands to the active site [77], where it generates an intermediate binding site prior to the 
ligand adopting a more ‗reactive‘ position in the cavity [90]. This is similar to the 
intermediate binding pocket occupied by warfarin in the crystal structure of the 
S-warfarin/CYP2C9 complex, but apparently inconsistent with the mutation E216F 
transforming CYP2D6 into a quinidine demethylase. This issue may be resolved when 
co-crystallization of substrates [72] in CYP2D6 becomes available.  
1.3.4 Combinational Model Study 
De Groot et al. developed a combined pharmacophore and homology model for CYP2D6 
which consisted of a set of two pharmacophores (one for O-dealkylation and oxidation 
reactions and a second one for N-dealkylation reactions catalyzed by CYP2D6) 
embedded in a homology model based on bacterial CYP101 (P450cam), CYP102 
(P450BM3) and CYP108 (P450terp) crystal structures [76, 152]. It is the first time to 
combine the strengths of pharmacophore models (atom-atom overlap and reproducible 
starting points and thus the most reactive sites in the substrates could be identifed) and 
homology models (steric interactions, conformational and stereochemical constraints 
imposed by the active site, and the possibility to identify amino acids involved in 
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substrate binding). The independent generation of the pharmaphore and protein 
homology models provided the opportunity to cross-validate the approaches used. The 
combined model contained 51 substrates involving 72 metabolic pathways, mostly 
N-dealkylation and was used to predict the metabolism of seven test compounds 
including betaxolol, fluoxetine, loratidine, MPTP, procainamide, ritonavir, sumatriptan. 
The combined model correctly predicted 6 of the 8 observed metabolites except for the 
highly unusual metabolism of procainamide (N-hydroxylation) and ritonavir (marked as a 
non-substrate as it contains no basic nitrogen atom but it was metabolized by CYP2D6. 
[96, 148].  
Several more modelling studies have pointed to a possible role for a second carboxylate 
group, that of Glu216 [77, 152, 165]. This residue may provide an explanation for the 
metabolism of the larger substrates with a basic nitrogen atom ≥10 Å from the site of 
oxidation. Basic substrates are metabolized by all four known P450s that contain a 
residue equivalent to both Glu216 and Asp301: CYP2D6, CYP2D14 (bovine) [171], 
Cyp2d4 (rat) [172], and CYP2J1 (rabbit) [173]. Both Asp301 and Glu216 were indicated 
as important parts in the metabolism of these substrates.  
1.4 Herb-CYP2D6 Interaction 
Herbal medicines, such as St. John's wort, garlic, gingko, and ginseng, are freely 
available over the counter and very often self-administered complements along with 
therapeutic drugs [174, 175]. This has given rise to potential adverse herb-drug 
interactions (AHDI) in clinical settings when co-administered with prescribed medicines. 
A number of adverse herb-drug interactions have been identified in humans and 
frequently impacted medications are those with a narrow therapeutic window and 
extensively metabolized by CYP enzymes, such as warfarin, digoxin and cyclosporine 
[176-178]. One of the most commonly reported herbs is St. John's wort which interacts 
with a broad therapeutic drugs, including cyclosporine, digoxin, theophylline, oral 
contraceptives, methadone, fluoxetine, and buspirone [179-187]. Gingko biloba was also 
reported to interact with ibuprofen, trazodone, fluoxetine, buspirone and phenytoin. It 
should be noted that both warfarin and cyclosporine are well-known substrates of 
CYP2C9 and 3A4, respectively, while St. John's wort is a potent inducer of CYP3A4 and 
P-glycoprotein (P-gp). An additional example is licorice (Glycyrrhiza glabra) which was 
reported to increase the plasma concentrations of prednisolone [188] by inhibiting the 
  25 
metabolism of prednisolone, and also potentiated the skin vasoconstrictive action of 
hydrocortisone [189].  
Drug interactions may occur during recent or concurrent use of another drug or drugs or 
ingestion of food. It was defined as the action of a drug that may affect the activity, 
metabolism, or toxicity of another drug. A drug interaction is any pharmacological 
modification of an exogenous substance (in drug, herb and food) in a body caused by 
another exogenous compound (in drug, herb and food) during a diagnostic or therapeutic 
period [190]. This relates to so-called drug-drug interactions (interactions between drugs), 
herb-herb interactions (interactions between herbs) or drug-food interactions (interactions 
between drug and food). 
Most drug interactions are involved in pharmacodynamic and/or pharmacokinetic 
mechanisms. Pharmacodynamic interactions involve synergistic or antagonistic 
interactions on drug targets, e.g. receptors, which can often be predicted and avoided. For 
example, Ma Huang contains ephedrine-like alkaloids which exhibit sympathomimetic 
activities. Thus, Ma Huang may interact with other sympathomimetic agents and then 
increase the actions of monamine oxidase inhibitors and adrenergic agonists such as 
clonidine, and decrease the actions of bethanidine and guanethidine [191]. On the other 
hand, pharmacokinetic interactions are much more difficult to anticipate, which occur 
through multiple mechanisms, including alterations of compounds‘ absorption, 
distribution, metabolism and excretion. Most reported drug interactions are 
pharmacokinetic interactions. Coadministration of two or more drugs or herbs may give 
rise to drug interactions due to an alteration of CYPs activity [192] if the drugs or herbs 
are metabolized by the same enzyme system(s). The drug interactions may potentially 
result in altered pharmacokinetics for one or all of the coadministered compounds due to 
either inhibition or induction of a specific CYP enzyme. If these effects of the drug 
interaction occur to certain extent, clinical efficacy of those drugs may be lost and 
furthermore adverse drug interactions, including some fatal interactions may overcome 
their therapeutic anticipation [20, 193]. 
Herb may inhibit CYPs by three mechanisms: competitive inhibition, non-competitive 
inhibition, and mechanism-based inhibition. Mutual competitive inhibition may occur 
between a herbal constituent and a drug, as both are often metabolised by the same CYP 
isoform. For example, diallyl sulfide from garlic is a competitive inhibitor of CYP2E1 
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[194]. Non-competitive inhibition is caused by the binding of herbal constituents 
containing electrophilic groups (e.g. imidazole or hydrazine group) to the heme portion of 
CYP. For example, piperine inhibited arylhydrocarbon hydroxylase (CYP1A) and 
7-ethoxycourmarin deethylase (CYP2A) by non-competitive mechanism [195]. 
Hyperforin present in St John‘s wort is also a potent noncompetitive inhibitor of 
CYP2D6 activity in vitro [142]. The mechanism-based inhibition of CYP is due to the 
formation of a complex between herbal metabolite with CYP. For example, diallyl 
sulfone derived from diallyl sulfide is a suicide inhibitor of CYP2E1 by forming a 
complex via an epoxide metabolite [196], leading to autocatalytic destruction of CYP2E1  
[197].  
S. baicalensis is the root of Baical Skullcap belonging to labiates, which is a Chinese 
herbal drug in common use. For many years, global research boost of rhubarb is in the 
ascendant. S. baicalensis applies apprehensively in clinical practice especially in the 
basic medical care of the developing countries on bacterial infections, virus infections, 
allergic diseases, tumors and some other common diseases. The pharmaceutical effects of 
S. baicalensis are complicated that included anti-inflammatory, antibacterial, anti-virus, 
anti-allergic, antioxidant, scavenging free radicals, anti-tumor, protecting of neurons, 
inhibiting aldose reductase activity, blocking calcium channels and cellular apoptosis and 
so on. On the other hand, being a well-known classic formula from ―Synopsis of 
Prescription of the Golden Chamber‖ for clinical practice on treatment of edema, chronic 
congestive heart failure, atrial fibrillation, gouty arthritis et. al., Fangjifuling decoction is 
another popular remedy in China for more than 2,000 years. The formula mainly consists 
of Stephania tetrandra, Poria cocos (Schw.), Astragalus membranaceus, Cinnamomum 
cassia, and Glycyrrhiza uralensis. 
The natures of herbs and also formulae are built upon the breadth and complexity of their 
active ingredients. The effective ingredients of S. baicalensis are mainly flavonoids, and 
also other chemicals such as phenols, alcohols, organic acids, glycosides, terpenoids, 
enzymes and trace elements. A number of studies have suggested that flavonoids can also 
directly modulate the activities of various CYPs. Some naturally occurring flavonoids are 
potent inhibitors of CYP1A1, 1A2, 1B1, 3A4, 3A6, and CYP19. In contrast, some 
flavonoids enhanced/stimulated the activities of CYP3A4 and 1A2. The different effects 
of various flavonoids on CYP3A4 may be partly explained by the presence of distinct 
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ligand binding sites on CYP3A4. Structure-activity analysis indicated that flavonoids 
containing hydroxyl groups inhibited CYP activity, whereas those lacking hydroxyl 
groups stimulated the enzyme activity. For example, non-substituted 7,8-benzoflavone 
increased CYP3A4 activity. In another study, quercetin inhibited the activity of aryl 
hydrocarbon hydroxylase (CYP1A), but enhanced the activity of cDNA-expressed human 
CYP1A2. Likewise, 7,8-benzoflavone was an inhibitor of human CYP1A1 and 1A2, but 
an activator of CYP3A4. 
As a main drug metabolic enzyme, CYP2D6 plays an important effect that should not be 
ignored to the bioavailability of herbs. Numbers of research have shown that herbs, single 
herb or formula, were of underlying substrates or inhibitors of CYPs. However, no 
literature could be found for the interaction between CYP2D6 and ingredients of S.  
baicalensis/Fangjifuling decoction.  
1.5 Hypothesis and General Aims 
First of all, ligand-CYP binding is determined by the balance of different energetic 
contributions mainly including hydrogen-bonding, aromatic stacking interaction, van der 
Waals‘, and electrostatic interaction [198]. Hydrogen bonds are specific, short-range, 
directional nonbonded interactions, which are predominantly electrostatic in character 
and are key signatures of secondary elements in CYPs and other proteins [199]. The 
number of hydrogen bonds in a drug molecule is limited for requiring polarity for 
absorption and permeation. The Lipinski rule-of-five has suggested that compounds with 
more than five hydrogen bond donors or more than 10 hydrogen bond acceptors are more 
likely to absorb or permeate poorly [200]. Aromatic stacking interaction, also called 
phenyl stacking or π-π interaction, is a common phenomenon in organic chemistry that 
affected aromatic compounds and functional groups, which acts strongly on flat 
polycyclic aromatic hydrocarbons for many delocalized π-electrons [201]. Thus, 
hydrogen bond formation and π-π interaction are two crucial parameters to describe 
molecular interaction.  
Secondly, CYP2D6 is an important enzyme, since it metabolize about 25% of clinical 
drugs and is subjected to inhibition and polymorphism with significant clinical 
consequences [202, 203]. The elucidation of its crystal structure has provided very useful 
information on how ligands (e.g., substrates or inhibitors) interact with this enzyme and 
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how CYP2D6 to determine its substrate specificity and inhibitor selectivity [53]. 
However, the resolved structure of CYP2D6 (PDB Code: 2F9Q) is ligand-free [53], and 
thus how and whether ligand binding induces conformational changes of the active site 
are unknown. Although there are reports on the binding of ligands to CYP2D6 using 
pharmacophore [19], homology [43] and QSAR approaches [204], the molecular factors 
affect the binding of ligand to the enzyme are not fully elucidated.  
Last but not least, with herbal medicines becoming more popular as alternative medicines 
in western world, these herbs are often coadministered with therapeutic drugs, raising the 
potential of herb-drug interactions. The underlying mechanism for the interaction 
included the binding affinity and binding mode of ingredients of herbs to CYPs.  
In this regard, we hypothesize that a number of physicochemical factors, especially 
hydrogen bonding and aromatic stacking interaction, determine the binding of 
compounds to human CYP2D6, and that a number of ingredients from herb and/or 
formula share the similar structural features of CYP2D6 substrates/inhibitors, and bind to 
the ensyme in a similar mode to CYP2D6 substrates/inhibitors, which can be revealed 
with in silico approaches. 
Thus, the objectives of the project are: 
1. To develop exact pharmacophore models for the revelation of structural properties of 
CYP2D6 substrates/inhibitors; 
2. To construct effective QSAR models for the prediction of binding affinity of existing 
or new compounds to CYP2D6; 
3. To further explore the molecular factors determining the binding of a compound to 
native and mutated CYP2D6; 
4. To examine the binding of Chinese herbal compounds from Huangqin & Fangjifuling 
decoction with wild-type CYP2D6. 
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Figure 1-1. Ribbon Diagram of the CYP2D6 Structure. Figure 1-1 shows the ribbon 
diagram of the CYP2D6 structure. The 3.0 Å crystal structure of 2D6 shows the 
characteristic P450 fold as seen in other members of the family. The lengths and 
orientations of the individual secondary structural elements in CYP2D6 are very similar 
to those seen in 2C9 [71]. 
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Figure 1-2. Active Site Cavity in CYP2D6. Figure 1-2 shows the active site cavity in 
CYP2D6. A. ribbon diagram of the ―right foot‖-shaped active site cavity, showing the 
location of the B‘, F, G, and I helices (labeled). Also shown are the B‘-C loop (lower left), 
the loop between 4-1 and 4-2 (upper right), and the loop between hellx K and  1-4 
(lower right). The cavity shape was generated using a 1.4 Å radius probe occupled 
volume. B. close up of the residues surrounding the cavity, with some of the key residues 
labeled [71]. 
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Figure 1-3. Schematic Diagram of the Residues around the Cavity. Figure 1-3 shows 
the schematic diagram of residues around the cavity. The approximate locations of the 
amino acid side chains are indicated with labels, color-coded according to the secondary 
structure (red, α-helix; green, β-strand; blue, loop). The loops and strands all lie ―in front 
of‖ the cavity, whereas many of the side chains labeled in the I helix, running from left to 
right, are ―behind‖ the cavity [71]. 
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Figure 1-4. Metabolism of Bufuralol by CYP2D6, 2C19 and 1A2. Figure 1-4 shows 
the metabolism of bufuralol by CYP2D6, 2C19 and 1A2. Bufuralol, a -adrenoceptor 
blocker, has been extensively used as a probe substrate for the in vitro study of CYP2D6. 
Bufuralol was metabolized to three metabolites, namely 1‘-hydroxybufuralol, 1‘- 
oxobufuralol, and 1‘,2‘-ethenylbufuralol. 1‘,2‘-Ethenylbufuralol is considered to be 
formed both from bufuralol by ethenylation and from 1‘-hydroxybufuralol by 
dehydration. 1',2'-Ethenylbufuralol formation from bufuralol has been demonstrated to be 
mediated by CYP2D6. The level of 1‘-hydroxybufuralol, a major metabolite of bufuralol, 
is often measured as an index of CYP2D6 activity and/or levels, and the amount of 1‘- 
hydroxybufuralol formed from bufuralol is known to be small in CYP2D6-deficient 
metabolizers. However, bufuralol, but not sparteine and debrisoquine, is also extensively 
metabolized by CYP2C19 and to a lesser extent by 1A2 and this may affect its specificity 
as a prototypical substrate of CYP2D6 [91]. 
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Figure 1-5 Metabolism of Quinidine by CYP Enzymes and Mutated CYP2D6. Figure 
1-5 shows the metabolism of quinidine by CYP3A4, other CYP enzymes, and mutated 
CYP2D6. The major metabolic pathways for quinidine are 3-hydroxylation, N-oxidation, 
and vinylic hydroxylation. Heterologously expressed CYP3A4 has been shown to 
actively metabolize quinidine, whereas CYP3A5 does not. The wild-type CYP2D6 does 
not metabolize quinidine, but the mutant protein with the Glu216Phe mutation forms 
O-demethylated quinidine, and the mutant proteins with double Glu216Gln/Asp301Gln 
mutations or Phe120Ala results in both O-demethylated quinidine and 3-hydroxyl- 
quinidine [91]. 
 
  34 
CHAPTER 2  CONSTRUCTION OF COMPREHENSIVE 
COMPUTATIONAL MODEL OF CYP2D6 SUBSTRATES 
2.1 Introduction 
Before the crystal structure of CYP2D6 was resolved in 2006, computational approaches 
including pharmacophore modeling, SAR and QSAR analysis and homology modeling 
have been employed to investigate the interaction of CYP2D6 with its substrates and 
inhibitors. The first substrate models for CYP2D6 were constructed by manual 
alignments based on a set of substrates containing a basic nitrogen atom at either 
5 Å [118] or 7 Å [144] from the site of oxidation,
 
and a planar aromatic rings close to the 
site of oxidation which were fitted to be coplanar [118, 144]. The distance between the 
basic nitrogen atom and the site of oxidation in debrisoquine is about 5 Å, whereas in the 
rigid substrate dextromethorphan this distance is about 7 Å. Many early models for the 
active site of CYP2D6 suggested the involvement of a negatively charged carboxylate 
group in the enzyme forming a salt bridge with the basic nitrogen atom of the substrate 
[75-77, 126, 144, 146, 152, 154, 157, 164, 165]. A number of structural
 
models have 
pointed to Asp301 being the important residue in the I-helix responsible for substrate 
recognition [71, 72, 143, 151, 202, 203]. These homology models and structure-based 
alignments have located Asp301 in the central region of helix I of CYP2D6 which maps 
to one of the substrate-recognition sites (SRS) identified by Gotoh [205]  as being 
important in substrate binding in the CYP2 family. Further modeling studies 
incorporating information from the rabbit CYP2C5 structure (PDB: 1DT6) indicate that a 
second acidic residue, Glu216, is
 
in a position where it may play an important role in 
binding to the basic
 
nitrogen of CYP2D6 substrates [75, 205]. These studies have 
provided useful information on the binding modes and how substrates/inhibitors interact 
with CYP2D6.  
The crystal structure of human CYP2D6 (PDB: 2F9Q) has been determined in 2006 and 
refined to a 3.0 Å resolution [71]. The structure showed the typical CYP fold as found in 
other members of the CYP superfamily, with the lengths and orientations of the 
individual secondary structural elements being very similar to those seen in CYP2C9 and 
other CYPs. Rowland et al. [71] found that the active site cavity of CYP2D6 is bordered 
by the
 heme and lined by residues from helix B‘ (side chain of Ile106), loop B‘-C (side 
chains of Leu110, Phe112, Phe120, and
 
Leu121 and main chain atoms of Gln117, Gly118, 
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Val119, and
 
Ala122), helix F (side chains of Leu213, Glu216, Ser217,
 
and Leu220), helix 
G (side chains of Gln244, Phe247,
 
and Leu248), helix I (side chains of Ile297, Ala300,
 
Asp301, Ser304, Ala305, Val308, and Thr309), the loop between
 
helix K and strand 4 of 
-sheet 1 (side chains of Val370 and Met374 and main chain atoms of Gly373), and 
residues from the loop
 
between the strands of -sheet 4 (side chains of Phe483 and 
Leu484). The 2D6 structure has a well defined active site cavity above the heme group 
with a volume of 540 Å3. The determined crystal structure of CYP2D6 has several 
limitations. For example, it is ligand-free and information on how a ligand binds to 
CYP2D6 is scant. The role of individual amino acids in the active site in catalytic 
reaction and ligand binding is unclear.  
Only few naturally occurring SNPs are located in the active site of CYP2D6 and the 
functional impact of most active site residues is unknown [206, 207]. Given that the 
molecular determinants that governing the interactions of a ligand with wild-type and 
mutated CYP2D6 are unknown, we further explored the interaction of a large number of 
substrates with wild-type and mutated CYP2D6 using the molecular docking approach. 
The pharmacophore and QSAR models of CYP2D6 were also developed to examine the 
role of these models in substrate-CYP2D6 interaction studies. 
2.2 Materials and Methods 
2.2.1 Hardware and Software 
The Discovery Studio (DS) 2.1 (Accelrys Software Inc., San Diego, CA) was used 
throughout this study. Several functional Modules in Discovery Studio 2.1 were applied, 
including Common Feature Pharmacophore, Diverse Conformation Generation, Calculate 
Molecular Properties, Create Multiple Linear Regression Model, CDOCKER, Build 
Mutants, and Mapping Feature. The program was run using a Dell optiplex755 server. 
Chemoffice2002 (CambridgeSoft, Cambridge, MA) was used for compound structural 
refinement. 
2.2.2 Methods 
2.2.2.1 Generation of Libraries: 
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Twenty known substrates of CYP2D6 (Table 2-1) were selected as training set to 
generate pharmacophore models. A total of 75 CYP2D6 substrates (Table 2-2) were 
selected as testing set to validate the assumptions. To generate QSAR models, a set of 
CYP2D6 substrates with diverse Km values was selected as library (Table 2-3). Five 
substrates of CYP2D6 were selected as testing sets for the accuracy test of docking 
algorithm in our molecular docking study (Table 2-4). Overall, 120 substrates of 
CYP2D6 were selected for the construction of our different libraries and shown in Table 
2-5(A). All the molecular structures of selected substrates of CYP2D6 were obtained 
from PubChem (http://pubchem.ncbi.nlm.gov/) as ‗sdf‘ format, then redrawn as ‗cds‘ 
format and converted to ‗mol‘ format with Chemoffice2002. 
2.2.2.2 Construction and Validation of Pharmacophore Models of CYP2D6 
Substrates  
A 3D pharmacophore is a collection of chemical features in space that are required for a 
desired biological activity. These may include hydrophobic (HY) group, 
charged/ionizable group, hydrogen bond donor (HBD), hydrogen bond acceptor (HBA) 
and other features properly assembled in 3D space to reflect structural requirements. On 
the basis of assumption that the most active compounds share all or most of the required 
features for binding with the active site, only the active molecules with low Km values 
were included in the training set. As the inactive compounds may experience steric 
hindrance and other disfavored interactions, these compounds were excluded during 
pharmacophore generation. Therefore, 20 substrates were included in the training set. For 
each of the 20 substrates of CYP2D6 in the training set, a conformational search followed 
by an energy minimization was performed using the BEST method in DS 2.1. The 
number of conformers generated for each compound was limited to a maximum of 255 
with an energy range of 20 kcal/mol. Although we also used the FAST and CAESAR 
methods to generate conformers, the BEST method was chosen as it provides a complete 
coverage of conformational space by optimizing the conformations in both torsional and 
cartesian space. The routine steps in the BEST method include: a) conjugate-gradient 
minimization in torsion space; b) conjugate-gradient minimization in Cartesian space; 
and c) quasi-Newton minimization in Cartesian space. The BEST approach employs a 
version of the CHARMM force field for energy calculation and a poling mechanism for 
forcing the search into unexplored regions of conformer space. 
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In the present study, pharmacophore models were developed using the HypoGen module 
implemented in DS 2.1 with the conformers generated for the molecules in the training 
set (n=20). Predictive pharmacophores were generated in three phases, namely a 
constructive, a subtractive and an optimization phase. In the constructive phase, 
pharmacophores were generated that were common among the active molecules of the 
training set. HypoGen identified all allowable pharmacophores consisting of up to five 
features among the two most active substrates and explored the remaining active 
compounds. The subtractive phase dealt with the pharmacophores that were created in the 
constructive phase and the program removed pharmacophores from the data structure 
which were not likely to be useful. Finally, the optimization was conducted using the 
well-known simulated annealing algorithm. The algorithm applies small perturbations to 
the pharmacophores created in the constructive and subtractive phases in an attempt to 
improve the score. All improvements and some detrimental steps based on a probability 
function are accepted and finally the highest scoring pharmacophores are exported.  
HypoGen allows a maximum of five features in pharmacophore generation. HBA, HBD, 
and HY were selected as features of our pharmacophore hypothesis. Ten hypotheses were 
generated for each set of conformers from the BEST method. The hypotheses generated 
were analyzed with regard to their correlation coefficients and the cost function values. 
The HypoGen module performs a fixed cost calculation which represents the simple 
model that fits all the data and a null cost calculation that assumes that there is no 
relationship in the data-set and that the experimental activities are normally distributed 
about their average value. A small range of the total hypotheses cost obtained for each of 
the hypotheses indicates homogeneity of the corresponding hypothesis and that the 
training set selected for the purpose of pharmacophore generation is adequate. Again, 
values of total cost close to those of fixed cost are indicative of the fact that the 
hypotheses generated are statistically robust. 
Validation of the obtained pharmacophore models was performed using a test set of 
CYP2D6 substrates. Pharmacophore model mapping in the testing set was done using the 
Feature Mapping module in DS 2.1. Assessment was made according to the coincidence 
rate of mapped molecules in the testing set. 
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2.2.2.3 Construction and Validation of QSAR Models of CYP2D6 Substrates 
The main objective of QSAR analysis is that the developed model should be robust 
enough to be capable of making accurate and reliable predictions of biological activities 
of new compounds. The module of Calculate Molecular Properties in DS 2.1 was applied 
to the calculation of relevant molecular properties with parameters set properly. The 
module of Create Multiple Linear Regression model was used to generate regressive 
equations. Initially we selected 24 CYP2D6 substrates to develop the QSAR models and 
then 5 substrates of CYP2D6 were finally used to construct the QSAR models. For the 
development of the QSAR models, the statistical technique used was Genetic function 
approximation (GFA). GFA technique was employed to generate a population of 
equations rather than one single equation for correlation between biological activity (Km 
in this study) and various physicochemical properties. GFA involves the combination of 
multivariate adaptive regression splines algorithm with genetic algorithm to evolve 
population of equations that best fit the training set data. It provides an error measure, 
called the lack of fit (LOF) score that automatically penalizes models with too many 
features. 
In addition, the module of Calculate Molecule Properties was used for the calculation of 
virtual Km values of CYP2D6 substrates. The QSAR models were validated by 
comparing the predicted and experimental Km values in the library (Table 2-3). 
2.2.2.4 Molecular Docking 
In the present study, we collected the crystal structure of CYP2D6 from Protein Data 
Bank (http://www.rcsb.org/pdb/, PDB ID: 2F9Q) and conducted a docking study for the 
substrates of CYP2D6 using the CDOCKER module in DS 2.1 with the CHARMM 
engine. The CDOCKER algorithm adopts a strategy involving the generation of several 
initial ligand orientations in the active site of target protein followed by molecular 
dynamics (MD)-based simulated annealing, and final refinement by energy minimization 
[206] . The annealing schedule engages a series of heating and cooling stages and is 
implemented as a set of scripts for the CHARMM package using its replica feature. 
The whole protein of 2F9Q was selected and hydrogen atoms were added to it. The pH of 
the protein was set in the range of 6.5-8.5. The water molecules in the picture of single 
crystal diffraction of CYP2D6 were removed with DS 2.1, and the ferrous ion in heme 
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was charged to coordinate with physiological state, and finally the protein was refined 
with CHARMM in DS 2.1. The active site of CYP2D6 was auto-searched with DS 2.1. 
The MD simulated annealing process was performed using a rigid protein and flexible 
ligand. The ligand-CYP2D6 interactions were computed from either GRID I, GRID II, or 
the full force field. A final minimization step was applied to each of the ligand‘s docking 
poses.  For ligand preparation, all the duplicate structures were removed and the options 
for ionization change, tautomer generation, isomer generation, Lipinski filter and 3D 
generator were set true. After refined with CHARMM, the compounds were docked into 
the protein. The docking was performed with consideration of electrostatic energy and 
van der Waals (vdW) force, which were softened at different levels during the docking 
process, but this softening is removed for the final minimization [206] .The grid origin 
was located at the center of the active site of CYP2D6 with a minimum of 21.0 Å or the 
largest ligand dimension +5.0 Å as the side length. A grid spacing of 0.5 Å was used. For 
each defined vdW or electrostatic probe, the interactions with all protein atoms were 
stored at these grid points. For ligand atoms located between grid points, a tri-linear 
interpolation was used to approximate the energies. A harmonic potential with the force 
constant of 300 kcal/mol was applied outside the grid boundary. 
Starting from the new ligand configuration, a set of 10 different orientations are randomly 
generated and docked into the protein (2F9Q), i.e. moved into the center of the grid. Once 
the randomized ligand has been docked into the active site, a MD simulation was run 
consisting of a heating phase from 300 K to 700 K with 2000 steps, followed by a cooling 
phase back to 300 K with 5,000 steps. Maximum bad pose number was 800. The energy 
threshold for vdW force was set at 300 K. Finally, we refined the simulation result by 
running a short energy minimization. The minimization consisted of 50 steps of steepest 
descent followed by up to 200 steps of conjugate-gradient using an energy tolerance of 
0.001 kcal/mol. In the end, we used the energy of binding as the scoring function to rank 
the docked ligands and returned the lowest energy structure as the solution to the docking 
trial. Twenty trials were run for each complex to ascertain the optimal number of trials 
that should constitute an attempt at docking. The top 10 docking poses saved for each 
compound were ranked according to their dock score function based on the total docking 
energy including the intramolecular energy for ligands and the ligand-protein interactions. 
The pose (conformation) having the highest dock score was selected and analyzed to 
investigate the type of interactions. Only the substrate and amino acid residues within 5.0 
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Å were allowed during the analysis. A docking without any output pose is considered as a 
failure.  
To validate the accuracy of the docking algorithm, a testing set of CYP2D6 substrates 
with trendence of experimental Km was subject to the assessment of consistency of their 
virtual and experimental activities.  
2.2.2.5 Virtual Mutation Study 
The Build Mutants protocol from the ―Protein modeling‖ module in DS 2.1 (Accelrys 
Software Inc., San Diego, CA) was applied for the substitution of residues in the active 
site of CYP2D6 (e.g. Asp301 with Glu, or Glu216 with Asp). A panel of mutants of 
CYP2D6 was generated using 2F9Q as the template. Energy minimization for 
optimization of residue geometry was applied to the mutant models using the algorithm 
of smart minimization until the gradient tolerance was satisfied (RMS Gradient ~0.1 
kcal/mol/Å). Bufuralol, debrisoquine, dextromethorphan, tramadol and sparteine were 
selected as the probe substrates in our docking studies with wild-type and mutated 
CYP2D6. Binding energy for the probes was calculated. Chemoffice2002 was applied for 
the generation of 3D structures of the probes, which were then refined with CHARMM in 
DS 2.1.  
2.3 Results 
2.3.1 Pharmacophore Models for CYP2D6 Substrates and Their Validation   
Calculated with the HypoGen algorithm in DS 2.1, ten hypotheses were generated for 
each set of conformers from the BEST method. Finally, a best pharmacophore model for 
CYP2D6 substrates was developed. The optimized pharmacophore derived from 20 
CYP2D6 substrates consisted of two hydrophobic features (HY1 and HY2) and one HBA 
feature (Figure. 2-1). The distance from HBA to HY1 and HY2 was 3.053 and 7.406 Å, 
respectively. The distance between HY1 and HY2 was 6.587 Å. The pharmacophore had 
a rank score of 62.94, directly hit 18 of 20 leads as indicated by the direct hit mark; none 
of the hits was partial as indicated by the partial hit mark, and the maximum fit value was 
three. For the pharmacophore assumptions about CYP2D6 substrates, 57 out of 75 could 
be mapped in the testing set with a relevance ratio (RR) of 76%.  
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2.3.2 QSAR Models for CYP2D6 Substrates and Their Validation 
The QSAR model generated from 24 CYP2D6 substrates gave a regressive equation of 
y=0.085x+82.824 with R
2
 = 0.085, where y is the sum of the number of aromatic ring and 
hydrogen bond donor and x is the experimentally observed Km value (Figure 2-2A). The 
QSAR model generated from 6 CYP2D6 substrates including antipyrine, 
diphenhydramine, progesterone, selegiline, acetaminophen and acetaminophen had a 
relationship of y=0.980x+2.829 with R
2
=0.980 (Figure 2-2B). When 24 CYP2D6 
substrates with experimentally determined Km were used to validate the two QSAR 
models, the prediction accuracy was generally poor (Table 2-3). 
2.3.3 Binding Modes of Substrates with Wild-type and Mutated CYP2D6 
2.3.3.1 Validation of Molecular Docking Algorithm 
Perphenazine, tropisetron, diltiazem, selegiline, and acetaminophen were selected as 
testing set of CYP2D6 substrates. Their experimental active values (EAV:Km) were 1.9, 
3.9, 5, 56, and 440 respectively, which generated a trend of y=92.83x-177.13 with 
R
2
=0.5926. Their virtual active values (VAV) were 50.174, 40.41, 30.768, 29.282, and 
26.698 respectively, which developed a trend of y=-5.808x+52.89 with R
2
=0.8925. VAV 
represented the binding energy (CIE: CDOCKER interaction energy) calculated from 
scoring function of CDOCKER algorithm (Figure 2-3). 
2.3.3.2 Selection of Most Appropriate Active Site of CYP2D6 
A total of 19 sites with diverse location, volume and point count were found after 
auto-search with DS 2.1 based on the crystal structure of CYP2D6 (2F9Q) resolved by 
Rowland et al. [71] (Table 2-6A). Among them, site 2 showed closest structural features 
compared to that of 2F9Q (Figure 2-2A). Amino acid residues in site 2 within 5 Å to the 
center included Ile106, Leu110, Phe112, Phe120, Ala122, Leu121, Leu213, Lys214, 
Glu216, Ser217, Gln244, Phe247, Leu248, Ile297, Ala300, Asp301, Ala305, Val308, 
Thr309, Val370, Gly373, Met374, Ser304, Ala482, Phe483, and Leu484. Site 2 also had 
the shortest distance from heme with a shape of ―right foot‖. Thus, site 2 was selected as 
the active site in our docking study (Figure 2-2B).   
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A well defined cavity above the heme in site 2 was described as a shape of ―right foot‖. 
The "heel" lied above the heme, toward the propionate side. The foot "arch" was formed 
by the side chain of Phe120. The "ball" of the foot was bordered by residues from the 
B'-C loop and the N-terminal end of helix I. Additional residues in helix I lined the whole 
length of the right side of the foot. The "toe" area was bordered by residues from the B' 
and G helices. The upper part of the foot was bordered by residues in the F helix, which 
was perpendicular to the foot axis. The back of the heel was shaped by residues in the 
loop following helix K. The "ankle" region marked a narrowing of the cavity and leads 
up to protein outside and the cavity entrance. It was bordered by residues of helix F at the 
front and residues of helix I on the right, with the back of the ankle being defined entirely 
by residues from the loop between the strands of -sheet 4. The back left side and toe 
areas of the cavity are strongly hydrophobic in character. The upper part and right side of 
the foot contained several important hydrophilic side chains including Glu216 in helix F, 
Gln244 in helix G, and Ser304 in helix I. Asp301 in helix I lied under the ball of the foot. 
Above the ankle region, the cavity entrance was bordered by a number of long 
charged/hydrophilic side chains from F helix F (Gln210, Glu211, Lys214, and Arg221) 
and residues from the region between the two strands of -sheet 4 (side chains of Ala482 
and Ser486 and main chain atoms of Val485), with the side chains of Asp179 of helix E 
and Thr312 of helix I also in the vicinity.   
2.3.3.3 Binding Modes of Substrates to CYP2D6 
Totally, 117 out of 120 substrates could be docked into the active site cavity of CYP2D6 
in our docking study using the CDOCKER algorithm. As shown in Table 2-5, the binding 
patterns of 117 substrates to CYP2D6 were presented according to the formation of 
hydrogen bonds, π-π interactions, and residues involved with the order of CDOCKER 
interaction energy (CIE, i.e. docking score). Among the 117 substrates, 41 of them 
formed hydrogen bonds with 1-4 residues of the active site of CYP2D6 (35.04%). A 
slightly higher number of these substrates (54, 46.15%) displayed - interaction with 
CYP2D6, predominantly with Phe120 (53/54), while only carvedilol formed - 
interaction with Phe483. 
There were 10 residues in the active site of CYP2D6 involved in hydrogen bond 
formation with 41 substrates (Table 2-5). These included Leu213, Lys214, Glu216, 
Ser217, Gln244, Asp301, Ser304, Ala305, Phe483, and Phe484, with distinct roles in 
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hydrogen bond formation for different substrates. Glu216 formed hydrogen bond with 13 
substrates, including aripiprazole, bisoprolol, bunitrolol, debrisoquine, flecainide, 
MAMC, oxatomide, perphenazine, phenformin, timolol, and vernakalant. Ser304 also 
interacted with 13 substrates via hydrogen bond formation, including bufuralol, 
dolasetron, donepezil, fluoxetine, fluvoxamine, gepirone, ibogaine, metoprolol, 
phenformin, propafenone, propranolol, and verapamil. Ala305 formed hydrogen bond 
with 12 substrates, including bufuralol, dihydrocodeine, E-doxepin, fluvoxamine, 
metoprolol, ondansetron, oxymorphone, pranidipine, procainamide, propranolol, timolol, 
and tramadol. In addition, Asp301 formed hydrogen bond with bufuralol, estrone, 
metoprolol, phenformin, and terfenadine, and Phe483 formed hydrogen bond with 
allopregnanolone, flecainide, imatinib, and monocrotaline. Ser217 formed hydrogen bond 
with flecainide and halofantrine, and Lys214 formed hydrogen bond with fluvastatin and 
iloperidone. Moreover, Gln244 formed hydrogen bond with perphenazine, and Leu484 
formed hydrogen bond with flecainide. These results reflect the critical role of Glu216, 
Ser304, Asp301, Phe483, Ser217, Lys214 and Gln244 in substrate binding and 
recognition. 
2.3.3.4 Effect of Virtual Mutations on the Topology of CYP2D6 (Asp301Glu 
and Glu216Asp as Cases) 
After substitution of Asp301 with Glu or Glu216 with Asp, remarkable geometric 
changes in the active site cavity of CYP2D6 were observed. First of all, total 19 sites 
were found in wild-type CYP2D6, but 17 sites and 20 sites could be searched for 
Asp301Glu and Glu216Asp, respectively (Table 2-6B,C). Secondly, site 1 in Asp301Glu 
and site 2 in Glu216Asp shared a similar topology and ―foot‖ shape with site 2 in 
wild-type CYP2D6 (Figure 2-2 C,D), but with different active site volumes: 320.00 Å
3
 
for site 2 in the wild-type, 713.63 Å
3 
for site 1 in Asp301Glu, and 327.75 Å
3 
for site 2 in 
Glu216Asp (Table 2-6 B,C). Thirdly, the interactions between Asp301 or Glu216 with 
neighboring residues after mutation varied considerably. In the wild-type CYP2D6, 
Asp301 formed four hydrogen bonds with Val119, Phe120, Ala305, and Ile297 each. 
After substitution of Asp301 with Glu, no hydrogen bond formation was found between 
Glu301 with proximal residues. On the other hand, Glu216 only formed hydrogen bond 
each with neighboring Gly212 and Leu220 in the wild-type enzyme. Substitution of 
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Glu216 with Asp resulted in five hydrogen bonds with neighboring residues including 
Gly212, Phe219, Leu220, and Gln244 (Figure 2-5). 
2.3.3.5 Effect of Virtual Mutation on the Binding Mode of Probe Substrates to 
Wild-type and Mutant CYP2D6  
To further explore the effects of mutations of residues in the active site of CYP2D6 on 
the binding modes of substrates, a series of mutants (n=28, Table 2-7) were generated 
using the Build Mutants module in DS 2.1 and five probe substrates of CYP2D6 
including bufuralol, tramadol, sparteine, debrisoquine and dextromethorphan were 
docked into the active sites in comparison with the wild-type protein. The mutants 
generated included Ile106Glu, Leu110Phe, Phe112Ala, Gln117Trp, Gly118Trp 
Val119Met, Phe120Ala, Leu121Trp, Ala122Ser, Leu213Glu, Glu216Asp, Ser217Phe, 
Leu220Asp, Gln244Phe, Phe247Gln, Leu248Asp, Ile297Leu, Ala300Glu, Asp301Glu, 
Ser304Ala, Ala305Asp, Val308Phe, Thr309Val, Val370Phe, Gly373Trp, Met374Val, 
Phe483Ala, and Leu484Asp (Table 2-7). Most of these substitutions were non-conserved 
mutations, with changes from polar to non-polar residue or vice versa, from aromatic to 
non-aromatic residue or vice versa, and from hydrogen-bond forming to non-hydrogen- 
bind forming residue or vice versa. 
Our further docking studies demonstrated remarkable effects of above mutations on the 
binding of five probe substrates including bufuralol, tramadol, sparteine, 
dextromethorphan, and debrisoquine to the active site of CYP2D6 (Table 2-7). Three 
mutations including Asp301Glu, Thr309Val and Met374Val caused failure of docking of 
dextromethorphan. Tramadol and sparteine could not be docked into the active site in 
CYP2D6 with the mutation of Thr309Val. These findings indicated the critical role of 
these three residues in the binding of substrates to CYP2D6. 
Most mutants in our study displayed considerably altered interactions with neighboring 
residues with regard to hydrogen-bond forming capacity and - stacking (Table 2-7). 
The impact on the binding modes was dependent on the type of mutation and the 
physico-chemical properties of the probes. 
The probe substrate of CYP2D6 bufuralol was able to form hydrogen bonds with 
proximal residues Asp301, Ser304, and Ala305 in the active site. Different mutations 
showed differential effects on the formation of hydrogen bonds of bufuralol with these 
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three residues. The Leu110Phe, Gln117Trp, Gly118Trp, Leu121Trp, Glu216Asp, 
Ser217Phe, Leu220Asp, Glu244Phe, Phe247Gln, Ile297Leu, Ala300Gln, Ala305Asp, 
Val308Phe, Thr309Val, Val370Phe, Gly373Trp, Met374Val, and Phe483Ala mutations 
eliminated the hydrogen bond of bufuralol with Asp301. In the wild-type enzyme, 
bufuralol formed a hydrogen bond with Ala304, but this hydrogen bond disappeared in 
mutants Gly118Trp, Leu121Trp, Ala122Ser, Leu220Asp, Glu244Phe, Ala300Glu, 
Asp301Glu, Ser304Ala, Ala305Asp, Val308Phe, Val370Phe, an Met374Val. In addition, 
many mutations also abolished the hydrogen bond of bufuralol with Ala305. These 
included Ile106Gln, Leu110Phe, Phe112Ala, Gln117Trp, Gly118Trp, Phe120Ala, 
Leu121Trp, Ala122Ser, Glu216Asp, Ser217Phe, Leu220Asp, Glu244Phe, Phe247Gln, 
Leu248Asp, Ala300Glu, Asp301Glu, Ser304Ala, Ala305Asp, Thr309Val, Val370Phe, 
Gly373Trp, Met374Val, and Phe483Ala. Ten mutations completely abolished the 
hydrogen-bond forming capacity of bufuralol with all three residues, including 
Gly118Trp, Leu121Trp, Ser217Phe, Leu220Asp, Glu244Phe, Ala305Asp, Val308Phe, 
Val370Phe, Met374Val, and Phe483Ala.  
On the other hand, many mutations conferred bufuralol the ability to form new hydrogen 
bonds with other residues rather than Asp301, Ala304, and Ala305. For example, ten 
mutations led to hydrogen bond formation between bufuralol with Glu216, including 
Ile106Gln, Leu110Phe, Gln117Trp, Val119Met, Phe120Ala, Leu213Glu, Glu244Phe, 
Phe247Gln, Phe483Ala, and Leu484Asp. Bufuralol formed new hydrogen bond(s) with 
Ser217 in Leu121Trp, Arg101 and Phe120 in Ala122Ser, Gln244 in Ser217Phe, Ser217, 
Gly273, and Phe483 in Leu220Asp, Lys245 in Phe247Gln, Val298 and Val299 in 
Asp301Glu, Val299 in Ser304Ala, Leu484 in Ala305Asp, Ser217 in Val308Phe, Ala209 
in Thr309Val, and Leu213 and Ser217 in Val370Phe. 
Different mutations showed distinct effects on the binding of probe substrates to the 
mutated CYP2D6 proteins compared to that to the wild-type enzyme (Table 2-7). With 
regard to hydrogen bond formation and - stacking interaction, the mutations may cause 
their loss or forming new interaction(s) with neighboring residues. Thus, mutations in 
these residues are predicted to affect substrate binding affinity and metabolic activity.   
In our study, we built the Phe120Ala mutation where the aromatic residue Phe120 was 
replaced by a non-aromatic residue Ala. Bufuralol, tramadol and dextromethorphan 
formed hydrogen bond with Ser304 in the Phe120Ala mutant, and the hydrogen bond 
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formation of Glu216 with debrisoquine was not affected. Glu216 was able to form a new 
hydrogen bond with bufuralol in the mutant, which was not seen in the wild-type enzyme. 
Additional hydrogen bond formation capacity of the mutant may suggest enhanced 
binding affinity to substrates and metabolic activity. 
In the Glu216Asp mutant, bufuralol formed hydrogen bonds with Asp216 and Ser304, 
but not with Asp301 and Ala305 as seen in the wild-type (Table 2-7). This mutation 
abolished the hydrogen bond between tramadol with Ala305. However, it formed a new 
hydrogen bond between debrisoquine with Ser304 in addition to the original one with 
Asp216. Dextromethorphan formed a new - stacking with Phe120 in the Glu216Asp 
mutant, which was not seen in the wild-type protein. 
Ile297Leu is a naturally occurring mutation (CYP2D6*24) with a low frequency in 
humans[207]. In our docking study, we found that this mutant lost hydrogen bond 
between bufuralol and Asp301, but debrisoquine formed a new hydrogen bond with 
Ser304 while the hydrogen bond formation with Glu216 was not affected. Debrisoquine 
also formed a - stacking with Phe120 in the Ile297Leu mutant which was not seen in 
the wild-type enzyme. In addition, dextromethorphan enhanced its binding with the 
mutated CYP2D6 with Ile297Leu by forming two new hydrogen bonds with Ser304 and 
Ala305 
Substitution of Asp301 with Glu also significantly changed the binding mode of bufuralol 
to CYP2D6 (Table 2-7). Bufuralol formed several hydrogen bonds with Asp301, Ser304 
and Ala305, and one π-π stacking with Phe120 in the wild-type enzyme. In the 
Asp301Glu mutant, bufuralol formed two new hydrogen bonds with Val298 and Val299 
in addition to that original one with Asp301, and no - stacking was found. Tramadol 
formed a hydrogen bond with Ala305 in the wild-type enzyme, but it disappeared in the 
Asp301Glu mutant. Debrisoquine also formed a hydrogen bond with Glu216 in the 
wild-type enzyme, but this hydrogen bond was abolished in the Asp301Glu mutant where 
two new hydrogen bonds were formed between debrisoquine with Val298 and Val299. 
Moreover, dextromethorphan was readily docked into the active site of wild-type 
CYP2D6, but it failed to be docked into the active site in the Asp301Glu mutant. The 
conformational binding of bufuralol to wild-type and mutated CYP2D6 was statistically 
different with a root mean square deviation (RMSD) of 11.093.  
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2.4 Discussion 
Computational modeling has become an efficient approach for the investigation of 
ligand-CYP interactions at atomic levels [87, 210, 211]. For the prediction of spatial 
arrangement features of molecular structures which behave as CYP substrates and/or 
inhibitors, pharmacophore model, which is defined as the common characteristics that a 
set of compounds posses, shares a reputation with its high throughput screening in the 
ligand-based design of biologically active molecules [212-214]. Furthermore, the 
mathematical relationship between structural attributes and activities of CYP 
substrates/inhibitors can be described with QSAR [215, 216]. The application of such 
mathematical relationship to predict the target property of interest for a variety of 
potential CYP substrates prior to, or in lieu of, expensive and labor-intensive 
experimental work has been efficient in nature. On the other hand, intermolecular events 
such as binding modes and binding energy and intramolecular events such as folding and 
conformational changes of CYPs can be easily and clearly revealed via molecular 
docking [217-219]. Therefore, computational modeling techniques have been widely 
used in drug development involving CYPs [211, 220, 221]. In this study, we employed 
above three approaches to examine the interactions of substrates and human CYP2D6 at 
molecular levels. The enzyme was subject to virtue mutations of critical residues in the 
active site of CYP2D6 and consequently the changes in binding modes and binding 
energy were determined.  
Ligand-CYP binding is determined by the balance of different energetic contributions 
mainly including hydrogen-bonding, aromatic stacking interaction, van der Waals‘, and 
electrostatic interaction [198]. In this study, we have chosen hydrogen bonding and 
aromatic stacking interaction as the major parameters determined in molecular docking. 
Hydrogen bonds are specific, short-range, directional nonbonded interactions, which are 
predominantly electrostatic in character and are key signatures of secondary elements in 
CYPs and other proteins [199]. The number of hydrogen bonds in a drug molecule is 
limited for requiring polarity for absorption and permeation. The Lipinski rule-of-five has 
suggested that compounds with more than five hydrogen bond donors or more than 10 
hydrogen bond acceptors are more likely to absorb or permeate poorly [200]. Aromatic 
stacking interaction, also called phenyl stacking or π-π interaction, is a common 
phenomenon in organic chemistry that affected aromatic compounds and functional 
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groups, which acts strongly on flat polycyclic aromatic hydrocarbons for many 
delocalized π-electrons [201]. Thus, hydrogen bond formation and π-π interaction are two 
main parameters to describe molecular interaction. 
We have developed one optimized pharmacophore model from 20 substrates of CYP2D6 
when hydrogen bond acceptor, hydrogen bond donor, hydrophobic region were selected 
as features of hypothesis. This model consisted of two hydrophobic features and one 
hydrogen bond acceptor feature, giving an RR of 76% when a validation set of substrates 
was tested. Our pharmacophore model is consistent with those of CYP2D6 substrates 
reported previously where different sets of substrates are used in model construction [72, 
74, 76, 115, 123, 141, 146, 149, 154, 161, 165].   
To explore the determinants of the binding affinity of CYP2D6 substrates, we further 
constructed two QSAR models. The relatively high R
2
 values implicated the degree of 
satisfaction of linear relationship and a reliable predictive potential. However, the two 
models did not result in good prediction of the validation set of substrates. The reasons 
for this may be due to: a) the choice of training set of CYP2D6 substrates was on a 
random basis; b) the binding affinity (determined as the Km values) of substrates with 
CYP2D6 was determined by a number of factors and many of them were not included in 
our QSAR model construction. 
To further explore the molecular factors that determine the binding affinity and binding 
energy of substrates with CYP2D6, we conducted detailed molecular docking of a large 
number of substrates (n=120) to the active site of CYP2D6 using the CDOCKER module 
in DS 2.1. CDOCKER is an implementation of a CHARMM based docking tool using a 
rigid receptor where many of the steps in protocol use a non-bond energy grid, rather than 
the full potential energy terms usually used by CHARMM for better performance. Our 
docking study demonstrated that 117 out of 120 substrates (97.50%) could be docked into 
the active site of CYP2D6. Among them, 41 out of 117 substrates (35.04%) formed 
hydrogen bonds with the active site residues and 53 (45.30%) substrates formed a strong 
- interaction with Phe120 (53/54), with only carvedilol forming - interaction with 
Phe483. The active site residues involving hydrogen bond formation with substrates 
included Leu213, Lys214, Glu216, Ser217, Gln244, Asp301, Ser304, Ala305, Phe483, 
and Phe484. Therefore, these 10 residues play an important role in substrate binding and 
consequently metabolic activity towards the substrates. 
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In this study, the CDOCKER algorithm was further applied to study the impact of 
mutations of 28 active site residues (mostly non-conserved) in CYP2D6 on substrate 
binding modes using five probe substrates including bufuralol, debrisoquine, 
dextromethorphan, sparteine, and tramadol. All single mutations of the residues altered 
the hydrogen bond formation and/or aromatic interactions, depending on the probe used 
in molecular docking. Apparent changes of the binding modes have been observed with 
the Phe120Ile, Glu216Asp, and Asp301Glu mutants. For example, bufuralol formed 
hydrogen bonds with Asp301, Ser304 and Ala305, and one π-π interaction with Phe120 
in the wild-type CYP2D6. Bufuralol formed hydrogen bond with Ser304 only in the 
Phe120Ala mutant. Glu216 was able to form a new hydrogen bond with bufuralol in the 
mutant, which was not observed in the wild-type CYP2D6. In the Glu216Asp mutant, 
bufuralol formed hydrogen bonds with Asp216 and Ser304, but not with Asp301 and 
Ala305 as seen in the wild-type protein. In the Asp301Glu mutant, bufuralol formed two 
new hydrogen bonds with Val298 and Val299, phenyl stacking with Phe120 was 
abolished. These results are in agreement with previous observations from site-directed 
mutagenesis studies on Phe120, Glu216 and Asp301. 
Consistent with our findings in the present study, the role of Phe120 and Phe483 of 
CYP2D6 in substrate binding and catalytic activity has been documented in numerous 
previous site-directed mutation studies. Phe120Ile is a naturally occurring mutation 
present in CYP2D6*53. The mutation Phe120Ile can be found in a small percentage of 
the Southeast Asian population [222]. Individuals harboring CYP2D6*53 might exhibit 
an ultrafast phenotype. The aromatic residues Phe120, Phe481 and Phe483 in the active 
site of CYP2D6 have been proposed to play an important role in substrate binding using 
homology modeling and docking studies [78, 84, 154, 163]. Flanagan
 
et al. [169] 
revealed that the relative rates of O- vs N-demethylation
 
of dextromethorphan were 
altered by the Phe120Ala mutation, although the removal of the Phe120 aromatic side 
chain by substitution with Ala displayed negligible effect on the Km for either 
1‘-hydroxylation of bufuralol or the O-demethylation of dextromethorphan. Replacement 
of Phe120 with Leu, Ser or His caused 10- to 32-fold increase in Km for 
dextromethorphan O-demethylation (wild-type vs Phe120Leu, Phe120Ser or Phe120His: 
1: 32, 10 and 16 M, respectively), whereas only the His substitution caused a 2.5-fold 
increase in Km for bufuralol 1‘-hydroxylation [169]. Phe120 replacement produced a 
greater effect on Km values for dextromethorphan O-demethylation than for bufuralol 1‘- 
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hydroxylation, indicating that Phe120 is more important in dextromethorphan than in 
bufuralol binding.  
A number of mutation studies have demonstrated a critical role of Asp301 and Glu216 in 
substrate recognition, catalytic activity, and expression and stability of the protein. Ellis 
et al. [74] reported that the level of holoprotein (heme-containing) expression of the 
Asp301Ala mutant was only 10% of the level of the other mutants (8 vs 49 pmol/mg 
protein) and no holoprotein was detectable in microsomes from the Asp301 mutant[74]. 
They also observed perturbed structural integrity of the active site to varying degrees 
when Asp301 was replaced with a neutral residue (Asn, Ala, or Gly). Replacement of the 
negatively charged residue 301 with a neutral side chain (Asn, Ala or Gly) resulted in 
substantial decreases in the binding capacity of debrisoquine (loss of type I spectrum) and 
quinidine (1000-fold greater Kd value). Replacement of Asp301 with neutral residues in 
yeast-expressed CYP2D6 almost abolished (1-2% of the wild-type) catalytic activity 
towards debrisoquine and racemic metoprolol, two classical substrates of CYP2D6. 
These findings from the study by Ellis et al. [74] have demonstrated that substitution of 
Asp301 with neutral amino acids (e.g. Asn, Ala, or Gly), differing in size and polarity, 
results in marked reductions in enzyme catalytic activity. The attenuation of enzyme 
activity had been proposed to be due to the disruption of an electrostatic bond between 
Asp301 and the substrate. Substitution of the Asp301 carboxylate residue with a similar 
functional moiety (Glu), on the other hand, did not significantly affect the catalytic 
competence of the enzyme, although a subtle change in the regio-selective oxidation of 
metoprolol and a 10-fold reduction in quinidine binding have been observed. The study 
has provided initial evidence that Asp301 may serve as a critical anionic charge to dock 
the basic nitrogen atom of ligands of CYP2D6 and/or to maintain the integrity of the 
active site. 
Site-directed mutagenesis experiments have provided further evidence that Asp301 is the 
negatively charged amino acid responsible for binding to the nitrogen atom of substrate 
molecules [151]. Mackman and colleagues [151] reported that substitution of Asp301 
with an Asn or Gly, which removed the negatively charged side chain, suppressed 
migration of the aryl groups to pyrrole ring B without impairing migration to pyrrole ring 
A and virtually abolished catalytic activity [151]. Hanna et al. [153] found that 
substitution of Asp301 with Glu, Asn, Ser or Gly significantly decreased CYP2D6- 
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mediated bufuralol 1‘-hydroxylation. The proposed key role of Glu216 and Asp301 by 
homology modeling studies was further confirmed by a series of site-directed 
mutagenesis experiments [80]. Conservative replacements of Glu216 or
 
Asp301 with Asp 
and Glu, respectively, resulted in small (2-6-fold)
 
increases in Km values and had 
negligible effects on turnover rate for both bufuralol
 
and dextromethorphan [80]. 
However, replacement of Asp301 by Asn or Gln led to a 130- to 145-fold increase in Km 
values for bufuralol; the increase was 80-fold for the Asp301Gln
 
mutant, but as much as 
1,400-fold for Asp301Asn for dextromethorphan [80]. Substitution of Glu216 with 
neutral residues such as Gln, Phe,
 
or Leu significantly decreased the Km values by 100- to 
170-fold for bufuralol 1‘-hydroxylation; smaller effect (10- to 25-fold increase in Km) 
was observed with dextromethorphan O-demethylation. The mutation of Glu216 altered 
the substrate specificity to such an extent that the mutant protein catalyzed testosterone 
6-hydroxylation [80] which is typically mediated by CYP3A4 [223]. Furthermore, the 
Glu216Ala/Lys and Asp301Gln mutants with removal of the negative charge
 
from either 
the 216 or 301 positions catalyzed the metabolism of atypical CYP2D6 substrates, 
including anionic compounds such as diclofenac and tolbutamide that lack a basic 
nitrogen atom and are used as model substrates of CYP2C9 [80]. In addition, Guengerich 
et al. [205] found that replacement of Glu216 with a residue (e.g. Gln, Ala, His or Asn) 
other than Asp significantly decreased the binding of quinidine, bufuralol, propranolol, 
debrisoquine, MPTP, encainide, amitriptyline and sparteine. Catalytic activity towards 
bufuralol (1‘-hydroxylation) and 4-methoxyphenethylamine (O-demethylation) was 
significantly reduced or almost abolished by neutral or basic mutations at Glu216, to the 
same extent as the substitution of Asp301 with Asn. Overall, these results demonstrate an 
electrostatic interaction of amine substrates with Glu216 and Asp301 and at least another 
residue(s). 
Ser304, a neutral, polar residue located in helix I of CYP2D6, is located in the active site 
of CYP2D6 [71]. This residue may play a role in the binding of many substrates as 
shown in out docking studies. However, site-directed mutagenesis studies suggest that 
this residue is not a critical one as Asp301. The metabolism of -hydroxymetoprolol and 
4-hydroxydebrisoquine by the wild-type enzyme and Ser304Ala mutant was comparable 
[224]. Replacement of Ser304 with Ala (a non-polar residue without a hydroxyl group) 
did not change the enantio- and region-selective oxidation towards debrisoquine, 
metoprolol and propranolol compared to the wild-type protein [224]. However, the 
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expression level of holoprotein in the Asp301Gly/Ser304Ala double mutant was 
significantly lower than that in the wild-type and the Ser304Ala mutant, while 
holoprotein was not detected with the Asp301Ser/Ser304Asp double mutant [224]. The 
Asp301Gly/Ser304Ala double mutant also showed reduced activity to debrisoquine. 
Therefore, Ser304 and Asp301 may interact in helix I to facilitate proper protein folding 
and heme incorporation. 
In conclusion, we present our findings upon construction and validation of 
comprehensive computational models of CYP2D6 with the hope that it provides further 
insights into the factors that determining the binding modes of substrates to CYP2D6 and 
thus allows us to accurately predict the potential of compounds as CYP2D6 substrates. 
Functional benchmarking studies are ongoing at our laboratory to validate our major 
findings from these computational studies on CYP2D6. 
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Table 2-1: CYP2D6 Substrates as the Training Set for Pharmacophore Development 
Substrate Structure Substrate  Structure  
Name: 
Sparteine 
MF
1
: 
C31H90N2 
MW
2
: 
491.1 
 
 
Name: 
Perphenazine 
MF: 
C21H26N3OSCl 
MW: 
404.0 
 
 
 
Name: 
Clomipramine 
MF: 
C19H23N2Cl 
MW: 
314.9 
 
 
Name: 
Risperidone 
MF:C23H27N4O2F 
MW:410.5 
 
 
 
 
Name: 
E-doxepin 
MF:  
C19H21NO 
MW:  
279.4 
 
 
Name: 
Fluvoxamine 
MF: 
C15H21N2O2F3 
MW: 
318.3 
 
 
 
 
Name: 
Thioridazine 
MF: 
C21H26N2S2 
MW: 
370.6 
 
 
 
Name: 
Zuclopenthixol 
MF: 
C22H25N2OSCl 
MW: 
401.0 
 
 
 
Name: 
Paroxetine 
MF: 
C19H20NO3F 
MW: 
329.4 
 
 
 
Name: 
Aripiprazole 
MF: 
C23H27N3O2Cl2 
MW: 
448.4 
 
 
 
 
 
Name: 
Dihydrocodeine 
MF: 
C18H21NO3 
MW: 
299.4 
 
 
 
Name: 
Prasugrel 
MF: 
C20H20NO3FS 
MW: 
373.4 
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Name: 
Chlorpromazine 
MF: 
C17H19N2SCl 
MW:318.9 
 
 
 
Name: 
Bisoprolol 
MF: 
C18H31NO4 
MW: 
325.5 
 
 
 
Name: 
Clozapine 
MF: 
C18H19N4Cl 
MW:326.8 
 
 
 
Name: 
Carvedilol 
MF: 
C24H26N2O4 
MW: 
406.5 
 
 
Name: 
Propranolol 
MF: 
C15H19NO2 
MW: 
245.3 
 
 
 
Name: 
Iloperidone 
MF: 
C24H27N2O4F 
MW: 
426.5 
 
 
 
Name: 
Olanzapine 
MF: 
C17H20N4S 
MW:312.4 
 
 
 
Name: 
Pranidipine 
MF: 
C25H24N2O6 
MW: 
448.5 
 
 
 
Note: 
1  
MF: molecular formula 
2  
MW: molecular weight 
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Table 2-2: 75 Substrates of CYP2D6 as the Testing Set for Pharmacophore Development 
Substrate Structure Substrate Structure  
Name:  
Imipramine 
MF:  
C19H24N2  
MW:  
280.415 
 
 
 
Name: 
Azelastine 
MF： 
C22H24N3OCl 
MW： 
381.908 
 
 
Name:  
Maprotiline  
MF: 
C21 H27 N 
MW:  
293.454 
 
 
 
Name： 
Citalopram 
MF： 
C20H21N2OF 
MW： 
324.4 
 
 
 
Name： 
Trimipramine 
MF： 
C20H26N2 
MW： 
294.442 
 
 
 
Name: 
Cinnarizine 
MF： 
C26H28N2 
MW： 
368.524 
 
 
Name: 
Chlorpheniramine 
MF： 
C16H19N2Cl 
MW： 
274.795 
 
 
 
Name: 
Flunarizine 
MF： 
C26H26N2F2 
MW： 
404.504 
 
 
 
Name： 
Sertraline 
MF： 
C17H17NCl2 
MW： 
306.236 
 
 
 
Name： 
Gepirone 
MF： 
C19H29N5O2 
MW： 
359.476 
 
 
 
Name： 
Mianserin 
MF： 
C18H20N2 
MW： 
264.372 
 
 
Name: 
Oxatomide 
MF： 
C27H30N4O 
MW： 
426.565 
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Name： 
Mirtazapine 
MF： 
C18H20N2 
MW： 
264.372 
 
 
 
Name: 
terfenadine 
MF： 
C32H41NO2 
MW： 
471.687 
 
 
 
Name： 
Venlafaxine 
MF： 
C17H27NO2 
MW： 
277.41 
 
 
 
Name: 
Indinavir 
MF： 
C36H47N5O4 
MW： 
613.807 
 
 
 
Name： 
Duloxetine 
MF： 
C18H19NOS 
MW： 
297.423 
 
 
 
Name: 
Ritonavir 
MF： 
C37H48N6O5S2 
MW： 
720.965 
 
 
 
Name: 
Loratadine 
MF： 
C22H23N2O2Cl 
MW： 
382.893 
 
 
Name: 
Saquinavir 
MF： 
C38H50N6O5 
MW： 
670.86 
 
 
 
Name： 
Haloperidol 
MF： 
C21H23NO2FCl 
MW： 
375.873 
 
 
 
Name: 
Delavirdine 
MF： 
C22H28N6O3S 
MW： 
456.574 
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Name: 
Nevirapine 
MF： 
C15H14N4O 
MW： 
266.305 
 
 
 
Name： 
Hydrocodone 
MF： 
C18H21NO3 
MW： 
299.373 
 
 
 
Name： 
Methadone 
MF： 
C21H27NO 
MW： 
309.454 
 
 
Name： 
Dolasetron 
MF： 
C19H20N2O3 
MW： 
324.383 
 
 
 
 
Name: 
Amodiaquine 
MF： 
C20H22N3OCl 
MW： 
355.87 
 
 
Name: 
Chloroquine 
MF： 
C18H26N3Cl 
MW： 
319.88 
 
 
 
Name： 
Ezlopitant 
MF： 
C31H38N2O 
MW： 
454.659 
 
 
 
Name: 
Halofantrine 
MF： 
C26H30NOF3Cl2 
MW： 
500.433 
 
 
Name： 
Ondansetron 
MF： 
C18H19N3O 
MW： 
293.371 
 
 
Name: 
Fluvastatin 
MF： 
C24H26NO4F 
MW： 
411.477 
 
 
 
Name： 
Metoclopramide 
MF： 
C14H24N3O2Cl 
MW： 
301.82 
 
 
 
Name： 
Donepezil 
MF： 
C24H29NO3 
MW： 
379.503 
 
 
Name： 
Almotriptan 
MF： 
C17H25N3O2S 
MW： 
335.474 
 
 
Name: 
Indomethacin 
MF： 
C18H14NO4Cl 
MW： 
343.77 
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Name： 
Tacrine 
MF： 
C13H14N2 
MW： 
198.269 
 
 
 
Name: 
Phenformin 
MF： 
C10H15N5 
MW： 
205.265 
 
 
Name: 
Tolterodine 
MF： 
C22H31NO 
MW： 
325.497 
 
 
 
Name: 
Tamoxifen 
MF： 
C26H29NO 
MW： 
371.525 
 
 
 
Name:  
Galantamine 
MF： 
C17H21NO3 
MW： 
287.362 
 
 
Name: 
Enclomifene 
MF： 
C26H28NOCl 
MW： 
405.97 
 
 
 
Name: 
Methamphetamine 
MF： 
C10H15N 
MW： 
149.237 
 
 
Name: 
Sildenafil 
MF： 
C22H30 N6O4S 
MW： 
474.59 
 
 
 
Name:  
Bicifadine 
MF： 
C12H15N 
MW： 
173.259 
 
 
Name: 
Imatinib 
MF： 
C29H33N7O 
MW： 
495.632 
 
 
 
Name: 
Perhexiline 
MF： 
C19H35N 
MW： 
277.496 
 
 
 
Name:  
Nicergoline 
MF： 
C24H26N3O3Br 
MW： 
484.397 
 
 
 
Name: 
Aprindine 
MF： 
C22H30N2 
MW： 
322.496 
 
 
 
Name: 
MDMA 
MF： 
C11H15NO2 
MW： 
193.248 
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Name: 
Cibenzoline 
MF： 
C18H18N2 
MW： 
262.356 
 
 
 
Name: 
Harmine 
MF： 
C13H12N2O 
MW： 
212.253 
 
 
Name: 
Pinoline 
MF： 
C12H16N2O 
MW： 
204.274 
 
 
 
Name: 
Encainide 
MF： 
C22H28N2O2 
MW： 
352.48 
 
 
 
Name: 
MPBP 
MF： 
C15H21NO 
MW： 
231.34 
 
 
Name: 
Flecainide 
MF： 
C17H20N2O3F6 
MW： 
414.349 
 
 
 
Name: 
Lidocaine 
MF： 
C14H22N2O 
MW： 
234.344 
 
 
 
Name: 
MPPP 
MF： 
C14H19NO 
MW： 
217.313 
 
 
 
Name: 
Mexiletine 
MF： 
C11H17NO 
MW： 
179.264 
 
 
Name: 
Procainamide 
MF： 
C12H21N3O 
MW： 
223.321 
 
 
Name: 
5-MeO-DMT 
MF： 
C13H18N2O 
MW： 
218.301 
 
 
 
Name: 
5-MeO-DIPT 
MF： 
C17H26N2O 
MW： 
274.409 
 
 
 
Name: 
Propafenone 
MF： 
C21H27NO3 
MW： 
341.454 
 
 
 
Name: 
Vernakalant 
MF： 
C20H31NO4 
MW： 
349.475 
 
 
 
Name: 
MAMC 
MF： 
C11H13NO3 
MW： 
207.232 
 
 
Name: 
Ibogaine 
MF： 
C20H28N2O 
MW： 
312.458 
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Name: 
Ticlopidine 
MF： 
C14H14NSCl 
MW： 
263.792 
 
 
 
Name: 
Lasiocarpine 
MF： 
C21H33NO7 
MW： 
411.502 
 
 
 
Name: 
Name: 
Diuron 
MF： 
C9H10N2OCl2 
MW： 
233.099 
 
 
 
Name: 
Monocrotaline 
MF： 
C16H23NO6 
MW： 
325.367 
 
 
 
Name: 
5-methoxytryptami
ne 
MF： 
C11H14N2O 
MW： 
190.247 
 
 
 
Name: 
Verapamil 
MF： 
C27H38N2O4 
MW： 
454.615 
 
 
Name: 
Testosterone 
MF： 
C19H28O2 
MW： 
288.433 
 
 
 
Name: 
Estrone 
MF： 
C18H22O2 
MW： 
270.374 
 
 
 
Name: 
Allopregnanolone 
MF： 
C21H34O2 
MW： 
318.503 
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Table 2-3: Library of CYP2D6 Substrates with Experimental Active Values (EAV) 
Substrate Predictive Km(M)
1
 Predictive Km(M )
2
 Experimental 
Km(M)
3 
Reference  
Acetaminophen 145.724 460.261 440 [208, 209] 
Amiodarone -91.842 0.815 8.4 [210] 
Amitriptyline 14.775 15.755 5-13 [211-213] 
Antipyrine 121.872 30.695 14.4 [214] 
Atomoxetine 39.005 230.538 1.73（149） [215] 
Bufuralol 47.841 445.321 3.4 [79] 
Bunitrolol 157.21 460.261 0.1 [216] 
Codeine 141.19 245.478 1079 [217] 
Debrisoquine 130.832 460.261 73.7 [218] 
Dextromethorphan 111.398 30.695 2.97 [219] 
Diltiazem 52.22 15.755 5 [220, 221] 
Diphenhydramine 29.413 15.755 1.12 [116] 
Fluoxetine 32.208 230.538 0.834 [222, 223] 
Mequitazine 32.822 15.755 0.72 [108] 
Metoprolol 154.812 460.261 17-22 [83, 224, 225] 
Nortriptyline 26.134 230.538 0.74 [211-213] 
Oxymorphone 162.394 460.261 130 [226] 
Pactimibe 136.017 460.261 1.74(25.1) [227] 
Perphenazine 55.872 230.538 1.9 [228] 
Progesterone 189.979 45.635 31 [229] 
Selegiline 110.13 30.695 56 [230] 
Timolol 184.217 460.261 6.95 [231] 
Tramadol 133.861 245.478 286 [232, 233] 
Tropisetron 53.519 230.538 3.9& 4.66 [234] 
Note: 
1.
 Predictive Km (M): Calculated with the QSAR model, which was generated from 24 
CYP2D6 substrates; 
2.
 Predictive Km (M): Calculated with the QSAR model, which was generated from 5 CYP2D6 
substrates; 
3.
 Experimental Km (M): Quoted from references listed in the table.  
 
 
 
 
 
 
 
  62 
Table 2-4: 5 CYP2D6 Substrates as the Testing Set for the Accuracy Test of Docking 
Algorithm 
Substrate Structure  Km (M) Reference 
Name: Acetaminophen 
MF: C8H9NO2 
MW: 151.167 
 
 
440 [208, 209] 
Name: Diltiazem 
MF: C22H27N2O4SCl 
MW: 450.991 
 
 
 
5 [220, 221] 
Name: Perphenazine 
MF: C21H26N3OSCl 
MW: 403.979 
 
 
 
1.9 [228] 
Name: Selegiline 
MF: C13H17N 
MW: 187.286 
 
 
56 [230] 
Name: Tropisetron 
MF: C13H18N2O2 
MW: 234.301 
 
 
 
3.9 [234] 
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Table 2-5: Binding Modes of 120 Known Substrates to Wild-type CYP2D6 
Substrate Virtual Km 
(M)
1
 
CDOCKEK 
Interaction 
Energy 
(CIE) 
Binding Mode H-bond 
Number 
Residues 
Involved 
in H-bond 
Formation 
π-π 
Interaction 
Residues 
Involved 
in π-π 
Interaction 
5-MeO-DIPT 230.54 42.45 
 
0 - √ Phe120 
5-MeO-DMT 230.54 35.18 
 
0 - √ Phe120 
5-Methoxytryptamine 445.32 33.76 
 
0 - √ Phe120 
Almotriptan 230.54 45.41 
 
0 - √ Phe120 
  64 
Aamitriptyline 15.76 41.32 
 
0 - × - 
Amodiaquine 430.38 35.72 
 
0 - × - 
Aprindine 15.76 44.19 
 
0 - √ Phe120 
Aripiprazole 230.54 46.58 
 
1 N16-Glu216 × - 
  65 
Azelastine 15.76 44.33 
 
0 - × - 
Acetaminophen 460.26 26.70 
 
0 - × - 
Allopregnanolone 260.42 6.59 
 
1 O15-Phe483 × - 
Amiodarone 0.82 26.29 
 
0 - √ Phe120 
  66 
Antipyrine 30.70 26.76 
 
0 - √ Phe120 
Atomoxetine 230.54 37.00 
 
0 - × - 
Bicifadine 245.48 28.80 
 
0 - √ Phe120 
Bisoprolol 460.26 55.66 
 
2 
N15-Glu216 
O14-Glu216 
√ Phe120 
  67 
Bunitrolol 460.26 40.01 
 
1 N13-Glu216 × - 
Bortezomib 874.89 57.95 
 
1 O19-Glu216 × - 
Bufuralol 445.32 40.00 
 
5 
O12-Asp301 
O12-Ser304 
O12-Ala305 
N13-Asp301 
N13-Ser304 
√ Phe120 
Carvedilol 630.22 45.40 
 
1 N19-Ala305 √ Phe483 
  68 
Chloroquine 230.54 41.72 
 
0 - √ Phe120 
Chlorpheniramine 15.76 37.73 
 
0 - √ Phe120 
Chlorpromazine 15.76 37.19 
 
0 - × - 
Cibenzoline 230.54 37.51 
 
0 - √ Phe120 
  69 
Cinnarizine 0.82 46.74 
 
0 - × - 
Citalopram 15.76 46.25 
 
0 - × - 
Clomipramine 15.76 43.01 
 
0 - × - 
Clozapine 230.54 34.49 
 
0 - √ Phe120 
  70 
Codeine 245.48 29.86 
 
0 - × - 
Delavirdine 645.16 38.67 
 
1 N10-Glu216 √ Phe120 
Dihydrocodeine 245.48 29.20 
 
1 O16-Ala305 √ Phe120 
Diuron 245.48 31.43 
 
0 - × - 
  71 
Dolasetron 230.54 23.67 
 
1 N17-Ser304 × - 
Donepezil 15.76 37.77 
 
1 O25-Ser304 √ Phe120 
Duloxetine 215.60 25.81 
 
0 - √ Phe120 
Debrisoquine 460.26 27.07 
 
1 N12-Glu216 × - 
  72 
Dextromethorphan 30.70 37.86 
 
0 - × - 
Diltiazem 15.76 30.77 
 
0 - × - 
Diphenhydramine 15.76 38.13 
 
0 - √ Phe120 
E-Doxepin 15.76 38.52 
 
1 O14-Ala305 √ Phe120 
  73 
Eencainide 230.54 45.97 
 
0 - √ Phe120 
Enclomifene 0.82 49.09 
 
0 - √ Phe120 
Estrone 445.32 17.96 
 
1 O20-Asp301 √ Phe120 
Ezlopitant 215.60 2.53 
 
0 - × - 
  74 
Flecainide 460.26 53.25 
 
4 
N16-Glu216 
F28-Ser217 
F27-Phe483 
F27-Leu484 
× 
 
- 
Flunarizine 0.82 49.59 
 
0 - × - 
Fluoxetine 230.54 38.55 
 
1 F21-Ser304 √ Phe120 
  75 
Fluvastatin 645.16 27.76 
 
1 O4-Lys214 √ Phe120 
Fluvoxamine 245.48 48.70 
 
2 
N22-Ala305 
F8-Ser304 
 
√ Phe120 
Galantamine 245.48 38.25 
 
0 - × - 
  76 
Gepirone 30.70 49.55 
 
1 N19-Ser304 × - 
Harmine 215.60 27.73 
 
0 - × - 
Halofantrine 215.60 -34.34 
 
2 
O29-Leu213 
Cl24-Ser217 
× - 
  77 
Haloperidol 230.54 51.51 
 
0 - × - 
Hydrocodone 30.70 28.79 
 
0 - × - 
Ibogaine 245.48 29.14 
 
1 O15-Ser304 × - 
  78 
Iloperidone 0.815 50.59 
 
1 F29-Lys214 - Phe120 
Imatinib 430.38 1.20 
 
1 N20-Phe483 - Phe120 
Imipramine 15.76 40.23 
 
0 - × - 
Indinavir  859.95 Failed to dock 
  79 
Indomethacin 215.60 43.36 
 
0 - √ Phe120 
Lasiocarpine 475.20 32.92 
 
0 - × - 
Lidocaine 245.48 37.00 
 
0 - × - 
  80 
Loratadine 15.76 43.84 
 
0 - × - 
MAMC 460.26 31.10 
 
1 N15-Glu216 √ Phe120 
MDMA 245.48 31.33 
 
0 - √ Phe120 
  81 
Mequitazine 15.76 23.87 
 
0 - √ Phe120 
Methadone 15.76 26.48 
 
0 - × - 
Methamphetamine 245.48 25.68 
 
0 - × - 
  82 
Metoprolol 460.26 47.53 
 
4 
N12-Asp301 
N12-Ser304 
O11-Ser304 
O11-Ala305 
× - 
Mexiletine 245.48 28.79 
 
0 - √ Phe120 
Maprotiline 30.70 33.66 
 
0 - √ Phe120 
  83 
Metoclopramide 475.20 44.03 
 
0 - × - 
Mianserin 15.76 33.60 
 
0 - √ Phe120 
Mirtazapine 15.76 34.81 
 
0 - × - 
  84 
Monocrotaline 475.20 25.92 
 
1 O20-Phe483 × - 
MPBP 30.70 37.44 
 
0 - √ Phe120 
MPPP 30.70 33.63 
 
0 - √ Phe120 
Nevirapine 230.54 32.60 
 
0 - × - 
  85 
Nicergoline 0.82 26.18 
 
0 - √ Phe120 
Nortriptyline 230.54 36.88 
 
0 - × - 
Olanzapine 230.54 36.67 
 
0 - √ Phe120 
  86 
Ondansetron 0.82 33.57 
 
1 O14-Ala305 √ Phe120 
Oxatomide 215.60 40.49 
 
1 
N26-Glu216 
 
× - 
Oxymorphone 460.26 25.88 
 
2 
O11-Ala305 
O17-Ala305 
× - 
Pactimibe 460.26 38.39 
 
0 - √ Phe120 
  87 
Perphenazine 230.54 50.17 
 
0 - × - 
Paroxetine 230.54 43.38 
 
0 - √ Phe120 
Perhexiline 260.42 38.25 
 
0 - × - 
Perphenazine 230.54 47.48 
 
2 
O27-Gln244 
O27-Glu216 
× - 
  88 
Phenformin 1104.61 32.79 
 
3 
N14-Ser304 
N14-Asp301 
N15-Glu216 
× - 
Pinoline 460.26 26.72 
 
0 - √ Phe120 
Pranidipine 230.54 58.10 
 
1 O32-Ala305 
× 
 
- 
Prasugrel 15.76 45.13 
 
0 - √ Phe120 
  89 
Procainamide 460.26 40.19 
 
1 O10-Ala305 √ Phe120 
Propafenone 445.32 54.70 
 
1 N4-Ser304 × - 
Propranolol 445.32 40.85 
 
2 
O19-Ser304 
O19-Ala305 
√ Phe120 
  90 
Progesterone 45.64 13.74 
 
0 - × - 
Risperidone 15.76 42.08 
 
0 - × - 
Ritonavir  845.01 Failed to dock 
Saquinavir  1074.73 Failed to dock 
Selegiline 30.70 29.28 
 
0 - × - 
  91 
Sertraline 230.59 31.63 
 
0 - √ Phe120 
sparteine 45.64 31.147 
 
- - × - 
Sildenafil 230.54 41.71 
 
0 - √ Phe120 
  92 
Tacrine 230.54 24.46 
 
0 - √ Phe120 
Terfenadine 430.38 4.67 
 
1 O20-Asp301 × - 
Timolol 460.26 43.90 
 
3 
N10-Ala305 
N16-Glu216 
O21-Glu216 
× - 
  93 
Tamoxifen 0.82 41.63 
 
0 - ×  
Testosterone 260.42 3.96 
 
0 - × - 
Thioridazine 15.76 41.87 
 
0 - × - 
Ticlopidine 15.76 32.92 
 
0 - √ Phe120 
  94 
Tolterodine 230.54 38.45 
 
0 - × - 
Tramadol 245.48 40.48 
 
1 O13-Ala305 √ Phe120 
Trimipramine 15.76 41.13 
 
0 - × - 
  95 
Tropisetron 230.54 40.41 
 
0 - √ Phe120 
Venlafaxine 245.48 36.08 
 
0 - √ Phe120 
Verapamil 15.76 27.94 
 
1 N13-Ser304 × - 
  96 
Vernakalant 245.478 48.56 
 
1 
O25-Glu216 
 
× - 
Zuclopenthixol 230.54 44.07 
 
0 - × - 
Note: 
1. Virtual Km (M): calculated with the QSAR model, which was generated from 6 CYP2D6 substrates; 
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Figure 2-1: Pharmacophore Model Developed from 20 CYP2D6 Substrates. Figure 
2-1 shows the pharmacophore model developed from 20 CYP2D6 substrates. The 
distance from HBA to HY1 and HY2 was 3.053 and 7.406 Å, respectively. The distance 
between HY1 and HY2 was 6.587 Å. The vector indicates the direction of putative 
hydrogen bond. The pharmacophore consists of 2 Hydrophobic features (HH), and 1 
HBA feature (A), the pharmacophore has a rank score of 62.941, directly hits 18 of 20 
leads as indicated by the direct hit mark (DH:11111110111101111111), none of the hits 
are partial hits as indicated by the partial hit mark (PH:00000000000000000000), and the 
maximum fit value is 3. For accuracy test, 57 out of 75 could be mapped in the testing set 
with RR of 76%. 
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Figure 2-2: QSAR Models Generated from CYP2D6 Substrates. Figure 2-2 shows 
QSAR models generated from 24 (A) or 6 (B) CYP2D6 Substrates. Axis Y refers to the 
molecular properties of substrates including numbers of aromatic rings and hydrogen 
donors, while Axis X represents the activity values (Km values) of substrates.  A: 
multiple linear regression generated from 24 CYP2D6 substrates with regressive equation 
of y=0.085x+82.824 (R
2
=0.085). B: multiple linear regression generated from 6 CYP2D6 
substrates with regressive equation of y=0.980x+2.829 (R
2
=0.980). y represented 
molecular properties, including number of hydrogen acceptors and donors, number of 
aromatic rings, and molecular weight, while x represented molecular activity (Km). 
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Figure 2-3: Comparison of VAV and EAV of Substrates as Validation of Docking 
Algorithm. Figure 2-3 shows the comparison of VAV and EAV of substrates as 
validation of docking algorithm. Perphenazine, tropisetron, diltiazem, selegiline, and 
acetaminophen were selected as testing set of CYP2D6 substrates with known 
experimental active values (EAV: Km) of 1.9, 3.9, 5, 56, and 440 respectively, which 
represented a decreasing trend of actual binding energy. Correspondingly, their binding 
affinity calculated from CDOCKER developed a similar decreasing trend of binding 
energy with VAV of 50.174, 40.410, 30.768, 29.282, and 26.698 respectively. (Note: 
VAV refers to virtual active value. Bigger VAV meant smaller binding affinity. ) 
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Table 2-6: Changes of Active Sites in CYP2D6 Subject to Mutation in Asp301 and Glu216 
Site A: Before Mutation B: After Mutation (Asp301Glu) C: After Mutation (Glu216Asp) 
Axis X Axis Y Axis Z Volume Point 
Count 
Axis X Axis Y Axis Z Volume Point 
Count 
Axis X Axis Y Axis Z Volume Point 
Count 
Site 1 -18.919 38.126 -20.595 337.875 2703 -19.419 59.376 -2.595 713.625 5709 -18.919 38.126 -20.595 337.875 2703 
Site 2 -22.919 57.626 -8.345 320 2560 -18.919 38.126 -20.595 337.875 2703 -21.669 57.626 -8.595 327.75 2622 
Site 3 -16.169 63.876 -14.345 40.75 326 -17.419 64.376 -15.345 85 680 -17.419 64.376 -14.595 48.25 386 
Site 4 -8.169 38.626 -1.595 39.125 313 -8.169 38.626 -1.595 39.125 313 -8.169 38.626 -1.595 39.125 313 
Site 5 -18.669 61.876 -23.095 37.875 303 -18.669 61.876 -23.095 37.875 303 -18.669 61.876 -23.095 37.875 303 
Site 6 -16.169 41.626 -10.845 32.125 257 -16.169 41.626 -10.845 32.125 257 -16.169 41.626 -10.845 32.125 257 
Site 7 -15.169 67.626 8.155 30.625 245 -15.169 67.626 8.155 30.625 245 -15.169 67.626 8.155 30.625 245 
Site 8 -20.169 59.126 8.405 28.5 228 -4.419 49.376 2.655 27.875 223 -20.169 59.126 8.405 28.5 228 
Site 9 -4.419 49.376 2.655 27.875 223 -14.919 37.126 12.155 27 216 -4.419 49.376 2.655 27.875 223 
Site 10 -14.919 37.126 12.155 27 216 -23.919 29.626 -9.595 23.875 191 -14.919 37.126 12.155 27 216 
Site 11 -23.919 29.626 -9.595 23.875 191 -15.669 36.376 -2.095 23.125 185 -23.919 29.626 -9.595 23.875 191 
Site 12 -15.669 36.376 -2.095 23.125 185 -27.419 40.876 -2.845 22.375 179 -15.669 36.376 -2.095 23.125 185 
Site 13 -27.419 40.876 -2.845 22.375 179 -10.419 58.126 -32.345 18.625 149 -27.419 40.876 -2.845 22.375 179 
Site 14 -10.419 58.126 -32.345 18.625 149 -20.669 49.376 -19.345 16.75 134 -10.419 58.126 -32.345 18.625 149 
Site 15 -20.669 49.376 -19.345 16.75 134 -8.919 52.376 -31.845 13.875 111 -20.669 49.376 -19.345 16.75 134 
Site 16 -8.919 52.376 -31.845 13.875 111 -18.669 61.626 11.905 13.75 110 -23.669 52.126 -2.345 15.125 121 
Site 17 -8.919 54.376 0.405 13.875 111 -19.419 36.376 2.655 13.375 107 -8.919 52.376 -31.845 13.875 111 
Site 18 -18.669 61.626 11.905 13.75 110     -8.919 54.376 0.405 13.875 111 
Site 19 -19.419 36.376 2.655 13.375 107     -18.669 61.626 11.905 13.75 110 
Site 20          -19.419 36.376 2.655 13.375 107 
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Figure 2-4. Active Site in CYP2D6. Figure 2-4 shows the active site (Site 2) in CYP2D6. 
(A) active site with a shape of ―right foot‖, which was described by Rowland et al. [71]. 
The ―heel‖ lied above the heme; (B) active site selected in present study with volume of 
320, which shared the similar features of locations, involved residues, and volumes with 
(A); (C) active site after Asp301Glu, which shared similar location with (B) but with 
much bigger volume of 713.625; (D): active site after Glu216Asp, which shared similar 
location with (B) but with bigger volume of 327.75 
 
  102 
 
Figure 2-5: Effect of Asp301Glu and Glu216Asp Mutations on Hydrogen Bond Formation in the Active Site of CYP2D6. Figure 2-5 shows 
the effect of Asp301Glu and Glu216Asp mutations on hydrogen bond formation in the active site of CYP2D6. (A) Asp301 of the wild-type 
CYP2D6 interacts with neighboring residues, forming four hydrogen bonds with Val119, Phe120, Ala305, and Ile297 each; (B) in mutated CYP2D6 
with Asp301Glu substitution, no hydrogen bond interaction of Asp301Glu with other residue; (C) Glu216 of the wild-type protein interacts with 
neighboring residues, forming one hydrogen bond with Gly212 and another one with Leu220; and (D) in mutated protein with Glu216Asp 
substitution, Asp216 formed five hydrogen bonds with Gly212, Phe219, Leu220, and Gln244. 
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Table 2-7: Binding Modes of Five Probe Substrates in the Active Site of Mutated CYP2D6 
Mutation Volume 
(Å
3
) 
Probe Substrate CDOCKER 
Interaction  
Energy 
(CIE) 
Hydrogen 
Bond  
Formation 
π-π 
Interaction 
Binding Mode 
Wild-type 320.000 Bufuralol 40.325 O12-Asp301 
N13-Asp301 
O12-Ser304 
N13-Ser304 
O12-Ala305 
Phe120 
 
Tramadol 34.936 O13-Ala305 Phe120 
 
Dextromethorphan 26.955 - - 
 
  104 
Debrisoquine 31.087 N12-Glu216 - 
 
Sparteine 31.139 - - 
 
Ile106Glu 336.75 Bufuralol 42.843 O13-Glu216 
(2) 
N15-Glu216 
O13-Ser304 
Phe120 
 
Tramadol 40.197 O2-Ser304 
O2-Ala305 
Phe120 
 
  105 
Dextromethorphan 30.063 - - 
 
Debrisoquine 29.201 N13-Asp301 
N13-Ser304 
Phe120 
 
 
Sparteine 22.958 - - 
 
Leu110Phe 442.25 Bufuralol 43.434 O10-Ser304 
O13-Glu216 
- 
 
  106 
Tramadol 36.605 O2-Ala305 Phe120 
 
Dextromethorphan 29.589 O15-Ser304 - 
 
Debrisoquine 26.229 N12-Glu216 Phe120 
 
Sparteine 17.374 - - 
 
  107 
Phe112Ala 447 Bufuralol 37.692 O13-Asp301 
N15-Asp301 
O13-Ser304 
Phe120 
 
Tramadol 37.314 - Phe120 
 
Debrisoquine 27.075 N12-Glu216 
N13-Ser304 
Phe120 
 
Dextromethorphan 17.335 - Phe120 
 
  108 
Sparteine 19.972 - - 
 
Gln117Trp 372.250 Bufuralol 39.488 O13-Glu216 
N15-Glu216 
O13-Ser304 
Phe120 
 
Tramadol 37.625 O2-Ala305 Phe120 
 
Debrisoquine 30.699 N12-Glu216 
N13-Ala305 
N13-Ser304 
Phe120 
 
  109 
Dextromethorphan 26.585 O15-Ser304 
O15-Ala305 
Phe120 
 
 
Sparteine 18.702 - - 
 
Gly118Trp 327.750 Tramadol 39.846 - Phe483 
 
  110 
Bufuralol 38.654 - Phe120 
 
Debrisoquine 31.626 N12-Glu216 
N13-Glu216 
Phe120 
 
Dextromethorphan 30.735 - Phe483 
 
  111 
Sparteine 31.714 - - 
 
Val119Met 323.5 Bufuralol 41.979 N15-Glu216 
O13-Asp301 
O13-Ser304 
O13-Ala305 
 
Phe120 
 
Tramadol 32.813 - - 
 
  112 
Debrisoquine 28.775 N12-Glu216 
N13-Asp301 
Phe120 
 
Dextromethorphan 24.576 - - 
 
Sparteine 13.351 - - 
 
  113 
Phe120Ala 428.25 Bufuralol 38.599 O13-Glu216 
N15-Glu216 
N15-Asp301 
O13-Ser304 
- 
 
Tramadol 37.822 O2-Ser304 - 
 
Dextromethorphan 35.769 O15-Ser304 - 
 
  114 
Debrisoquine 26.777 N12-Glu216 
N13-Glu216 
- 
 
Sparteine 30.285 - - 
 
Leu121Trp 289.625 Tramadol 39.738 O15-Met374 - 
 
Bufuralol 36.464 O13-Ser217 Phe120 
 
  115 
Dextromethorphan 34.644 N19-Ala305 - 
 
Debrisoquine 29.593 N12-Glu216 
N12-Ser304 
N13-Ala305 
- 
 
Sparteine 37.585 - - 
 
  116 
Ala122Ser 406.000 Bufuralol 30.32 O10-Arg101 
O13-Arg101 
O13-Phe120 
N15-Asp301 
Phe120 
 
Debrisoquine 27．328 N12-Gly373 
N13-Phe483 
Phe120 
 
Dextromethorphan -8.345 O15-Ser304 
O15-Ala305 
Phe120 
 
  117 
Tramadol 20.415 O2-Ser304 
O15-Ala305 
Phe120 
 
Sparteine 7.621 - - 
 
Leu213Glu 304 Bufuralol 27.351 O13-Glu216 
(2) 
N15-Glu216 
O13-Ser304 
(2) 
N15-Ser304 
O13-Ala305 
- 
 
  118 
Debrisoquine 23.801 - - 
 
Tramadol 23.379 O2-Gly212 
O2-Glu213 
Phe120 
 
 
Dextromethorphan 0.272 O15-Gly212 - 
 
  119 
Sparteine 26.513 - - 
 
Glu216Asp 327.750 Bufuralol 42.659 C18-Asp216 
O13-Ser304 
Phe120 
 
Tramadol 35.665 - Phe120 
 
  120 
Debrisoquine 27.306 N12-Asp216 
N13-Ser304 
 
Phe120 
 
Dextromethorphan 15.131 - Phe120 
 
Sparteine 29.955 - - 
 
  121 
Ser217Phe 494 Tramadol 42.879 O2-Ser304 
O2-Ala305 
Phe120 
 
Bufuralol 40.101 N15-Gln244 Phe120 
Phe483 
 
 
  122 
Dextromethorphan 35.408 N19-Ser304 Phe120 
 
 
Debrisoquine 28.184 N12-Asp301 
N13-Ser304 
- 
 
Sparteine 36.091 - - 
 
  123 
Leu220Asp 633.5 Bufuralol 39.15 O13-Ser217 
O13-Gly373 
O13-Phe483 
N15-Phe483 
Phe120 
 
 
Tramadol 35.974 O2-Ser217 - 
 
Dextromethorphan 34.318 - - 
 
  124 
Debrisoquine 22.668 N12- Phe483 
N13-Phe483 
N12-Glu216 
 
Phe120 
 
 
Sparteine 30.224 - - 
 
Glu244Phe 310.375 Bufuralol 39.7 O13-Glu216 
N15-Glu216 
Phe120 
 
  125 
Tramadol 36.873 - Phe120 
Phe483 
 
 
Debrisoquine 29.806 N12-Glu216 
N13-Ala305 
N13-Ser304 
Phe120 
 
 
Dextromethorphan 29.237 - × 
 
  126 
Sparteine 28.285 - - 
 
Phe247Gln 433.625 Debrisoquine 34.591 N12-Leu205 - 
 
Bufuralol 33.583 N15-Glu216 
N15-Lys245 
O13-Ser304 
N15-Ser304 
- 
 
Tramadol 1.061 N18-Lys245 
N18-Ser304 
- 
 
  127 
Dextromethorphan -127.347 - - 
 
Sparteine 18.593 - - 
 
Leu248Asp 468.5 Bufuralol 34.04 O13-Asp301 
N15-Asp301 
O13-Ser304 
Phe120 
 
Debrisoquine 27.779 N13-Glu216 
N12-Asp301 
N12-Ser304 
 
Phe120 
 
  128 
Tramadol 11.335 O15-Glu216 
(2) 
O15-Gln244 
- 
 
Dextromethorphan -35.467 O15-Ser304 - 
 
Sparteine 12.435 - - 
 
  129 
Ile297Leu 338.875 Bufuralol 34.969 O13-Ser304 
O13-Ala305 
Phe120 
 
Tramadol 34.452 O2-Ala305 Phe120 
 
Debrisoquine 27.692 N13-Glu216 
N12-Ser304 
Phe120 
 
  130 
Dextromethorphan 26.968 O15-Ser304 
O15-Ala305 
- 
 
Sparteine 31.615 - - 
 
Ala300Glu 281.625 Bufuralol 37.48 - Phe120 
 
  131 
Tramadol 35.041 O2-Ser304 Phe120 
 
Dextromethorphan 30.522 - - 
 
Debrisoquine 29.359 N12-Ser304 
N12-Glu216 
N13-Glu216 
Phe120 
 
  132 
Sparteine 23.758 - - 
 
Asp301Glu 713.625 Bufuralol 42.249 O13-Val298 
O13-Val299 
N15-Val299 
O13-Glu301 
(2) 
- 
 
Tramadol 37.322 - - 
 
  133 
Debrisoquine 29.173 N12-Val298 
N12-Val299 
- 
 
Dextromethorphan Failure to dock 
Sparteine 37.403 - - 
 
Ser304Ala 332.375 Tramadol 32.293 O15-Val298 - 
 
  134 
Debrisoquine 30.031 N12-Val299 - 
 
Bufuralol 11.994 N15-Val299 
O13-Val299 
O13-Asp301 
N15-Asp301 
 
- 
 
Dextromethorphan -5.944 - - 
 
  135 
Sparteine -43.061 - - 
 
Ala305Asp 128.5 Bufuralol 36.042 O13-Leu484 - 
 
Dextromethorphan 30.705 - Phe483 
 
  136 
Tramadol 30.087 - Lys214 
 
Debrisoquine 24.136 - Phe483 
 
Sparteine 24.098 - - 
 
  137 
Val308Phe 367.5 Tramadol 41.666 O2-Ala305 Phe120 
 
Dextromethorphan 38.902 - Phe120 
 
Bufuralol 37.504 O13-Ser217 Phe120 
 
  138 
Debrisoquine 28.153 N12-Glu216 Phe120 
 
Sparteine 34.55 - - 
 
Thr309Val 358.625 Bufuralol 31.443 O13-Ala209 
N15-Ala209 
O10-Ser304 
- 
 
  139 
Debrisoquine 14.541 N12-Phe303 
N13-Ser183 
- 
 
Tramadol Failure to dock 
Dextromethorphan Failure to dock 
Sparteine Failure to dock 
Val370Phe 310.75 Bufuralol 29.351 O13-Leu213 
N15-Leu213 
O13-Ser217 
Phe120 
 
Tramadol 18.448 O15-Ser304 - 
 
  140 
Debrisoquine 18.37 N12-Ser304 Phe120 
 
Dextromethorphan -34.544 - - 
 
Sparteine 11.941 - - 
 
  141 
Gly373Trp 283.375 Bufuralol 29.261 O13- Asp301 
N15- Asp301 
O13-Ser304 
Phe120 
 
Tramadol 21.702 O15-Glu216 
O15-Ser304 
Phe483 
 
 
  142 
Debrisoquine 20.254 N12-Glu216 Phe120 
 
Dextromethorphan -20.385 - Phe483 
 
Sparteine 12.33 - - 
 
  143 
Met374Val 409 Debrisoquine 23.277 - - 
 
Tramadol 20.609 O15-Gly373 Phe483 
 
Bufuralol 10.691 - Phe483 
 
 
Dextromethorphan Failure to dock 
  144 
Sparteine -31.699 - - 
 
Phe483Ala 400.25 Bufuralol 42.026 N15-Glu216 
N15-Ser304 
Phe120 
 
 
Tramadol 31.001 - - 
 
  145 
Debrisoquine 29.968 N12-Glu216 - 
 
Dextromethorphan 17.254 O15-Ala305 Phe120 
 
Sparteine 29.71 - - 
 
  146 
Leu484Asp 352.25 Bufuralol 26.137 N15-Glu216 
O13-Asp301 
O13-Ser304 
O13-Ala305 
- 
 
Debrisoquine 22.239 N12-Ser304 Phe120 
 
Tramadol 10.561 - - 
 
  147 
Dextromethorphan -31.033 N19-Ser304 - 
 
Sparteine 2.318 - - 
 
 
 
  148 
CHAPTER 3  CONSTRUCTION OF COMPREHENSIVE 
COMPUTATIONAL MODEL OF CYP2D6 INHIBITORS 
3.1 Introductio 
The interaction between ligands and CYPs results in induction and/or inhibition of CYPs. 
Induction of CYP enzymes usually occurs through two general mechanisms: stabilizing 
the mRNA or enzyme (e.g., CYP2E1) [235] and increasing gene transcription.  
In contrast to induction, inhibition of CYP enzymes is one of the most common causes of 
harmful adverse drug–drug interactions (ADDI) and has led to the withdrawn of several 
marketed drugs during the past decades. The nonsedating antihistamines terfenadine and 
astemizole, for instance, and the gastrointestinal motility agent cisapride, were all 
withdrawn from the U.S. market because metabolic inhibition by other drugs led to 
life-threatening arrhythmias [236]. The calcium channel blocker mibefradil was 
withdrawn from the U.S. market in 1998 because it was a potent mechanism-based 
enzyme inhibitor that increased the plasm concentration of other cardiovascular drugs to 
toxic levels [237]. 
Inhibition of CYPs activity can reduce metabolism and elimination of the parent 
compounds that are subject to first-pass metabolism and lead to increased bioavailability 
even toxicity of these compounds, especial for those extensively metabolized mainly by 
CYP enzymes. For example, a clinical trial had indicated that fluconazole, a potent 
inhibitor of CYP2C9, reduced approximately 70% of metabolic clearance of S-warfarin, 
leading to significant bleeding at clinical setting. With regard to prodrugs, inhibition may 
result in a decrease in the amount of the active drug form, leading to therapeutic failure 
due to lack of efficacy of the drug. Tamoxifen, a selective estrogen receptor modulator, 
could significantly reduce the conversion of prodrug losartan to its active form by 
inhibiting CYP2C9 activity in breast cancer patients [238]. 
The type of CYP inhibition can be either reversible (competitive or non-competitive) or 
irreversible (mechanism-based) [43, 200]. Reversible inhibition is the most common type 
of enzyme inhibition and takes place directly, while irreversible inhibition requires 
biotransformation of the inhibitor. Reversible inhibition can be further divided into 
competitive, noncompetitive, uncompetitive, and mixed-type inhibition [200]. In 
competitive situation, substrate and inhibitor are competitory to bind to the same position 
  149 
at the active site of an enzyme with hydrophobic, electrostatic or hydrogen-bond 
interactions, which are both formed and broken down easily[200]. In a noncompetitive 
inhibition, however, the binding site of the inhibitor is different from that of the substrate. 
As for mixed-type inhibition, both competitive and noncompetitive inhibitions are 
frequently observed. For example, in vitro studies have demonstrated that glyburide 
strongly inhibited CYP2C9-catalyzed S-warfarin and phenytoin metabolism in a 
competitive manner [239]. 
Irreversible inhibition, on the other hand, usually occurs by forming metabolite 
intermediate complexes, which bind to the residues or heme of the CYP with strong 
covalent bond leading to a long lasting inactivation. This process is called 
‗mechanism-based inhibition‘ or ‗suicide inhibition‘ — the metabolic product inactivates 
the enzyme completely [43]. Classical mechanism-based inhibitors include the CYP1A2 
inhibitor furafylline, the CYP3A4 inhibitor gestodene, and the CYP2E1 inhibitor 
disulfiram [240]. The typical feature of mechanism-based inhibition is the time-, 
concentration- and NADPH-dependent and is terminated by enzyme re-synthesis.  
CYP2D6 inhibitor may share unique structural features and binding mechanisms with the 
enzyme. In this study, we further explored the binding modes of inhibitors to CYP2D6 
and also the diversed structural features between CYP2D6 substrates and inhibitors. 
3.2 Materials and Methods 
3.2.1 Hardware and Software 
The Discovery Studio (DS) 2.1 (Accelrys Software Inc., San Diego, CA) was used 
throughout this study. Several functional Modules in Discovery Studio 2.1 were applied, 
including Common Feature Pharmacophore, Diverse Conformation Generation, Calculate 
Molecular Properties, Create Multiple Linear Regression Model, CDOCKER, Build 
Mutants, and Mapping Feature. The program was run using a Dell optiplex755 server. 
Chemoffice2002 (CambridgeSoft, Cambridge, MA) was used for compound structural 
refinement. 
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3.2.2 Methods 
3.2.2.1 Generation of Libraries: 
Six known CYP2D6 inhibitors (Table 3-1) were selected as training set to generate 
pharmacophore models. A total of 28 CYP2D6 inhibitors (Table 3-2) were selected as 
testing set to validate the assumptions. To generate QSAR models, a library of CYP2D6 
inhibitors (Table 3-3) with diverse Ki values was constructed. Five CYP2D6 inhibitors 
were selected as testing sets for the accuracy test of docking algorithm in our molecular 
docking study (Table 3-4). Overall, 33 CYP2D6 inhibitors were selected for the 
construction of our different libraries and shown in Table 3-5(A). All the molecular 
structures of selected CYP2D6 inhibitors were obtained from PubChem 
(http://pubchem.ncbi.nlm.gov/) as ‗sdf‘ format, then redrawn as ‗cds‘ format and 
converted to ‗mol‘ format with Chemoffice2002. 
3.2.2.2 Construction and Validation of Pharmacophore Models of CYP2D6 
Inhibitors 
Similar to CYP2D6 substrate, Hydrogen bond acceptor (HBA), Hydrogen bond Donor 
(HBD), and Hydrophobic region (HY) were selected as features of pharmacophore 
hypothesis. On the basis of assumption that the most active compounds share all or most 
of the required features for binding with the active site, only the active molecules with 
low Ki values were included in the training set. As the inactive compounds may 
experience steric hindrance and other disfavored interactions, these compounds were 
excluded during pharmacophore generation. Therefore, 6 inhibitors were included in the 
training set. For each of the 6 CYP2D6 inhibitors in the training set, a conformational 
search followed by an energy minimization was performed using the BEST method in DS 
2.1. The number of conformers generated for each compound was limited to a maximum 
of 255 with an energy range of 20 kcal/mol. Although we also used the FAST and 
CAESAR methods to generate conformers, the BEST method was chosen as it provides a 
complete coverage of conformational space by optimizing the conformations in both 
torsional and Cartesian space. The routine steps in the BEST method include: a) 
conjugate-gradient minimization in torsion space; b) conjugate-gradient minimization in 
Cartesian space; and c) Quasi-Newton minimization in Cartesian space. The BEST 
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approach employs a version of the CHARMM force field for energy calculation and a 
poling mechanism for forcing the search into unexplored regions of conformer space. 
In the present study, pharmacophore models were developed using the HypoGen module 
implemented in DS 2.1 with the conformers generated for the molecules in the training 
set (n=6). Predictive pharmacophores were generated in three phases, namely a 
constructive, a subtractive and an optimization phase. In the constructive phase, 
pharmacophores were generated that were common among the active molecules of the 
training set. HypoGen identified all allowable pharmacophores consisting of up to five 
features among the two most active substrates and explored the remaining active 
compounds. The subtractive phase dealt with the pharmacophores that were created in the 
constructive phase and the program removed pharmacophores from the data structure 
which were not likely to be useful. Finally, the optimization was conducted using the 
well-known simulated annealing algorithm. The algorithm applies small perturbations to 
the pharmacophores created in the constructive and subtractive phases in an attempt to 
improve the score. All improvements and some detrimental steps based on a probability 
function are accepted and finally the highest scoring pharmacophores are exported.  
HypoGen allows a maximum of five features in pharmacophore generation. HBA, HBD, 
and HY were selected as features of our pharmacophore hypothesis. Ten hypotheses were 
generated for each set of conformers from the BEST method. The hypotheses generated 
were analyzed with regard to their correlation coefficients and the cost function values. 
The HypoGen module performs a fixed cost calculation which represents the simple 
model that fits all the data and a null cost calculation that assumes that there is no 
relationship in the data-set and that the experimental activities are normally distributed 
about their average value. A small range of the total hypotheses cost obtained for each of 
the hypotheses indicates homogeneity of the corresponding hypothesis and that the 
training set selected for the purpose of pharmacophore generation is adequate. Again, 
values of total cost close to those of fixed cost are indicative of the fact that the 
hypotheses generated are statistically robust. 
Validation of the obtained pharmacophore models was performed using a test set of 
CYP2D6 inhibitors. Pharmacophore model mapping in the testing set was done using the 
Feature mapping module in DS 2.1. Assessment was made according to the coincidence 
rate of mapped molecules in the testing set. 
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3.2.2.3 Generation and Validation of QSAR Model of CYP2D6 Inhibitors 
The module of Calculate Molecular Properties in DS 2.1 was applied to the calculation of 
relevant molecular properties with parameters set properly. The module of Create 
Multiple Linear Regression model was used to generate regressive equations.  
Initially we selected 24 CYP2D6 inhibitors to develop a QSAR model and then 9 
CYP2D6 inhibitors were finally used to construct another QSAR model. For the 
development of the QSAR models, the statistical technique (e.g. GFA), used previously, 
was applied.  
In addition, the module of Calculate Molecule Properties was used for the calculation of 
virtual Ki values of CYP2D6 inhibitors. The QSAR models were validated by comparing 
the predicted and experimental Ki values in the library (Table 3-3). 
3.2.2.4 Molecular Docking 
CDOCKER in DS 2.1 was selected as molecular docking algorithm. Accuracy testing 
was performed as validation by comparison of binding energy from docking results and 
EAV (Ki).  
The three-dimensional crystal structure of CYP2D6 was selected from Protein Data Bank 
(http://www.rcsb.org/pdb/) with PDB ID: 2F9Q. The water molecules in the picture of 
single crystal diffraction of CYP2D6 were removed with DS 2.1, and the ferrous in heme 
(HEM600) was charged as Fe
2+ 
to coordinate with physiological state, finally the protein 
was refined with CHARMM in DS 2.1. 
The active site of CYP2D6 was auto searched with DS 2.1 and selected according to the 
relevant references. The MD simulated annealing process was performed using a rigid 
protein and flexible ligand. The ligand-CYP2D6 interactions were computed from either 
GRID I, GRID II, or the full force field. A final minimization step was applied to each of 
the ligand‘s docking poses. For ligand preparation, all the duplicate structures were 
removed and the options for ionization change, tautomer generation, isomer generation, 
Lipinski filter and 3D generator were set true. After refined with CHARMM, the 
compounds were docked into the protein. The docking was performed with consideration 
of electrostatic energy and vdW force, which were softened at different levels during the 
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docking process, but this softening is removed for the final minimization[206] The grid 
origin was located at the center of the active site of CYP2D6 with a minimum of 21.0 Å 
or the largest ligand dimension +5.0 Å as the side length. A grid spacing of 0.5 Å was 
used. For each defined vdW or electrostatic probe, the interactions with all protein atoms 
were stored at these grid points. For ligand atoms located between grid points, a tri-linear 
interpolation was used to approximate the energies. A harmonic potential with the force 
constant of 300 kcal/mol was applied outside the grid boundary. 
Starting from the new ligand configuration, a set of 10 different orientations are randomly 
generated and docked into the protein (2F9Q), i.e. moved into the center of the grid. Once 
the randomized ligand has been docked into the active site, a MD simulation was run 
consisting of a heating phase from 300 K to 700 K with 2000 steps, followed by a cooling 
phase back to 300 K with 5,000 steps. Maximum bad pose number was 800. The energy 
threshold for vdW force was set at 300 K. Finally, we refined the simulation result by 
running a short energy minimization. The minimization consisted of 50 steps of steepest 
descent followed by up to 200 steps of conjugate-gradient using an energy tolerance of 
0.001 kcal/mol. In the end, we used the energy of binding as the scoring function to rank 
the docked ligands and returned the lowest energy structure as the solution to the docking 
trial. Twenty trials were run for each complex to ascertain the optimal number of trials 
that should constitute an attempt at docking. The top 10 docking poses saved for each 
compound were ranked according to their dock score function based on the total docking 
energy including the intramolecular energy for ligands and the ligand-protein interactions. 
The pose (conformation) having the highest dock score was selected and analyzed to 
investigate the type of interactions. Only the substrate and amino acid residues within 5.0 
Å were allowed during the analysis. A docking without any output pose is considered as a 
failure.  
To validate the accuracy of the docking algorithm, a testing set of CYP2D6 inhibitors 
with trendence of experimental Ki was subjected to the assessment of consistency of their 
virtual and experimental activities. Totally 33 CYP2D6 inhibitors were subject to 
docking study for the analysis of detailed molecular mechanism of binding to CYP2D6. 
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3.2.2.5 Virtual Mutation Study 
The Build Mutants protocol from the ―Protein modeling‖ module in DS 2.1 was applied 
for the substitution of residues in the active site of CYP2D6 (e.g. Asp301 with Glu, or 
Glu216 with Asp). A panel of mutants of CYP2D6 was generated using 2F9Q as the 
template. Energy minimization for optimization of residue geometry was applied to the 
mutant models using the algorithm of smart minimization until the gradient tolerance was 
satisfied (RMS Gradient ~0.1 kcal/mol/Å). Quinidine, pimozide, fluoxetine, and 
halofantrine were selected as testing inhibitors in our docking studies with wild-type and 
mutated CYP2D6. Binding energy for the probes was calculated. Chemoffice2002 was 
applied for the generation of 3D structures of tested probes, which were then refined with 
CHARMM in DS 2.1.  
3.3 Results 
3.3.1 Pharmacophore Models for CYP2D6 Inhibitors and their Validation 
Calculated with the HypoGen algorithm in DS 2.1, ten hypotheses were generated for 
each set of conformers from the BEST method (Table 3-5). Finally, a best 
pharmacophore model for CYP2D6 inhibitors was developed (Figure 3-1). The optimized 
pharmacophore model derived from 6 CYP2D6 inhibitors consisted of two hydrophobic 
features (HY1 and HY2) and one HBA feature. The distance from HBA to HY1 and HY2 
was 5.069 and 9.464 Å, respectively. The distance between HY1 and HY2 was 7.549 Å. 
The pharmacophore had a rank score of 23.168, directly hit 5 of 6 leads as indicated by 
the direct hit mark; none of the hits was partial as indicated by the partial hit mark, and 
the maximum fit value was three. For the pharmacophore assumptions about CYP2D6 
inhibitors, 26 out of 33 could be mapped in the testing set with a RR of 78.8%. 
3.3.2 QSAR Models for CYP2D6 Inhibitors and their Validation 
The QSAR model generated from 24 CYP2D6 inhibitors gave a regressive equation of 
y=0.320x+9.879 with R
2
=0.320, where y is the sum of the number of aromatic ring and 
hydrogen bond donor and x is the experimentally observed Ki value (Figure 3-2A). The 
QSAR model generated from 9 CYP2D6 inhibitors including imipramine, fluoxetine, 
sertraline, venlafaxine, ticlopidine, metoprolol, indinavir, saquinavir, and testosterone had 
a relationship of y=0.948x+1.051 with R
2
=0.948 (Figure 3-2B). When 24 CYP2D6 
inhibitors with experimentally determined Ki were used to validate the two QSAR models, 
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the prediction accuracy was generally poor (Table 3-3). Totally, 33 CYP2D6 inhibitors 
were subject to the prediction of VAV via Module of Calculate Molecule Properties in 
DS 2.1 with the model from 9 inhibitors and listed in Table 3-7(B). 
3.3.3 Binding Modes of Inhibitors with Wild-type and Mutated CYP2D6 
3.3.3.1 Validation of Molecular Docking Algorithm 
Flecainide, thioridazine, metoclopramide, amitriptyline, venlafaxine, and testosterone 
were selected as testing set of CYP2D6 inhibitors. Their EAV (Ki) were 0.954, 1.4, 4.7, 
31, 33, and 63 respectively, which generated a trend of y=12.324x-20.791 with 
R
2
=0.8717. Their VAV were 50.628, 40.276, 38.668, 35.482, 34.277, and 3.775 
respectively, which developed a trend of y=7.2985x+59.396 with R
2
=0.7438 (Figure 3-3).   
3.3.3.2 Selection of Most Appropriate Active Site of CYP2D6 
Similar to the situation of CYP2D6 substrates, a total of 19 sites with diverse location, 
volume and point count were found after auto-search with DS 2.1 based on the crystal 
structure of CYP2D6 (2F9Q) resolved by Rowland et al. (Table 3-3A). Among them, site 
2 showed closest structural features compared to that of 2F9Q (Figure 2-2A). Amino acid 
residues in site 2 within 5 Å to the center included Ile106, Leu110, Phe112, Phe120, 
Ala122, Leu121, Leu213, Lys214, Glu216, Ser217, Gln244, Phe247, Leu248, Ile297, 
Ala300, Asp301, Ala305, Val308, Thr309, Val370, Gly373, Met374, Ser304, Ala482, 
Phe483, and Leu484. Site 2 also had the shortest distance from heme with a shape of 
―right foot‖. Thus, site 2 was selected as the active site in our docking study (Figure 
2-2B).   
3.3.3.3 Patterns of Inhibitors Binding to CYP2D6 
Thirty out of 33 inhibitors could be docked into the active site cavity of CYP2D6 in our 
docking study using the CDOCKER algorithm. As shown in Table 3-7, the binding 
pattern of 30 inhibitors to CYP2D6 is presented according to the formation of hydrogen 
bonds, π-π interactions, and residues involved with the order of CDOCKER interaction 
energy (CIE, i.e. docking score). Among the 30 substrates, 20 of them formed hydrogen 
bonds with 1-3 residues of the active site of CYP2D6 (66.67%). A slightly higher number 
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of these inhibitors (21, 70%) displayed - interaction with CYP2D6, all with Phe120, 
while only venlafaxine formed - interaction with Phe483 synchronously. 
There were 8 residues in the active site of CYP2D6 involved in hydrogen bond formation 
with 20/30 inhibitors (Table 3-7). These included Leu213, Glu216, Ser217, Gln244, 
Asp301, Ser304, Ala305, and Phe483, with distinct roles in hydrogen bond formation for 
different inhibitors, except Lys214 and Phe484, which were involved in substrates. 
Ser304 formed hydrogen bond with 9 inhibitors, including haloperidol, flecainide, 
fluvoxamine, perphenazine, zuclopenthixol, venlafaxine, amitriptyline, risperidone, and 
quinidine. Glu216 interacted with 8 inhibitors via hydrogen bond formation, including 
propafenone, perphenazine, metoprolol, zuclopenthixol, propranolol, oxatomide, 
quinidine, and terfenadine. Ala305 formed hydrogen bond with 6 inhibitors, including 
flecainide, fluvoxamine, metoclopramide, venlafaxine, paroxetine, and olanzapine. 
Asp301 formed hydrogen bond with 4 inhibitors, including flecainide, metoprolol, 
propranolol, and 17-estradiol. Gln244 formed hydrogen bond with halofantrine, 
perphenazine, and zuclopenthixol. In addition, Leu213 and haloperidol, Ser217 and 
testosterone, Phe483 and 17-estradiol could only form a hydrogen bond respectively. 
These results reflect the critical role of Leu213, Glu216, Ser217, Gln244, Asp301, 
Ser304, Ala305, and Phe483 in inhibitor binding and recognition. 
3.3.3.4 Effect of Virtual Mutation on the Binding Mode of Probe Inhibitors to 
Wild-type and Mutant CYP2D6 
To further explore the effects of mutations of residues in the active site of CYP2D6 on 
the binding modes of inhibitors, a series of mutants (n=28, Table 3-8) were generated 
using the Build Mutants module in DS 2.1 and four probe inhibitors of CYP2D6 
including quinidine, pimozide, fluoxetine, and halofantrine were docked into the active 
sites in comparison with the wild-type protein. The mutants generated included Ile106Glu, 
Leu110Phe, Phe112Ala, Gln117Trp, Gly118Trp Val119Met, Phe120Ala, Leu121Trp, 
Ala122Ser, Leu213Glu, Glu216Asp, Ser217Phe, Leu220Asp, Gln244Phe, Phe247Gln, 
Leu248Asp, Ile297Leu, Ala300Glu, Asp301Glu, Ser304Ala, Ala305Asp, Val308Phe, 
Thr309Val, Val370Phe, Gly373Trp, Met374Val, Phe483Ala, and Leu484Asp (Table 3-8). 
Most of these substitutions were non-conserved mutations, with changes from polar to 
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non-polar residue or vice versa, from aromatic to non-aromatic residue or vice versa, and 
from hydrogen-bond forming to non-hydrogen-bind forming residue or vice versa. 
Our further docking studies demonstrated remarkable effects of above mutations on the 
binding of four probe inhibitors including quinidine, pimozide, fluoxetine, and 
halofantrine to the active site of CYP2D6 (Table 3-8). All the four tested inhibitors could 
not be docked into the active site in CYP2D6 with the mutation of Thr309Val, while 
Ala305Asp caused failure of docking of pimozide, quinidine, and halofantrine. These 
findings indicated the critical role of these two residues in the binding of inhibitors to 
CYP2D6. The impact on the binding modes was dependent on not only the type of 
mutation, but also the physico-chemical properties of the probe. For example, 
halofantrine presented an unique physico-chemical property to bind to CYP2D6 via 5 
potential hydrogen bond formation with 5 residues and  - stacking interaction with 
Phe483, while it failed to be docked into the active site of most mutations, including 
Ala122Ser, Ala305Asp, Asp301Glu, Gly118Trp, Gly373Trp, Ile297Leu, Leu110Phe, 
Leu213Glu, Leu484Asp, Met374Val, Phe112Ala, Ser217Phe, Thr309Val, and 
Val370Phe.  
Most mutants in our study displayed considerably altered interactions with neighboring 
residues with regard to hydrogen-bond forming capacity and - stacking (Table 3-8). 
The probe inhibitor of CYP2D6 halofantrine was able to form hydrogen bonds with 
proximal residues Ser217, Ser304, Met374, Phe483, and Leu484 in the active site. 
Different mutations showed differential effects on the formation of hydrogen bonds of 
bufuralol with these residues. The Ala300Glu, Leu121Trp, Leu248Asp, Phe120Ala, 
Phe483Ala, Ser304Ala, and Val119Met mutations eliminated the hydrogen bond of 
bufuralol with Ser217. In the wild-type enzyme, halofantrine formed a hydrogen bond 
with Ser304, but this hydrogen bond disappeared in mutants Gln117Trp, Glu216Asp, 
Leu248Asp, Phe483Ala, and Ser304Ala. In addition, many mutations also abolished the 
hydrogen bond of bufuralol with Ala305. The similar situation also happened in Met374, 
Phe483, and Leu484. Leu248Asp and Ser304Ala completely abolished the 
hydrogen-bond forming capacity of halofantrine with all five residues.  
On the other hand, many mutations conferred halofantrine the ability to form new 
hydrogen bonds with other residues rather than these five residues. For example, some 
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mutations led to hydrogen bond formation between halofantrine with Gln244, including 
Gln117Trp, Leu121, and Glu216Asp.  
Different mutations showed distinct effects on the binding of probe inhibitors to the 
mutated CYP2D6 proteins compared to that to the wild-type enzyme (Table 3-8). With 
regard to hydrogen bond formation and - stacking interaction, the mutations may cause 
their loss or forming new interaction(s) with neighboring residues. Thus, mutations in 
these residues are predicted to affect inhibitor binding affinity and metabolic activity.   
In our study, to compare with the situation in substrates, we built the same mutation of 
Phe120Ala where the aromatic residue Phe120 was replaced by a non-aromatic residue 
Ala. Fluoxetine could not formed hydrogen bond with Ser304 in the Phe120Ala mutant, 
which presented in the wild-type CYP2D6. But the hydrogen bond formation of Glu216 
with pimozide and halofantrine was not affected. Ser304 was able to form more new 
hydrogen bonds with halofantrine in the mutant. Additional hydrogen bond formation 
capacity of the mutant may suggest enhanced binding affinity to substrates and metabolic 
activity. 
Some observations could be noted in mutation of Ile297Leu, which is a naturally 
occurring mutation (CYP2D6*24) with a low frequency in humans [207]. In our docking 
study, we found that this mutant formed new hydrogen bond between quinidine and 
Ala305, but pimozide and halofantrine could not be docked into the active site of the 
enzyme with Ile297Leu, with a notable distinction that they all could be binded with 
wild-type lots of hydrogen bonds or high interaction energy.  
Substitution of Ala122 with Ser also significantly changed the binding mode of quinidine 
to CYP2D6 (Table 3-8). Quinidine only formed two hydrogen bonds with Glu216 and 
Ser304, one π-π stacking with Phe120, but shared higher interaction energy (38.093) in 
the wild-type enzyme. In Ala122Ser mutant, quinidine formed up to 6 hydrogen bonds 
with Arg101, Phe120, Asp301, Ser304, and Ala305. The - stacking was not affected, 
but lower interaction appeared (-2.203).  
3.4 Discussion 
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Hydrogen bond formation and π-π interaction were still selected as two main parameters 
to describe molecular interaction in this study of inhibitors binding to CYP2D6, because 
of their crucial role in ligand-CYP2D6 interaction described in our previous study. 
We have developed another optimized pharmacophore model from 6 inhibitors of 
CYP2D6 when hydrogen bond acceptor, hydrogen bond donor, hydrophobic region were 
selected as features of hypothesis. This model consisted of two hydrophobic features (HH) 
and one hydrogen bond acceptor feature (HBA), giving an RR of 78.8% when a 
validation set of inhibitors was tested. The model shared the same features with that of 
substrates, which indicated the similar structural features between substrates and 
inhibitors of CYP2D6. But the distinction is still notable: inhibitors model presented 
bigger distance from HBA to HY1 and HY2 (5.069 Å and 9.464 Å for inhibitors, 3.053 Å 
and 7.406 Å for substrates, respectively), and between HY1 and HY2 (7.549 Å for 
inhibitors and 6.587 Å for substrates, respectively). Our pharmacophore model is also 
consistent with those of CYP2D6 inhibitors reported previously where different sets of 
inhibitors were used in model construction [75, 86]. 
To explore the determinants of the binding affinity of CYP2D6 inhibitors, we further 
constructed two QSAR models. The relatively high R
2
 values implicated the degree of 
satisfaction of linear relationship and a reliable predictive potential. Although the two 
models did not result in similar prediction of the validation set of inhibitors, the 
regressive equation from 9 inhibitors showed relative high satisfactive degree with 
R
2
=0.948. But the model from 24 CYP2D6 inhibitors presented poor prediction. The 
reasons for this may be due to: a) the choice of training set of CYP2D6 inhibitors was on 
a random basis; and b) the binding affinity (determined as the Ki values) of inhibitors 
with CYP2D6 is determined by a number of factors and many of them are not included in 
our QSAR model construction. 
To further explore the molecular factors that determine the binding affinity and binding 
energy of inhibitors with CYP2D6, we conducted detailed molecular docking of a large 
number of inhibitors (n =33) to the active site of CYP2D6 using the CDOCKER module 
in DS 2.1, which was applied in previous substrates docking study. Our docking study 
demonstrated that 30 out of 33 inhibitors (90.91%) could be docked into the active site of 
CYP2D6. Among them, 20 out of 30 inhibitors (66.67%) formed hydrogen bonds with 
the active site residues and 21 (70%) inhibitors formed a strong - interaction with 
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Phe120 (21/21), with only venlafaxine forming one more - interactions with Phe483. 
Our results indicated that inhibitors owned potential to form more hydrogen bonds and 
- interactions within CYP2D6. 
The active site residues involving hydrogen bond formation with inhibitors included 
Leu213, Glu216, Ser217, Gln244, Asp301, Ser304, Ala305, and Phe483. Therefore, these 
8 residues play an important role in inhibitor binding and consequently metabolic activity 
towards the inhibitors. But Lys214 and Phe484 did not form any hydrogen bond in our 
inhibitors docking study, which generated hydrogen bonds in some substrates in our 
previous study. 
To compare with substrates, the CDOCKER algorithm was also further applied to study 
the impact of the same mutations of 28 active site residues (mostly non-conserved) in 
CYP2D6 on inhibitor binding modes using four probe inhibitors including pimozide, 
quinidine, fluoxetine, and halofantrine.  
From the point of hydrogen bond formation, the potential to form hydrogen bond for the 
residues in active site of wild-type and mutant was similar to those in substrate. Ser304 
and Glu216 all shared 10 out of 38 hydrogen bonds in wild-type, then Ala305 (6/38), Asp 
301 (5/38), Gln244 (4/38), and Ser217 (1/38) in turn. In total 28 mutants docked with 
four probe inhibitors, Ser304 shared 70 out of 260 hydrogen bonds, then Glu216 (29/260), 
Ala305 (23/260), Asp 301 (14/260), Gln244 (13/260), and Ser217 (13/260) in turn. Thus, 
our results indicated that even in the case of mutant, Ser304, Glu216, Ala305, Asp301, 
Gln244, and Ser217 all maintained their potential to form hydrogen bonds with inhibitors 
as what they showed in wild-type CYP2D6. 
All single mutations of the residues altered the hydrogen bond formation and/or aromatic 
interactions, depending on the probe used in molecular docking. Apparent changes of the 
binding modes have been observed with the Phe120Ile, Glu216Asp, and Asp301Glu 
mutants. For example, pimozide only formed a hydrogen bond with Glu216 in the 
wild-type CYP2D6, but it formed up to four hydrogen bonds with Leu121, Ser304, 
Ala305, and Phe483 in the Phe120Ala mutant. In the Glu216Asp mutant, pimozide could 
form new hydrogen bonds with Gln244 and Ser304, but not with Glu216 as seen in the 
wild-type protein. In the Asp301Glu mutant, pimozide formed two new hydrogen bonds 
with Thr190 and Val299, but not with Glu216 as seen in the wild-type protein. These 
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results are in agreement with previous observations from site-directed mutagenesis 
studies on Phe120, Glu216 and Asp301, which indicated the similar change in substrate 
docking. 
The role of Phe120 and Phe483 of CYP2D6 in inhibitor binding and catalytic activity 
have been validated in our present study, which also has been documented in numerous 
previous site-directed mutation studies, when substrates were used for test. Phe120Ile is a 
naturally occurring mutation present in CYP2D6*53. The mutation Phe120Ile can be 
found in a small percentage of the Southeast Asian population [222]. Individuals 
harboring CYP2D6*53 might exhibit an ultrafast phenotype. Our results indicated that the 
aromatic residues Phe120, Phe481 and Phe483 in the active site of CYP2D6 played an 
important role not only in substrate but also in inhibitor binding to the protein.  
Our results have clearly shown that Glu216 is needed in the binding of most basic 
inhibitors. The Glu216 mutants appeared to contain the same complement of heme as the 
wild-type enzyme, in contrast to the Asp301 mutants [71, 205]. Glu216, sitting at the top 
of the active-site cavity, is more likely to serve as a recognition residue that attracts basic 
ligands to the pocket and forms an intermediate binding site prior to the substrate 
migrating to a productive position within the cavity. 
In the 2F9Q structure, Rowland et al. have proposed that Asp301 can act as binding 
residue for ligands (both substrates and competitive inhibitors) of CYP2D6. The two 
rotameric states, trans- and gauche-, of the aspartate can provide an explanation for 
various pharmacophore models of CYP2D6. Asp301 has been proposed to play a 
structural role in CYP2D6 and has at least part of its role in the folding and structure of 
CYP2D6 [71, 205]. 
A number of mutation studies also have demonstrated a critical role of Asp301 and 
Glu216 in inhibitor recognition, catalytic activity, and expression and stability of the 
protein [43, 74, 204]. Ellis et al. [74] reported that the level of holoprotein 
(heme-containing) expression of the Asp301Ala mutant was only 10% of the level of 
the other mutants (8 vs 49 pmol/mg protein) and no holoprotein was detectable in 
microsomes from the Asp301 mutant [74]. They also observed perturbed structural 
integrity of the active site to varying degrees when Asp301 was replaced with a neutral 
residue (Asn, Ala, or Gly). Replacement of the negatively charged residue 301 with a 
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neutral side chain (Asn, Ala or Gly) resulted in substantial decreases in the binding 
capacity of quinidine (1000-fold greater Kd value). These findings from the study by Ellis 
et al. [74] have demonstrated that substitution of Asp301 with neutral amino acids (e.g. 
Asn, Ala, or Gly), differing in size and polarity, results in marked reductions in enzyme 
catalytic activity. The attenuation of enzyme activity had been proposed to be due to the 
disruption of an electrostatic bond between Asp301 and the inhibitor. Substitution of the 
Asp301 carboxylate residue with a similar functional moiety (Glu), on the other hand, did 
not significantly affect the catalytic competence of the enzyme, although a subtle change 
in the regio-selective oxidation of a 10-fold reduction in quinidine binding have been 
observed. The study has provided initial evidence that Asp301 may serve as a critical 
anionic charge to dock the basic nitrogen atom of ligands of CYP2D6 and/or to maintain 
the integrity of the active site. Overall, these results demonstrate an electrostatic 
interaction of amine substrates with Glu216 and Asp301 and at least another residue(s). 
In conclusion, we present our findings upon construction and validation of 
comprehensive computational models of CYP2D6 with the hope that it provides further 
insights into the factors that determining the binding modes of inhibitors to CYP2D6 and 
thus allows us to accurately predict the potential of new compounds as CYP2D6 
inhibitors.  
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Table 3-1: 6 CYP2D6 Inhibitors as the Training Set for Pharmacophore Development 
Inhibitor  Structure Inhibitor  Structure 
Name: 
Amitriptyline 
MF:  
C20H23N 
MW:  
277.4 
 
 
 
Name:  
Ticlopidine 
MF:  
C14H14NSCl 
MW:  
263.8 
 
 
Name:  
Fluoxetine 
MF:  
C17H18NOF3 
MW:  
309.3 
 
 
 
Name:  
Oxatomide 
MF:  
C27H30N4O 
MW:  
426.6 
 
 
 
Name:  
Venlafaxine 
MF:  
C17H27NO2 
MW:  
277.4 
 
 
 
Name:  
Saquinavir 
MF:  
C38H50N6O5 
MW:  
670.9 
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Table 3-2: 28 CYP2D6 Inhibitors as the Testing Set for Pharmacophore Development 
Inhibitor  Structure  Inhibitor  Structure  
Name:  
Quinidine 
MF:  
C20H24N2O2 
MW:  
324.4 
 
 
 
 
 
Name:  
Metoclopramide 
MF:  
C14H24N3O2Cl 
MW:  
301.8 
 
 
Name:  
Imipramine  
MF:  
C19H24N2 
MW:  
280.4 
 
 
 
Name:  
Atomoxetine 
MF:  
C18H22O 
MW:  
254.4  
Name:  
Fluvoxamine 
MF:  
C15H21N2O2F3 
MW:  
318.3 
 
 
Name:  
Flecainide 
MF:  
C17H20N2O3F6 
MW:  
414.3 
 
 
 
Name:  
Paroxetine 
MF:  
C19H20NO3F 
MW:  
329.4 
 
 
 
Name:  
Propafenone 
MF:  
C21H27NO3 
MW:  
341.5 
 
 
 
Name:  
Sertraline 
MF:  
C17H17NCl2 
MW:  
306.2 
 
 
 
Name:  
Metoprolol 
MF:  
C15H25NO3 
MW:  
267.4 
 
 
 
Name:  
Mianserin 
MF:  
C18H20N2 
MW:  
264.4 
 
 
Name:  
Propranolol 
MF:  
C15H19NO2 
MW:  
245.3 
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Name:  
Chlorpromazine 
MF:  
C17H19N2SCl 
MW:  
318.9 
 
 
Name:  
Loratadine 
MF:  
C22H23N2O2Cl 
MW:  
382.9 
 
 
 
Name:  
Clozapine 
MF:  
C18H19N4Cl 
MW:  
326.8 
 
 
 
Name:  
Terfenadine 
MF:  
C32H41NO2 
MW:  
471.7 
 
 
 
Name:  
Haloperidol 
MF:  
C21H23NO2FCl 
MW:  
375.9 
 
 
 
Name:  
Indinavir 
MF:  
C36H47N5O4 
MW:  
613.8 
 
 
 
Name:  
Olanzapine 
MF:  
C17H20N4S 
MW:  
312.4 
 
 
 
Name:  
Ritonavir 
MF:  
C37H48N6O5S2 
MW:  
721.0 
 
 
 
Name:  
Perphenazine 
MF:  
C21H26N3OSCl 
MW:  
404.0 
 
 
 
 
Name:  
Halofantrine 
MF:  
C26H30NOF3Cl2 
MW:  
500.4 
 
 
Name:  
Risperidone 
MF:  
C23H27N4O2F 
MW:  
410.5 
 
 
 
Name:  
17β-estradiol 
MF:  
C18H24O2 
MW:  
272.4 
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Name:  
Thioridazine 
MF:  
C21H26N2S2 
MW:  
370.6 
 
 
 
Name:  
Testosterone 
MF:  
C19H28O2 
MW:  
288.4 
 
 
Name:  
Zuclopenthixol 
MF:  
C22H25N2OSCl 
MW:  
401.0 
 
 
Name:  
Pimozide 
MF:  
C28H29N3OF2 
MW:  
461.6 
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Table 3-3: Library of CYP2D6 Inhibitors with Experimental Active Valures 
Inhibitor Predicted  
Ki (M)
1
 
Predicted  
Ki (M)
2
 
Experimental  
Ki (M)
3
 
Reference 
Quinidine 13.539  13.966 0.03～92 [241-243] 
Amitriptyline  -2.063 5.462 31 [244] 
Imipramine  1.345 7.332 3.9 [130, 245, 246] 
Fluoxetine  6.724 10.227 0.2 [245, 247] 
Fluvoxamine  38.499 28.779 8.2 [248] 
Sertraline  3.317 8.357 0.7 [248] 
Mianserin  1.345 7.332 6.7 [241, 242] 
Venlafaxine  35.092 26.909 33 [245] 
Chlorpromazine  4.752 9.202 6.3 [249] 
Haloperidol  10.132 12.096 7.2 [249] 
Olanzapine  41.907 30.648 89 [242, 250] 
Perphenazine  16.947 15.836 0.16～0.8 [241, 249] 
Thioridazine  8.159 11.071 0.52～1.4 [241, 249] 
Metoclopramide  43.879 31.674 4.7 [251] 
Flecainide  43.879 31.674 0.954 [70] 
Ticlopidine  -2.063 5.462 3.4 [252] 
Metoprolol  43.879 31.674 37 [248] 
Oxatomide  -14.828 -2.716 0.15～57.4 [115] 
Terfenadine  -9.449 0.179 4.6 [107, 253] 
Indinavir  14.94 13.447 15 [130] 
Ritonavir  -10.02 -1.365 4.84 [130] 
Saquinavir  20.32 16.342 24 [130] 
Halofantrine  -18.236 -4.586 4.3 [254] 
Testosterone  56.645 39.852 63 [130, 248, 249, 255] 
Note: 
1
 Predictive Ki (M): Calculated from the QSAR model, which was generated from 24 CYP2D6 
inhibitors; 
2
 Predictive Ki (M): Calculated from the QSAR model, which was generated from 9 CYP2D6 
inhibitors; 
3
 Experimental Ki (M): Quoted from the references listed in the table.  
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Table 3-4: 5 CYP2D6 Inhibitors as the Testing Set for Docking Algorithm 
Inhibitor Structure Ki (M) Reference 
Name: Flecainide 
MF: C17H20N2O3F6 
MW: 414.349 
 
 
 
0.954 [70] 
Name: Thioridazine 
MF: C21H26N2S2 
MW: 370.585 
 
 
 
1.4 [241, 249] 
Name: Metoclopramide 
MF: C14H24N3O2Cl 
MW: 301.82 
 
 
 
4.7 [251] 
Name: Amitriptyline 
MF: C20H23N 
MW: 277.411 
 
 
 
31 [244] 
Name: Venlafaxine 
MF: C17H27NO2 
MW: 277.41 
 
 
 
33 [245] 
Name: Testosterone 
MF: C19H28O2 
MW: 288.433 
 
 
 
63 [130, 248, 249, 255] 
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Table 3-5: Pharmacophore Models Developed from 6 Inhibitors of CYP2D6. 
 
01 HHHD Rank: 29.197 DH: 101101 
PH: 000000 Max Fit: 4 
 
02 HHHD Rank: 26.688 DH: 101101 
PH: 000000 Max Fit: 4 
 
03 HHHA Rank: 26.433 DH: 101101 
PH: 000010 Max Fit: 4 
 
04 HHHD Rank: 24.894 DH: 101101 
PH: 000000 Max Fit: 4 
 
05 HHHD Rank: 24.342 DH: 101101 
PH: 000000 Max Fit: 4 
 
06 HHHD Rank: 23.998 DH: 101101 
PH: 000000 Max Fit: 4 
 
07 HHHA Rank: 23.869 DH: 001101 
PH: 100010 Max Fit: 4 
 
08 HHHA Rank: 23.558 DH: 001101 
PH: 100010 Max Fit: 4 
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09 HHA Rank: 23.168 DH: 101111 
PH: 000000 Max Fit: 3 
 
10 HHHA Rank: 22.872 DH: 001101 
PH: 100010 Max Fit: 4 
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Table 3-6: Results of Accuracy Testing of Pharmacophore Models 
Pharmacophore model Testing Number Mapped Number RR 
pharmacophore_of_CYP2D6_Inhibitors_01           33 15 45.5% 
pharmacophore_of_CYP2D6_Inhibitors_02         33 16 48.5% 
pharmacophore_of_CYP2D6_Inhibitors_03         33 18 54.5% 
pharmacophore_of_CYP2D6_Inhibitors_04          33 20 60.6% 
pharmacophore_of_CYP2D6_Inhibitors_05         33 20 60.6% 
pharmacophore_of_CYP2D6_Inhibitors_06          33 21 63.6% 
pharmacophore_of_CYP2D6_Inhibitors_07         33 20 60.6% 
pharmacophore_of_CYP2D6_Inhibitors_08 33 20 60.6% 
pharmacophore_of_CYP2D6_Inhibitors_09 33 26 78.8% 
pharmacophore_of_CYP2D6_Inhibitors_010          33 15 45.5% 
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Figure 3-1: Pharmacophore Model Developed from 6 CYP2D6 Inhibitors with 
Highest RR. Figure 3-1 shows the pharmacophore model developed from 6 CYP2D6 
inhibitors with highest RR. The distance from HBA to HY1 and HY2 was 5.069 and 
9.464 Å, respectively. The distance between HY1 and HY2 was 7.549 Å. The vector 
indicates the direction of putative hydrogen bond. The pharmacophore consists of 2 
Hydrophobic features (HH), and 1 Hydrogen Bond Acceptor feature, the pharmacophore 
has a rank score of 23.168, directly hits 5 of 6 leads as indicated by the direct hit mark 
(DH:101111), none of the hits are partial hits as indicated by the partial hit mark 
(PH:000000), and the maximum fit value is 3. For accuracy test, 26 out of 33 could be 
mapped in the testing set with RR of 78.8%. 
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Figure 3-2: QSAR Models Generated from 24 (A) or 9 (B) Inhibitors. Figure 3-2 
shows the QSAR models generated from 24 (A) or 9 (B) inhibitors. Axis Y refers to the 
molecular properties of inhibitors including numbers of aromatic rings and hydrogen 
donors, while Axis X represents the activity values (Ki values) of inhibitors.  A: multiple 
linear regression generated from 24 CYP2D6 inhibitors with regressive equation of 
y=0.320x+9.879 (R
2
=0.320). y represents molecular properties, including number of 
hydrogen acceptors and donors, number of aromatic rings, and molecular weight, while x 
represents molecular activity (Ki ). B: multiple linear regression generated from 9 
CYP2D6 inhibitors with regressive equation of y=0.948x+1.051 (R
2
=0.948). y represents 
molecular properties, including number of hydrogen acceptors and donors, number of 
aromatic rings, and molecular weight, while x represents molecular activity (Ki ). 
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Figure 3-3: Comparison of VAV and EAV of Inhibitors as Validation of Docking 
Algorithm. Figure 3-3 shows the comparison of VAV and EAV of inhibitors as 
validation of docking algorithm. Flecainide, thioridazine, metoclopramide, amitriptyline, 
venlafaxine, and testosterone were selected as testing set of CYP2D6 inhibitors with 
known experimental active values (EAV: Ki) of 0.954, 1.4, 4.7, 31, 33, and 63 
respectively, which represented a decreasing trend of actual binding energy. 
Correspondingly, their binding affinity calculated from CDOCKER developed a similar 
decreasing trend of binding energy with 50.628, 40.276, 38.668, 35.482, 34.277, and 
3.775 respectively. (Note: VAV represents virtual active values. Bigger valure means 
smaller binding energy.) 
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Table 3-7: Binding Modes of 33 Known Inhibitors to Wild-type CYP2D6 
Substrate Virtual 
Km 
(M)1 
CDOCK 
Interaction 
Energy (CIE) 
Binding Mode H-bond 
Number 
Residues 
Involved 
in H-bond 
Formation 
π-π 
Interaction 
Residues 
Involved 
in π-π 
Interaction 
Propafenone 18.919 54.148 
 
2 
N4-Glu216 
O7-Glu216 
√ Phe120 
Haloperidol 10.132 51.355 
 
1 O23-Ser304 × - 
Halofantrine -18.236 50.064 
 
3 
F27-Leu213 
F27- Gln244 
F28-Gln244 
× - 
  176 
Flecainide 43.879 49.445 
 
 
4 
O9-Ala305 
O17- Ser304 
F21-Asp301 
F22- Ser304 
√ Phe120 
Fluvoxamine 38.499 49.266 
 
2 
F8-Ser304 
N22-Ala305 
√ Phe120 
Perphenazine 16.947 47.896 
 
3 
O27-Glu216 
O27- Gln244 
O27-Ser304 
× - 
  177 
Metoprolol 43.879 46.76 
 
2 
O15-Glu216 
N16-Asp301 
√ Phe120 
Zuclopenthixol 13.539 44.416 
 
3 
O1-Glu216 
O1- Gln244 
O1-Ser304 
× - 
Metoclopramide 43.879 44.319 
 
1 O10-Ala305 √ Phe120 
Propranolol 15.512 43.937 
 
3 
N3-Asp301 
N3-Glu216 
O19-Glu216 
√ Phe120 
  178 
Venlafaxine 35.092 43.805  
 
2 
O15-Ser304 
O15-Ala305 
√ 
Phe120 
Phe483 
Loratadine 4.752 43.115 
 
0 - √ Phe120 
Paroxetine 13.539 42.991 
 
1 O24-Ala305 √ Phe120 
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Oxatomide -14.828 42.141 
 
1 N26-Glu216 × - 
Thioridazine 8.159 41.588 
 
0 - √ Phe120 
Amitriptyline -2.063 40.936  
 
1 N2-Ser304 √ Phe120 
  180 
Risperidone 8.159 40.688 
 
 
2 
N22-Ser304 
O23-Ser304 
√ Phe120 
Imipramine 1.345 39.953 
 
0 - × - 
Fluoxetine 6.724 39.416 
 
0 - √ Phe120 
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Atomoxetine 6.724 37.608 
 
0 - √ Phe120 
Chlorpromazine 4.752 37.19 
 
0 - × - 
Mianserin 1.345 34.553 
 
0 - √ Phe120 
Olanzapine 41.907 34.234 
 
1 N7-Ala305 √ Phe120 
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Ticlopidine -2.063 32.849 
 
0 - √ Phe120 
Sertraline 3.317 32.688 
 
0 - √ Phe120 
Clozapine 38.499 30.418 
 
0 - √ Phe120 
  183 
17β-estradiol 37.064 19.381 
 
2 
O19-Phe483 
O20-Asp301 
√ Phe120 
Testosterone 56.645 15.222 
 
1 O23-Ser217 × - 
Quinidine 13.539 8.587 
 
2 
N19-Ser304 
O25-Glu216 
√ Phe120 
Terfenadine -9.449 -95.518 
 
1 O15-Glu216 × - 
Indinavir 14.94 Fail to dock 
Ritonavir  -10.02 Fail to dock 
Saquinavir  20.32 Fail to dock 
Note: 
1. Virtual Ki (M): Calculated with the QSAR model, which was generated from 6 CYP2D6 substrates; 
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Table 3-8: Binding Modes of Four Inhibitors in the Active Site of Mutated CYP2D6. 
Mutation Volume 
(Å
3
) 
Probe 
Substrate 
CDOCKER 
Interaction  
Energy 
(CIE) 
Hydrogen 
Bond  
Formation 
π-π 
Interaction 
Binding Mode 
Wild-type 320.000 Pimozide  39.79 N7-Glu216 
 
- 
 
Quinidine 8.587 N19-Ser304 
O25-Glu216 
 
Phe120 
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Fluoxetine  38.093 F15-Ser304 
 
Phe120 
 
Halofantrine  14.256 Cl23-Met374 
F26-Ser217 
F28-Leu484 
F28-Phe483 
O29-Ser304 
 
Phe483 
 
 
  186 
Ala122Ser 405.875 Pimozide  -14.211 O10-Arg101 
N7-Ser122 
O10-Ser122 
O10-Arg441 
F34-Met374 
Phe120 
 
Quinidine  -2.203 O25-Ser304 
O25-Asp301 
O25-Ala305 
N19-Ser304 
N3-Phe120 
N19-Arg101 
Phe120 
 
Fluoxetine  23.727 O5-Arg101 
N2-Ser304 
 
Phe120 
 
Halofantrine  Failure to dock 
  187 
Ala300Glu 282.25 Pimozide  7.45 N7- Glu216(2) 
O10-Gln244 
N7- Glu300(2) 
N7-Asp301(2)  
O10- Ser304 
Phe120 
 
 
Quinidine 29.157 N19-Ser304 
O25-Glu216 
O24-Phe483 
Phe120 
 
  188 
Fluoxetine  39.099 F14-Ser304 
F15-Ser304 
Phe120 
 
Halofantrine  -77.243 O29-Ser304 
 
- 
 
Ala305Asp 447 Pimozide  Failure to dock 
Quinidine  Failure to dock 
Fluoxetine  -67.932 N2-Val298 
N2-Asp301 
N2-Val299 
 
- 
 
Halofantrine  Failure to dock 
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Asp301Glu 713.625 Pimozide  36.126 F33-Thr190 
N7-Val299 
 
- 
 
Quinidine 22.857 O25- Val298 
O25- Val299 
 
- 
 
Fluoxetine  40.711 N2-Glu301 
N2-Val299 
F15-Gln244 
 
Phe120 
 
Halofantrine  Failure to dock 
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Gln117Trp 373.500 Pimozide  45.297 N7-Gln244 
O10-Ser304 
N7-Glu216 
N7- Ser304 
- 
 
Quinidine 14.84 N19- Ser304 
N19-Ala305 
O25-Glu216 
O24-Leu121 
Phe120 
 
Fluoxetine  38.929 N2-Ala305 
F15-Ser304 
Phe120 
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Halofantrine  18.792 Cl23-Leu484 
Cl24-Ser217 
O29-Glu216 
Cl23-Met374 
F28-Gln244 
 
Phe120 
 
Gln244Phe 310.375 Pimozide  14.539 O10- Ser304 
O10- Ala305 
N7- Glu216 
N7- Asp301 
 
Phe120 
Phe244 
 
Quinidine 23.767 O25-Glu216 Phe120 
 
Fluoxetine  40.124 F15-Ser304 
 
Phe120 
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Halofantrine  -14.456 O29- Ser304 
F28- Leu484 
Cl24-Lys214 
O29- Ser217 
 
Phe483 
 
 
Glu216Asp 327.125 Pimozide  41.342 N7-Gln244 
N7-Ser304 
O10-Ser304 
 
- 
 
Quinidine 35.909 - Phe120 
 
  193 
Fluoxetine  39.234 F14-Ser304 Phe120 
Phe483 
 
Halofantrine  3.894 Cl24-Ala305 
F27-Leu484 
Cl24-Ser217 
Cl24-Phe483 
F27-Gln244 
F28-Leu213 
 
Phe120 
Phe483 
 
 
Gly118Trp 358.125 Pimozide  Failure to dock 
  194 
Quinidine  20.978 O25-Ser304 
O25-Gly373 
N19-Ala305 
 
Phe120 
 
Fluoxetine  40.733 F13-Leu484 
F14-Phe483 
F15-Ser217 
Phe120 
 
 
Halofantrine  Failure to dock 
  195 
Gly373Trp 282.375 Pimozide  -51.612 N7-Glu216 
N7-Ser304 
O10-Ser304 
- 
 
Quinidine 22.41 - Phe483 
 
Fluoxetine  30.899 N2- Ala305 
O5- Ser304 
F14-Ser217 
Phe120 
Phe483 
 
Halofantrine  Failure to dock 
  196 
Ile106Glu 336.625 Pimozide  53.046 N7-Glu106 
 
- 
 
Quinidine 21.684 N3-Ser304 
O25-Glu216 
O25-Ala305 
 
Phe120 
 
Fluoxetine  40.004 F13-Ser217 
F14-Ser304 
F15-Ser217 
 
Phe120 
 
  197 
Halofantrine  21.37 Cl23-Met374 
F27-Leu484 
Cl24-Ser217 
F26-Phe483  
N2-Ser304 
 
Phe120 
 
Ile297Leu 338.875 Pimozide  Failure to dock 
Quinidine -0.294 O25-Glu216 
O24-Ser304 
O24-Ala305 
 
Phe120 
 
Fluoxetine  40.188 F15-Ser304 
 
Phe120 
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Halofantrine  Failure to dock 
Leu110Phe 423.250 Pimozide  46.081 O10-Ser304 
N7-Asp301 
Phe112 
Phe483 
 
Quinidine 13.245 N19-Ser304 
N19-Ala305 
O25-Glu216 
O24-Leu121 
 
Phe120 
 
 
Fluoxetine  39.295 F15-Ser304 Phe120 
 
Halofantrine  Failure to dock 
  199 
Leu121Trp 289.625 Pimozide  -20.024 N7-Gln244 
N7-Ser304 
O10-Gln244 
O10-Ser304 
N7-Asp301 
Phe483 
Trp121 
 
Quinidine 12.868 O24-Ser304 Phe483 
 
 
  200 
Fluoxetine  42.781 N2- Glu216 
N2-Asp301 
N2-Ser304 
F15-Ser217 
 
- 
 
Halofantrine  -22.885 F27-Gln244 
F27-Ser304 
F28-Ser304 
F28-Phe120 
 
Phe120 
 
  201 
Leu213Glu 304.000 Pimozide  11.037 N7-Asp301 
N14-Ser304 
N7-Glu216 
F34-Met374 
 
Phe120 
 
 
Quinidine -48.33 N3- Ser304 
O24- Ala305 
O25-Glu216 
 
Phe120 
 
 
  202 
Fluoxetine  42.809 F15-Gly212 
F13-Gly212 
N2- Glu216 
N2- Ser304 
N2-Ala305 
F14-Ser217 
F13-Glu213 
Phe120 
 
 
 
Halofantrine  Failure to dock 
  203 
Leu220Asp 623.500 Pimozide  59.052 F33-Arg221 
F34-Gly218 
O10-Glu222  
O10-Val223 
F33-Phe483 
Phe120 
Phe483 
 
 
Quinidine 40.318 O25-Ser217 Phe120 
 
  204 
Fluoxetine  37.081 N2- Ser217 
N2-Asp220 
N2-Gly373  
F13-Ser304 
Phe120 
 
Halofantrine  58.316 Cl23-Ser304 
O29-Ser217 
O29-Glu216  
F26- Glu222 
Phe120 
 
Leu248Asp 468.750 Pimozide  21.957 N14- Ser304 
O10-Gln244 
O10- Ser304(2) 
Phe120 
Phe483 
 
 
  205 
Quinidine -2.264 O24-Gln244 
O24- Ser304 
O25- Ala305 
 
- 
 
Fluoxetine  27.331 N2-Gln244 
O5-Ser304 
Phe120 
 
Halofantrine  -39.471 F26-Leu121 
O29-Glu216 
- 
 
Leu484Asp 352.250 Pimozide  Failure to dock 
  206 
Quinidine -45.999 O25-Ser304 
O25-Ala305 
- 
 
Fluoxetine  23.633 O5-Ser304 Phe120 
 
 
Halofantrine  Failure to dock 
Met374Val 408.875 Pimozide  Failure to dock 
  207 
Quinidine -11.215 - - 
 
Fluoxetine  21.155 -  Phe481 
 Phe483 
 
 
Halofantrine  Failure to dock 
  208 
Phe112Ala 446.750 Pimozide  52.81 N14-Ser304 
 O10-Leu121 
N7-Gln244 
Phe483 
Phe120 
 
Quinidine 14.18 N19-Ser304 
N19-Ala305 
O25-Glu216 
 
Phe120 
 
Fluoxetine  38.358 N2-Gln244 
N2-Ser304 
N2-Asp301 
F14-Ser304 
Phe120 
 
Halofantrine  Failure to dock 
  209 
Phe120Ala 428.250 Pimozide  51.488 N7-Ser304 
O10-Ala305 
O10-Leu121 
O10-Phe483 
 
- 
 
Quinidine 37.532 - - 
 
Fluoxetine  38.509 N2-Glu216 
F13-Leu484 
F14-Ser217 
Phe483 
 
 
  210 
Halofantrine  47.566 Cl24-Ser304 
O29-Ala305 
O29-Ser304 
 
- 
 
Phe247Gln 433.625 Pimozide  35.362 N14-Ser304 Phe483 
 
Quinidine -11.451 O25-Glu216 
N3-Lys245 
O25-Ala305 
 
- 
 
  211 
Fluoxetine  37.554 F13- Lys245 
F13-Ser304 
N2- Glu216 
O5- Asp301 
 
Phe120 
 
Halofantrine  -10.629 N2- Lys245 
N2-Ser304 
O29- Ser304 
O29- Ala305 
Cl24-Ser217 
Phe120 
 
Phe483Ala 400.250 Pimozide  49.087 N7-Ser304 
O10- Ser304 
N7-Glu216 
Phe120 
Phe481 
 
 
  212 
Quinidine 31.713 N19-Ala305 - 
 
Fluoxetine  41.603 F13-Ser304 Phe120 
 
Halofantrine  23.835 Cl23-Met374 
Cl24-Ala483 
 
- 
 
Ser217Phe 494.000 Pimozide  Failure to dock 
Quinidine 38.941 O25-Gln244 - 
 
  213 
Fluoxetine  43.464 - - 
 
Halofantrine  Failure to dock 
Ser304Ala 322.375 Pimozide  13.183 F34-Leu302 
F34-Phe303 
N7-Val298 
O10-Ser135 
F33-Val119 
F33-Phe120 
 
- 
 
Quinidine -28.489 O25-Val299 
O25-Asp301(2) 
- 
 
  214 
Fluoxetine  16.589 N2-Val299 
N2-Asp301 
F15-Leu302 
F13-Leu302 
F13-Phe303 
 
- 
 
Halofantrine  -19.936 Cl23-Ser135 
F26- Leu302 
F27-Leu302 
F26- Phe303 
O29-Asp301(2) 
Cl24-Thr190 
O29-Val299 
 
- 
 
Thr309Val 358.625 Pimozide  Failure to dock 
Quinidine Failure to dock 
Fluoxetine  Failure to dock 
Halofantrine  Failure to dock 
Val119Met 323.500 Pimozide  39.185 N7- Glu216 
N7- Ser304 
O10- Ser304 
- 
 
  215 
Quinidine 15.372 N19- Ser304 
O25- Glu216 
N19- Ala305 
Phe120 
 
Fluoxetine  39.404 F13- Ser217 
F15- Ser217 
F14- Ser304 
 
Phe120 
 
 
  216 
Halofantrine  9.338 Cl13-Met374 
F27- Phe483 
F27-Leu484 
O29- Ser304 
O29- Glu216 
 
Phe120 
 
 
Val308Phe 367.500 Pimozide  44.145 F34-Phe308 
F34-Thr309 
F34-Ser217 
Phe120 
 
  217 
Quinidine 40.563 N3- Ser217 
O25-Phe483 
Phe120 
 
Fluoxetine  40.296 F13-Ser217 
N2-Ala305 
N2-Glu216 
F13-Lys214 
 
- 
 
Halofantrine  38.032 O29-Ser304 
F27-Leu484 
- 
 
Val370Phe 310.750 Pimozide  Failure to dock 
  218 
Quinidine -34.355 O25-Ser304 
O25-Ala305 
- 
 
Fluoxetine  20.181 O5-Ser304  Phe120 
 
 
Halofantrine  Failure to dock 
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CHAPTER 4  APPLICATION TO HERBAL STUDIES: 
HUANGQIN/FANGJIFULING DECOCTION 
4.1 Introduction 
Herbal medicines are becoming popular as alternative medicines in Western world and an 
estimated one third of adults in the developed countries use herbal medicines. There are 
about 11,000 species of herbal plants for medicinal use and about 500 species of them are 
commonly used in Traditional Chinese Medicine (TCM) [21]. The World Health 
Organization (WHO) defines herbal supplements as "Finished, labelled medicinal 
products that contain active ingredients from aerial or underground parts of plants, or 
other plant material, or combinations thereof, whether crude state or as other 
preparations‖ [178]. These herbs are often coadministered with therapeutic drugs, raising 
the potential of adverse herb-drug interactions (AHDI). There are an increased number of 
reports on AHDI, although many of them are from case reports and limited clinical 
observations [177]. Most herbal medicines undergo Phase I and/or II metabolism, 
yielding inactive or active metabolites. To optimize the use of herbal remedies (e.g. 
dosage, regimen and administration route), knowledge on their biological fate including 
the disposition pathways and kinetics in the human body is certainly needed. Many herbal 
compounds have been reported to be substrates or inhibitors of CYPs and thus the 
activities of CYPs are important determinants of herbal concentrations in the body.  
To reveal the mechanisms of herbal medicines for their putative clinical boot, a number 
of efforts have been focussed on their pharmacologic aspects and pharmacodynamic 
potential for many years. But limited literatures have been found for their absorption, 
distribution, metabolism, excretion, and toxicity (ADMET) [21][178].  
As a main drug metabolic enzyme, CYP2D6 plays an important effect that should not be 
ignored to the bioavailability of herbs. Numbers of research have shown that herbs, single 
herb or formula, were of underlying substrates or inhibitors of CYPs. [256]  
Because of the complicated components of herbs, experimental access (e.g. in vivo or in 
vitro) to reveal their interaction within macromolecular protein was limited and 
inefficient. In the present study, we try to apply the models developed in previous 
research in the prediction of interactions between small molecules of herbs and 
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macromolecules of protein. Documented compounds from S. baicalensis and 
Fangjifuling decoction were subject to pharmacophore mapping and molecular docking. 
4.2 Materials and Methods 
4.2.1 Hardware and Software  
Dell optiplex 755 server; Chemoffice 2002 (CambridgeSoft); Modules in DS 2.1 (DS 
Catalyst: Accelrys): Feature Mapping ; Calculate Molecule Properties; CDOCKER.  
4.2.2 Methods 
4.2.2.1 Generation of Libraries of Components of S. baicalensis and 
Fangjifuling Decoction:  
Total 40 known components from S. baicalensis and 130 known components of 
Fangjifuling decoction identified in literatures have been shown in Table 4-1 and Table 
4-2. Their molecular structures were obtained from PubChem 
(http://www.ncbi.nlm.nih.gov/pccompound), and refined with DS 2.1 
4.2.2.2 Mapping Study with Pharmacophore Model of CYP2D6 Inhibitor in the 
Library 
Pharmacophore models optimized in Section 2.3.1 and Section 3.3.1 were subject to 
mapping study with Feature Mapping in DS 2.1to screen out the compounds with similar 
features of CYP2D6 inhibitors and substrates in the libraries respectively. The inhibitors 
model was for S. baicalensis and substrates model was for Fangjifuling decoction. 
4.2.2.3 QSAR Study 
To explore the determinants of the binding affinity of potential CYP2D6 
substrates/inhibitors, two QSAR models optimized in Section 2.3.2 and Section 3.3.2 
were applied to calculate virtual energy values for compounds from S. baicalensis and 
Fangjifuling decoction mapped out with previous pharmacophore models. The relatively 
high R
2
 values implicated the degree of satisfaction of linear relationship and a reliable 
predictive potential. Thus, y=0.980x+2.829 with R
2
=0.980 for Fangjifuling decoction 
(substrates) and y=0.948x+1.051 with R
2
=0.948 for S. baicalensis (inhibitors) were 
selected for the calculation with module of  Calculate Molecular Properties in DS 2.1. 
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4.2.2.4 Molecular Docking Study 
Compounds mapped out with pharmacophore models in Section 4.2.2.2 were subjected to 
molecular docking study with CDOCKER in DS 2.1 to explore the molecular factors that 
determine the binding pattern of the compounds to CYP2D6. The parameters for the 
algorithm were selected from previous optimization. 
4.3 Results 
4.3.1 Results of Mapping and QSAR Study 
Totally, 18 out of 40 compounds of S. baicalensis and 60 out of 130 compounds from 
Fangjifuling decoction were matched out from the libraries with optimized CYP2D6 
inhibitor/substrate pharmacophore models respectively, which indicated the compounds 
mapped out shared similar structural features with CYP2D6 inhibitor/substrate: two 
hydrophobic features (HY1 and HY2) and one hydrogen bond acceptor (HBA) feature 
but with different distance between grounds. Their virtual active values (VAV) were also 
calculated with the QSAR models, and listed in Table 4-3 and Table 4-4.   
4.3.2 Results of Molecular Docking Study 
All 18 compounds mapped out from S. baicalensis could be docked into the active site of 
wild-type protein (Table 4-3). As shown in Table 4-3, the binding pattern of 18 
comounds to CYP2D6 is presented according to the formation of hydrogen bonds, π-π 
interactions, and residues involved with the order of CDOCKER interaction energy (CIE, 
i.e. docking score). 15 out of 18 compounds could form up to 6 hydrogen bonds with 1-5 
residues of the active site of CYP2D6 (83.33%). 11 out of 18 compounds could form π-π 
interactions predominantly with Phe120, while 3 compounds could form π-π interactions 
with Phe483 synchronously. 
Residues involved in hydrogen bond formation included Glu216, Gln244, Asp301, 
Ser304, Ala305, and Phe483. Similar with CYP2D6 inhibitors, Glu216, Ser304, Ala305 
predominantly formed hydrogen bonds with the compounds. 
For example, baicalin could form up to 5 hydrogen bonds with Glu216, Gln244, and 
Ser304, one π-π interaction with Phe120, and with 41.272 CIE. Wogonside also formed 
up to 5 hydrogen bonds with Glu216, Asp301, Ser304, and Ala305, one π-π interaction 
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with Phe120, and with 39.472 CIE. Wogonin formed one hydrogen bond with Phe483, 
one π-π interaction with Phe120, and with 22.326 CIE. 
On the other hand, 54 out of 60 compounds mapped out from Fangjifuling decoction 
could be docked into the active site of wild-type protein (Table 4-4). 24 out of 54 
compounds could form up to 8 hydrogen bonds with 1-5 residues of the active site of 
CYP2D6 (44.44%). A slightly higher number of these compounds (46.30%) displayed 
π-π interaction with CYP2D6, totally with Phe120, while 3 compounds could form π-π 
interaction with Phe483 and one with Phe112. 
There were 11 residues in the active site of CYP2D6 involved in hydrogen bond 
formation with 24 compounds (Table 4-4). These included Leu121, Leu213, Glu216, 
Ser217, Gln244, Asp301, Ser304, Ala305, Phe483, and Phe484, with distinct roles in 
hydrogen bond formation for different compounds. Similar with CYP2D6 substrates, 
predominantly Ser304 (14/61), Asp301 (13/61), Glu216 (11/61), and Ala305 (11/61) 
formed hydrogen bonds with the compounds.  
These results suggested that Fangjifuling decoction contained numerous compounds that 
might behave as the substrates and/or inhibitors of CYP2D6. Fangjifuling decoction has a 
potential to interact with drugs that are metabolized by this enzyme. 
4.4 Discussion 
Huangqin (S. baicalensis ) is the root of Baical Skullcap belonging to labiates, which is a 
Chinese herbal drug in common use. For many years, global research boost of rhubarb is 
in the ascendant. S. baicalensis applies apprehensively in clinical practice especially in 
the basic medical care of the developing countries on bacterial infections, virus infections, 
allergic diseases, tumors and some other common diseases. The pharmaceutical effects of 
S. baicalensis are complicated that included anti-inflammatory, antibacterial, anti-virus, 
anti-allergic, antioxidant, scavenging free radicals, anti-tumor, protecting of neurons, 
inhibiting aldose reductase activity, blocking calcium channels and cellular apoptosis and 
so on. The nature of S. baicalensis is built upon its active ingredients‘ breadth and 
complexity. The effective ingredients of S. baicalensis are mainly flavonoids, and also 
other chemicals such as phenols, alcohols, organic acids, glycosides, terpenoids, enzymes 
and trace elements.  
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A number of studies have suggested that flavonoids can also directly modulate the 
activities of various CYPs. Some naturally occurring flavonoids are potent inhibitors of 
CYP1A1, 1A2, 1B1, 3A4, 3A6, and CYP19. In contrast, some flavonoids 
enhanced/stimulated the activities of CYP3A4 and 1A2. The different effects of various 
flavonoids on CYP3A4 may be partly explained by the presence of distinct ligand 
binding sites on CYP3A4. Structure-activity analysis indicated that flavonoids containing 
hydroxyl groups inhibited CYP activity, whereas those lacking hydroxyl groups 
stimulated the enzyme activity. For example, non-substituted 7,8-benzoflavone increased 
CYP3A4 activity. In another study, quercetin inhibited the activity of aryl hydrocarbon 
hydroxylase (CYP1A), but enhanced the activity of cDNA-expressed human CYP1A2 
[257]. Likewise, 7,8-benzoflavone was an inhibitor of human CYP1A1 and 1A2, but an 
activator of CYP3A4 [258].  
Baicalin, wogonoside, and wogonin are three of four main active components of S. 
baicalensis. Our in silico study showed that these three compounds owned the structural 
features similar to CYP2D6 inhibitors, which consisted of two hydrophobic features 
(HY1 and HY2) and one HBA feature, the distance from HBA to HY1 and HY2 was 
5.069 and 9.464 Å, respectively, and the distance between HY1 and HY2 was 7.549 Å. 
This was distinctly different from those of CYP2D6 substrates. 
Moreover, our results also revealed that their binding mechanism could be detailedly 
revealed, for example, baicalin could form up to 5 hydrogen bonds with Glu216, Gln244, 
and Ser304, one π-π interaction with Phe120, and with 41.272 CIE. Wogonside also 
formed up to 5 hydrogen bonds with Glu216, Asp301, Ser304, and Ala305, one π-π 
interaction with Phe120, and with 39.472 CIE. Wogonin formed one hydrogen bond with 
Phe483, one π-π interaction with Phe120, and with 22.326 CIE. 
On the other hand, Fangjifuling decoction is a well-known classic formula from 
―Synopsis of Prescription of the Golden Chamber‖ for clinical practice on treatment of 
edema, chronic congestive heart failure, atrial fibrillation, gouty arthritis et. al. for more 
than 2,000 years in China. The formula mainly consists of Stephania tetrandra, Poria 
cocos, Astragalus membranaceus, Cinnamomum cassia, and Glycyrrhiza uralensis. 
Overall, 60 compounds out of 130 (46.15%) from Fangjifuling decoction matched our 
pharmacophore model for CYP2D6 substrates. These compounds included tetrandrine, 
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fangchinoline, oxofangchirine, cyclanoline, pachymic acid, polyporenic acid, linalool, 
nonanal, thymol, -cedrol, tumulosic acid, spathulenol, etc. Most of these compounds 
contained at least one hydrophobic feature and one hydrogen bond acceptor. 
The subsequently docking study showed that the role of Phe120, Glu216, Asp301 and 
Ser304 in ligand recognition and binding has been further supported by our docking 
studies with 130 compounds from Fangjifuling decoction. Several of these compounds 
such as 7-hydroxy-4‘-methoxyisoflavone and linalool could form hydrogen bonds with 
Glu216 Asp301, and/or Ser304, suggesting that they may be substrates and/or inhibitors 
of CYP2D6. Up to 54 compounds from the herbal formula could be docked into the 
active site of CPY2D6, and these compounds may behave as substrates and/or inhibitors 
of CYP2D6, although experimental evidence is requested. Identification of herbal 
components as CYP2D6 substrates and/or inhibitors has important implication in AHDI 
and herbal drug development. 
CYP2D6 has been shown to metabolize many components from plants. Given that there 
are a large number of herbal plants are clinically used with each of them contains more 
than 50-100 compounds, computational models of CYP2D6 may represent a very 
efficient approach for high-throughput screening of potential ligands of this important 
enzyme. 
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Table 4-1: Library of 40 Compounds isolated from S. baicalensis 
Compound ID Compound Molecule Formula Molecule Weight 
243 Benzoic acid 122.125 C7H6O2 
985 Palmitic Acid 256.432 C16H32O2 
2758 Eucalyptol(e),cineole 154.254 C10H18O 
3515 Guaiazulene  198.309 C15H18 
5281 Stearic Acid 284.486 C18H36O2 
6054 Benzeneethanol 122.168 C8H10O 
6549 Linalool  154.254 C10H18O 
6557 Isoprene  68.119 C5H8 
6986 Menthone  154.254 C10H18O 
7410 Acetophenone  120.152 C8H8O 
8380 Decyl octyl phthalate 418.622 C26H42O4 
8970 Phthalic acid  334.46 C20H30O4 
11095 Eriodictyol 288.261 C15H12O6 
18827 1-Octen-3-ol 128.216 C8H16O 
19284 Diheptyl phthalate 362.514 C22H34O4 
31271 Dioctyl hexanedioate 370.578 C22H42O4 
33154 Decyl hexyl phthalate 390.568 C24H38O4 
64982 Baicalin 446.375 C21H18O11 
70962 (+)-Isomenthone 154.254 C10H18O 
101731 Beta-Patchoulene 204.357 C15H24 
102432 Cedrene 204.357 C15H24 
107152 Alpha-Guaiene 204.357 C15H24 
124211 SkullcapflavoneⅡ 374.353 C19H18O8 
159278 Salidroside  300.314 C14H20O7 
161271 Salvigenin 328.326 C18H16O6 
192240 Darendoside B 476.487 C21H32O12 
230920 Isoborneol 154.254 C10H18O 
442393 Beta-selinene 204.357 C15H24 
442495 (+)-Pulegone 152.238 C10H16O 
520957 Alpha-Longipinene 204.357 C15H24 
5280450 Linoleic Acid 280.454 C18H32O2 
5281515 Caryophyllene 204.357 C15H24 
5281605 Baicalein  270.245 C15H10O5 
5281607 Chrysin  254.245 C15H10O4 
5281674 Norwogonin 270.245 C15H10O5 
5281703 Wogonin  284.272 C16H12O5 
5317570 Germacrene D 204.357 C15H24 
5320315 Oroxylin  A 284.272 C16H12O5 
21668724 Darendoside  A 476.487 C21H32O12 
29927693 Wogonoside  460.402 C22H20O11 
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Table 4-2:  Library of 130 Compounds isolated from Fangjifuling Decoction 
Compound 
ID 
Compound Molecular 
Weight 
Molecular 
Formula 
176 Acetic acid 60.05 C2H4O2 
240 Benzaldehyde 106.12 C7H6O 
263 1-Butanol 74.12 C4H10O 
323 Coumarin 146.14  C9H6O2 
356 Octane 114.23  C8H18 
454 Octanal 128.21  C8H16O 
984 Hexadecanal 240.42  C16H32O 
985 Palmitic acid 256.42  C16H32O2 
998 Hyacinthin 120.15 C8H8O 
1254 1-Menthol 156.27 C10H20O 
1752 Nonylphenol 220.35  C15H24O 
2108 Pratensein-7-O-β-D-glucoside 194.18 C7H14O6 
2682 Hexadecanol 242.44 C16H34O 
3893 Dodecanoic acid 200.32 C12H24O2 
5281 Octadecanoic acid 284.48  C18H36O2 
5760 4-Methyl-octane 303.35  C17H21NO4 
5770 10-Hydroxy-3,9-dimethoxy-peterocarpan 608.68  C33H40N2O9 
5896 7-Hydroxy-4‘-methoxyisoflavone 239.27  C15H13NO2 
6549 Linalool 154.25  C10H18O 
6616 Camphene 136.23  C10H16 
6654 α-Pinene 136.23  C10H16 
6989 Thymol 150.22  C10H14O 
6998 Salicyladehyde 122.12  C7H6O2 
7187 5α,8α-Peroxide-hydrotum ulosic acid 242.23  C14H10O4 
7282 3-mMetbyl-pentane 86.18  C6H14 
7296 Methyl-cyclopentane 84.16  C6H12 
7311 2,4-di-Butylphenol 206.32  C14H22O 
7410 Acetophenone 120.15  C8H8O 
7460 α-Phellandrene 136.23  C10H16 
7461 -Terpinene 136.23  C10H16 
7462 α-Terpinene 136.23  C10H16 
7463 p-Cymene  134.22  C10H14 
7500 Ethylbenzene 106.17  C8H10 
7707 Benzenepropanal 134.18  C9H10O 
7892 2-Metbyl-pentane 86.18  C6H14 
7962 Methyl-cyclohexane 98.19  C7H14 
8051 2-Heptanone 114.19  C7H14O 
8058 Hexane 86.18  C6H14 
8103 1-Hexanol 102.17  C6H14O 
8130 Heptanal 114.19 C7H14O 
8141 Nonane 128.26  C9H20 
8217 1-Octadecene 252.48  C18H36 
8222 Eicosane 282.55  C20H42 
8554 Dimethyl phthalate 194.18  C10H10O4 
11005 Tetradecanoic acid 228.37  C14H28O2 
11142 β-Phellandrene 136.23  C10H16 
11229 3,3-Dimethyl-pentane 100.20  C7H16 
11260 2,3-Dimethyl-pentane 100.20  C7H16 
11463 Terpinolene 136.23  C10H16 
11542 2,2-Dimethyl-pentane 100.20  C7H16 
11549 1,1-Dimethyl-cyclohexane 112.21  C8H16 
11635 Octadecane 254.49  C18H38 
12048 3-Ethyl-pentane 100.20  C7H16 
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12391 Pentadecane 212.41  C15H32 
12398 Heptadecane 240.47  C17H36 
12401 Nonadecane 268.52  C19H40 
12403 Heneicosane 296.57  C21H44 
12405 Docosane 310.60  C22H46 
12534 Tricosane 324.63  C23H48 
13190 1-Undecene 154.29  C11H22 
13849 Pentadecanoic acid 242.40  C15H30O2 
14896 β-Pinene 136.23  C10H16 
15173 trans-O-Methoxycinnamaldehyde 162.19  C10H10O2 
15600 Decane 142.28  C10H22 
17100 α-Terpineol 154.25  C10H18O 
17148 1,2-Dimethyl-cyclopentane 98.19  C7H14 
18827 1-Octen-3-ol 128.21  C8H16O 
19725 Copaene 204.35  C15H24 
22311 Limonene 136.23  C10H16 
25913 1-Pentadecene 210.40  C15H30 
26049 3-Carene 136.23  C10H16 
28030 1-Ethyl-1-methyl-cyclopentane 112.21  C8H16 
31253 β-Myrcene 136.23  C10H16 
31289 Nonanal 142.24  C9H18O 
64685 Borneol 154.25  C10H18O 
65575 α-Cedrol 222.37  C15H26O 
69423 2-Nonadecanone 282.50  C19H38O 
73078 Tetrandrine dimer 622.75  C38H42N2O6 
73481 Fangchinoline 608.72  C37H40N2O6 
95593 Propanal,2-methyl-3-phenyl- 148.20  C10H12O 
101300 Dicentrine 339.39  C20H21NO4 
101708 α-Muurolene 204.35  C15H24 
102432 α-Cedrene 204.35  C15H24 
107736 BHT-quinone-methide 218.33  C15H22O 
124052 Glabridin 324.37  C20H20O4 
128108 Oxofangchirine 618.68  C37H34N2O7 
136729 1-Ethyl-2-methyl-cis-cyclopentane 112.21  C8H16 
136827 4,4-Dimethyl-heptane 128.26  C9H20 
388058 3-Epidehy  drotumulosic acid 413.47  C21H27N5O4 
440917 D-Limonene 136.23  C10H16 
442360 α-Curcumene 202.34  C15H22 
442813 Calycosin-7-O-β-D-glucoside 430.40  C22H22O9 
445639 Oleic acid 282.46  C18H34O2 
480786 Glisoflavanone 424.49  C25H28O6 
480865 Licoricidin 424.53  C26H32O5 
503737 Liquiritin 418.39  C21H22O9 
522266 Spathulenol 220.35  C15H24O 
522554 7-Methyl-1-undecene 168.32  C12H24 
530422 (+)-4-Carene 136.23  C10H16 
641115 Tetrandrine 259.30  C15H17NO3 
643008 2‘-Hydroxy-3‘4‘-dimethoxyisoflavone 
-7-O-glucopyranoside 
298.29  C17H14O5 
3082134 Cyclanoline 342.41  C20H24NO4
+
 
5280343 Quercetin 302.24  C15H10O7 
5280804 Isoquercetin 464.38  C21H20O12 
5280863 Kaempferol 286.24  C15H10O6 
5281377 Genistin 432.38  C21H20O10 
5281515 trans-Caryophyllene 204.35  C15H24 
5281553 E- β-Ocimene 136.23  C10H16 
5281671 Morusin 420.45  C25H24O6 
5282110 Cinnamyl acetate 176.21  C11H12O2 
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5284507 trans-Nerolidol 222.37  C15H26O 
5315206 Vicenin-2 626.52  C27H30O17 
5315892 Cinnamyl alcohol 134.18  C9H10O 
5318570 Isoglycyrol 366.36  C21H18O6 
5318591 Isoliquiritin 418.39  C21H22O9 
5318869 Kumatakenin 314.29  C17H14O6 
5318998 Licochalcone A 338.40  C21H22O4 
5319013 Licoricone 382.40  C22H22O6 
5319704 Licorisoflavan A 438.56  C27H34O5 
5320260 Odoratin 266.33  C15H22O4 
5320667 Polyporenic acid 482.69  C31H46O4 
5322174 Tumulosic acid 486.73  C31H50O4 
5354833 E-Z-Nonenal 140.22  C9H16O 
5362814 Z-4-Heptenal 112.17  C7H12O 
5363229 E-3-Octen-2-one 126.20  C8H14O 
5484385 Pachymic acid 528.76  C33H52O5 
6325281 Glycyroside 562.52  C27H30O13 
6432777 1-Ethyl-2-methyl-cis-cyclopentane 
(isomer) 
112.21  C8H16 
11127402 Isolongifolene 204.35  C15H24 
44427463 α-Cadinol 222.37  C15H26O 
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Table 4-3: The Binding Modes of 18 Compounds of S. baicalensis Matched by the Pharmacophore Model of CYP2D6 Inhibitors to Wild-type 
CYP2D6  
Compound 
ID 
Compound Virtual 
Active 
Value 
(VAV: Ki) 
CDOCKER 
Interaction 
Energy 
(CIE) 
Binding Mode H-bond 
Number 
Residues 
Involved 
in H-bond 
Formation 
π-π Residues 
Involved 
in π-π 
21668724 Darendoside A  98.037 67.58 
 
6 
O21-Glu216 
O22-Asp301 
O22-Ser304 
O22-Ala305 
O26-Ser304 
O30-Gln244 
- - 
31271 Dioctyl hexanedioate   58.08 48.674 
 
2 
O9-Ser304 
O9-Ala305 
- - 
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8380 Decyl octyl phthalate 33.12 48.331 
 
0 - √ Phe120 
192240 Darendoside B 98.037 45.627 
 
 
5 
O8-Ser304 
O8-Glu216 
O9-Ser304 
O9-Ala305 
O10-Glu216 
√ 
Phe120 
Phe483 
  231 
33154 Decyl hexyl phthalate 33.12 44.766 
 
0 - √ Phe120 
64982 Baicalin 64.29 41.272 
 
5 
O27-Glu216 
O27-Ser304 
O28-Gln244 
O29-Gln244 
O29-Ser304 
√ Phe120 
19284 Diheptyl phthalate 33.12 41.022 
 
1 O17-Ala305 √ Phe120 
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29927693 Wogonoside  64.29 39.472 
 
6 
O26-Glu216 
O28-Ala305 
O31-Asp301 
O33-Glu216 
O33-Ser304 
O34-Asp301 
√ Phe120 
5281 Stearic Acid 56.645 38.363 
 
4 
O1-Glu216 
O1-Gln244 
O20-Asp301 
O20-Ser304 
- - 
8970 Phthalic Acid 33.12 37.952 
 
1 O9-Ala305 √ Phe120 
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5280450 Linoleic Acid 56.645 37.416 
 
2 
O21-Glu216 
O21-Gln244 
- - 
985 Palmitic Acid 56.645 33.528 
 
1 O17-Gln244 - - 
161271 Salvigenin 20.354 32.302 
 
1 O18-Phe483 √ 
Phe120 
Phe483 
  234 
124211 Skullcapflavone Ⅱ 32.548 27.917 
 
3 
O23-Asp301 
O23-Ser304 
O23-Ala305 
√ Phe120 
5320315 Oroxylin A 22.326 27.083 
 
0 - √ 
Phe120 
Phe483 
5281703 Wogonin  22.326 26.051 
 
1 O19-Phe483 √ Phe120 
  235 
18827 1-Octen-3-ol 53.237 25.41 
 
1 O1-Ala305 - - 
6549 Linalool 53.237 18.35 
 
1 O9-Glu216 - - 
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Table 4-4: The Binding Modes of 60 Compounds from Fangjifuling Decoction to CYP2D6 
Compound 
ID 
Name Virtual 
Active 
Value 
(VAV: ) 
CIE Binding Mode H-bond 
Number 
Residues 
Involved  
in H-bond 
Formation 
π-π  Residues 
Involved  
in π-π 
454 Octanal 45.635 35.783 
 
0 - - - 
984 Hexadecanal 45.635 56.763 
 
0 - - - 
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985 Hexadecanoic acid 260.418 57.341 
 
0 - 
- 
 
- 
1254 
 
1-Menthol 260.418 27.497 
 
0 - - - 
1752 Nonylphenol 245.478 43.986 
 
1 O16-Ala305 - - 
  238 
2682 Hexadecanol 260.418 56.412 
 
1 O17-Ala305 - - 
3893 Dodecanoic acid 260.418 41.222 
 
0 - - - 
5281 Octadecanoic acid 260.418 60.248 
 
0 - 
- 
 
- 
  239 
5760 4-methyl-Octane 30.695 37.695 
 
1 
O18-Ala305 
 
- 
 
- 
5770 
10-Hydroxy-3,9-dimethoxy-peteroc
arpan 
215.598 failed to dock 
5896 7-Hydroxy-4‘-methoxyisoflavone 230.538 31.945 
 
2 
O15-Ser304 
O15-Asp301 
√ Phe120 
6549 Linalool 260.418 25.152 
 
2 
O8-Glu216 
O8-Ser304 
- - 
  240 
7187 
5α,8α-Peroxide-hydrotum ulosic 
acid 
15.755 32.859 
 
2 
O8-Ser304 
O13-Ala305 
√ Phe120 
7311 2,4-di-Butylphenol 245.478 28.507 
 
0 - √ Phe120 
8103 1-Hexanol 260.418 20.391 
 
0 - - - 
  241 
8130 Heptanal 45.635 33.433 
 
0 - - - 
8554 Dimethyl phthalate 30.695 31.908 
 
0 - √ Phe120 
11005 Tetradecanoic acid 260.418 47.303 
 
0 - - - 
  242 
13849 Pentadecanoic acid 260.418 53.131 
 
0 - - - 
18827 1-Octen-3-ol 260.418 24.39 
 
0 - - = 
31289 Nonanal 45.635 39.15 
 
0 - - - 
  243 
65575 α-Cedrol 260.418 15.049 
 
0 - - - 
69423 2-Nonadecanone 45.635 52.346 
 
0 - - - 
73078 
Tetrandrine dimmer 
-14.125 failed to dock 
73481 
Fangchinoline 
200.658 failed to dock 
95593 2-Methyl-3-phenyl- propanal 30.695 26.925 
 
0 - - - 
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101300 Dicentrine 15.755 28.579 
 
2 
O24-Ser304 
O24-Ala305 
√ Phe120 
107736 BHT-quinone-methide 45.635 28.684 
 
0 - √ Phe120 
124052 Glabridin 445.321 38.184 
 
2 
O23-Asp301 
O24-Glu216 
√ Phe120 
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128108 Oxofangchirine -29.065 failed to dock 
388058 3-Epidehy drotumulosic acid 645.164 52.024 
 
0 - √ Phe120 
442813 Calycosin-7-O-β-D-glucoside 874.887 51.757 
 
3 
O11- Ala305 
O25-Gly273 
O31-Ala305 
√ Phe120 
445639 Oleic acid 260.418 57.674 
 
0 - 
- 
 
- 
  246 
480786 Glisoflavanone 874.887 49.614 
 
2 
O19- Glu216 
O29-Ala305 
√ Phe120 
480865 Licoricidin 660.104 42.549 
 
4 
O25- Ala305 
O25-Ser304 
O25-Asp301 
O30-Glu216 
√ 
Phe120 
Phe483 
503737 Liquiritin 1089.67 63.141 
 
6 
O25-Glu216 
O26-Asp301 
O27-Asp301 
O28-Gln244(2) 
O28-Ser304 
√ Phe120 
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522266 Spathulenol 260.418 27.328 
 
1 O12-Phe483 - - 
641115 Tetrandrine 30.695 36.637 
 
0 - - - 
643008 
2‘-Hydroxy-3‘4‘-dimethoxy- 
isoflavone-7-O-glucopyranoside 
230.538 36.682 
 
0 - √ 
Phe120 
Phe483 
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3082134 Cyclanoline 445.321 36.96 
 
1 O24-Glu216 √ Phe120 
5281377 Genistin 1304.45 59.603 
 
6 
O25-Ser304 
O26-Asp301 
O27-Glu216 
O28-Gln244 
O29-Asp301 
(2) 
√ Phe120 
5281671 Morusin 660.104 23.729 
 
1 O29-Ser217 √ Phe120 
  249 
5282110 Cinnamyl acetate 30.695 28.775 
 
0 - √ Phe120 
5284507 trans-Nerolidol 260.418 36.432 
 
0 - - - 
5315206 
 
Vicenin-2 2378.37 57.838 
 
8 
O31-Gln244 
O36-Ser304 
O36-Glu216 
O45-Glu216 
O41-Asp301(2) 
O41-Leu121 
O46-Ser304 
√ Phe120 
  250 
5318570 Isoglycyrol 215.598 25.941 
 
2 
O27-Asp301 
O27-Ser304 
√ Phe120 
5318591 Isoliquiritin 1304.45 59.354 
 
4 
O34-Glu216 
O34-Ser304 
O36- Gln244 
O28-Asp301 
 
√ Phe120 
  251 
5318869 Kumatakenin 445.321 36.432 
 
3 
O20- Ala305 
O20-Ser304 
O20-Asp301 
 
√ 
Phe120 
Phe483 
5318998 Licochalcone A 445.321 41.638 
 
1 O11-Ser304 √ Phe120 
5319013 Licoricone 445.321 46.626 
 
3 
O10- Glu216 
O16-Ser304 
O28-Gln244 
√ Phe120 
  252 
5319704 Licorisoflavan A 660.104 36.129 
 
0 - √ Phe120 
5320260 Odoratin 475.201 37.356 
 
0 - - - 
5320667 Polyporenic acid 475.201 -63.024 
 
1 O25-Phe483 - - 
5322174 Tumulosic acid 689.984 failed to dock 
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5354833 E-Z-Nonenal 45.635 37.969 
 
0 - - - 
5362814 Z-4-Heptenal 45.635 30.676 
 
0 - - - 
5363229 E-3-Octen-2-one 45.635 27.195 
 
0 - - - 
5484385 Pachymic acid 475.201 failed to dock 
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6325281 Glycyroside 1304.45 52.313 
 
3 
O45-Leu213 
O47-Leu484 
O38-Ala305 
√ 
Phe120 
Phe112 
44427463 α-Cadinol 260.418 31.413 
 
0 - - - 
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CHAPTER 5  GENERAL DISCUSSION 
5.1 A Summary of Objectives Achieved 
In this study, we have developed and validated pharmacophore models for the CYP2D6 
substrates/inhibitors when HBA, HBD, hydrophobic region were selected as features of 
hypothesis. The model for substrates consisted of two hydrophobic features and one 
hydrogen bond acceptor feature, giving an RR of 76% when a validation set of substrates 
was tested. Similarly, another one for inhibitors also consisted of two hydrophobic 
features and one hydrogen bond acceptor, with an RR of 78.8%. There were longer 
distances between feature groups in the model for inhibitors than those of the model for 
substrates.   
We also have constructed and validated QSAR models for the prediction of binding 
affinity of existing or new compounds to CYP2D6. Unfortunately, when the training set 
was randomly chosen, models generated from 24 CYP2D6 substrates/inhibitors gave 
regressive equation of y=0.085x+82.824 with R
2
=0.085 for CYP2D6 substrates and 
y=0.320x+9.879 with R
2
=0.320 for inhibitors, which all showed poor prediction accuracy. 
But two QSAR models from selected 6 substrates and 9 inhibitors presented relatively 
high R
2
, in which equation of y=0.980x+2.829 with R
2
=0.980 was for substrates and 
y=0.948x+1.051 with R
2
=0.948 for inhibitors. The relatively high R
2
 values gave rise to a 
linear relationship and a better prediction. 
We further validated and applied CDOCKER in DS 2.1 to explore the molecular factors 
determining the binding of a compound to native and mutated CYP2D6. A large number 
of substrates (n=120) and inhibitors (n=33) were subject to detailed molecular docking to 
the active site of wild-type CYP2D6. Our docking study demonstrated that 117 out of 
120 substrates (97.50%) and 30 out of 33 inhibitors (90.91%) could be docked into the 
active site of CYP2D6. We demonstrated that 11 residues for substrates and 8 residues 
for inhibitors play an important role in their binding and consequently metabolic activity 
towards the substrates/inhibitors.  
In the present study, the CDOCKER algorithm was also applied to study the impact of 
mutations of 28 active site residues (mostly non-conserved) in CYP2D6 on 
substrate/inhibitor binding modes using five probe substrates (bufuralol, debrisoquine, 
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dextromethorphan, sparteine, and tramadol) and four known inhibitors (quinidine, 
pimozide, fluoxetine, and halofantrine). Apparent changes of the binding modes have 
been observed with Phe120Ile, Glu216Asp, Asp301Glu mutations for substrates and 
inhibitors. 
To examine the binding of active components from Chinese herbal with CYP2D6, 
libraries of compounds from S. baicalensis & Fangjifuling decoction were constructed 
and subsequently subjected to the docking algorithm. Overall, 18 out of 40 compounds 
from huangqin and 60 out of 130 compounds from Fangjifuling decoction were mapped 
out with our optimized pharmacophore models. Amond them, 100% compounds from S. 
baicalensis and 90% from Fangjifuling decoction could be docked into the active site of 
wild-type CYP2D6, which suggested that they may be substrates and/or inhibitors of 
CYP2D6. The role of Phe120, Glu216, Asp301, Ser304 for herbal compound binding to 
CYP2D6 has been further supported by our docking studies. 
5.2 Molecular Modeling Studies of CYP2D6 Substrates and Inhibitors 
In our study, CYP2D6 substrate and inhibitor have been divided into two part for 
exploration, which was based upon our hypothesis that their structures and also their 
binding mechanisms to the enzyme shared unique features in some way. And our results 
provided with evidence for this. 
First of all, although CYP2D6 substrate and inhibitor all shared the same structural 
features in our study, which was that they all consisted of two hydrophobic features (HY1 
and HY2) and one HBA feature, the distances between groups were different. The 
distance from HBA to HY1 and HY2 was 3.053 Å and 7.406 Å for substrate, but 5.069 Å 
and 9.464 Å for inhibitor respectively. The distance between HY1 and HY2 was 6.587 Å 
for substrate, but 7.549 Å for inhibitor. These results indicated that CYP2D6 inhibitors 
owned longer distances than that of substrate.   
Compared with previous studies, the first substrate models for CYP2D6 were constructed 
by manual alignments, based on a set of substrates containing a basic nitrogen atom at 
either 5 [259] or 7 Å [260] from the site of oxidation, and a planar aromatic ring close to 
the site of oxidation, which were fitted to be coplanar [118, 260]. The distance between 
the basic nitrogen atom and the site of oxidation in debrisoquine is about 5 Å, whereas in 
the rigid substrate, dextromethorphan, this distance is about 7 Å. In the 5-Å model, there 
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were no substrates superimposed onto each other [259]. As such, these initial models 
failed to rationalize the binding of other types of substrates. Islam et al. (1991) described 
an extended model with the incorporation of the heme moiety from the known structure 
of bacterial P450cam (CYP101), which indicated a distance between the basic nitrogen 
atom in substrate molecules and the site of oxidation of between 5 and 7 Å.  
An inhibitor-based model for CYP2D6 was developed by Strobl et al. (1993) by fitting 
six potent competitive inhibitors of CYP2D6 onto each other. The basic nitrogen atoms 
of all inhibitors examined were superimposed, and the aromatic planes of these inhibitors 
were fitted to be coplanar. The derived preliminary pharmacophore model was 
characteristic of a tertiary nitrogen atom and a flat hydrophobic region, the plane of 
which was almost perpendicular to the N-H axis and maximally extended up to a distance 
of 7.5 Å from the nitrogen atom [86]. 
Secondly, although CYP2D6 substrate and inhibitor all formed hydrogen bond and - 
interaction with 1-4 similar residues in active site of the protein, 66.67% inhibitors 
formed hydrogen bond and 70% inhibitors presented - interaction, which only 35.04% 
substrates formed hydrogen bond and 46.15% substrates presented - interaction. This 
differenciation indicated that hydrogen bond formation and - interaction played crucial 
role in the binding mechanism of inhibitor to CYP2D6. 
Last but not least, although CYP2D6 substrate and inhibitor all formed - interaction 
predominantly with the same residue Phe120, fewer residues in active site of CYP2D6 
were involved in hydrogen bond formation with inhibitors, compared to those of 
substrates.  In our study, the active site residues involving hydrogen bond formation 
with inhibitors included Leu213, Glu216, Ser217, Gln244, Asp301, Ser304, Ala305, and 
Phe483. Therefore, these 8 residues played an important role in inhibitor binding and 
consequently metabolic activity towards the inhibitors. But Lys214 and Phe484 did not 
form any hydrogen bond in our inhibitors docking study, which generated hydrogen 
bonds in few substrates. 
5.3 Molecular Modeling Studies of Chinese Medicine Binding to CYP2D6 
First of all, 45% (18/40) components from S. baicalensis and 46.15% (60/130) 
components from Fangjifuling decoction were mapped out respectively, when our 
  258 
optimized pharmacophore models of CYP2D6 inhibitor and substrate were applied. The 
results indicated that herbs (single herb or formula) possessed a number of ingredients 
sharing similar stractural features to CYP2D6 substrate and/or inhibitor. Although many 
ingredients from plants have been documented to be substrate and/or inhibitor of CYPs, 
our study indicated that even a single herb or a single formula owned large proportion of 
ingredients as potential substrate and/or inhibitor of CYP2D6. These results suggested a 
hazard of AHDI and AHHI.  
Secondly, 100% components from S. baicalensis and 90% components from Fangjifuling 
decoction mapped to our optimized pharmacophore models were docked into the active 
site of CYP2D6. Moreover,  components from S. baicalensis mapped out with CYP2D6 
inhibitor pharmacophore model presented similar binding mechanisms to those of 
inhibitor, while components from Fangjifuling decoction mapped out with CYP2D6 
substrate pharmacophore model showed similar binding mechanisms to those of substrate. 
The binding mechanisms involved hydrogen bond formation, - interaction, and other 
intaction forces. Our study also revealed that hydrogen bond formation and - 
interaction are important determinants of ingredients from herbs binding to CYP2D6. The 
crucial residues in active site of CYP2D6 affecting the interaction are those of Leu213, 
Glu216, Ser217, Gln244, Asp301, Ser304, Ala305, and Phe483. Thus, our results 
indicacted that our computational models could be applied to study herbal medicines with 
complicated ingredients. 
In silico approaches have been increasingly used to study herb-CYP interactions 
[286-288]. A structure-activity relationship analysis was used to investigate the effect of 
structural modifications of piperine (pentadienyl or piperidine) on the inhibition of the 
CYP-catalyzed reactions, arylhydrocarbon hydroxylation (CYP1A) and 7- 
methoxycoumarin-O-demethylation (CYP2) in microsomes prepared from untreated, 
3-methylcholanthrene- and phenobarbital-treated rat liver [289]. This study has indicated 
that saturation of the side chain resulted in a marked increase in the inhibition of CYPs; 
while modifications in the phenyl and basic moieties in a few analogues led to maximum 
selectivity in inhibiting either constitutive or inducible CYP activities [289]. QSAR 
studies have been used to analyze the inhibitory effects on caffeine N3-demethylation (a 
marker activity of CYP1A2) in human liver microsomes of naturally occurring 
flavonoids that exist in many herbs [91]. This study demonstrated that the number of 
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hydroxyl groups and their glycosylation had an important influence on the inhibitory 
effect of various flavonoids. QSAR analysis has indicated that the volume to surface area 
ratio was the most effective factor for producing the inhibition of caffeine 
N
3
-demethylation by these flavonoids, and the electron densities on the C3 and C4' atoms 
exercised significant influence on the inhibitory effect. The suppression of 
2-amino-3,4-dimethylimidazo[4,5-f]quinoline-induced umu gene expression by 
flavonoids was well correlated with their calculated CYP1A2 inhibitory potencies [91].  
Our present study documented the use of another effective approach to understanding the 
potential binding mechanisms between complicated components of herbs and protein. 
Identification innovative compounds from natural plants have became more widely 
popular all over the world. Gengerally, a lead compound should be readily redesigned to 
avoid selectivity for CYP2D6, so that saturation of a particular pathway is unlikely to 
occur, as this could lead to ADDI. Although ADDI mediated by some CYPs, e.g. 
CYP3A4, are regarded as more acceptable, it is crucial for a lead compound to be 
―designed-out‖ selectivity towards CYP2D6 and/or CYP2C19, as these enzymes are 
associated with polymorphic drug metabolism. Thus, with poor pharmacokinetics 
accounting for over 50% of lead compound failure in drug discovery and development, it 
is important to identify as early as possible the likely metabolic fate in CYP2D6 of new 
chemical entities. 
In conclusion, CYP2D6 has been shown to metabolize many components from plants. 
Given that there are a large number of herbal plants are clinically used with each of them 
contains more than 50-100 compounds, computational models of CYP2D6 may represent 
a very efficient approach for high-throughput screening of potential ligands of this 
important enzyme. 
5.4 Limitations of the Present Project 
There are several limitations in the present study. We just used literature data to validate 
our models without incorporating our own experimental data. When constructing our 
models, the choice of training sets was on a random basis and some factors were not 
considered. Our models could not distinguish CYP2D6 substrates and inhibitors and in 
particular the QSAR models gave a relatively poor prediction. We only used 
pharmacophore, QSAR and molecular docking approaches to studying the interaction of 
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ligands with CYP2D6, but we did not try other modeling approaches. In addition, we did 
not examine the molecular dynamics of ligand-CYP2C6 interaction. 
Therefore, well-designed experimental studies using in vitro models should be carried out 
to support the computational observations from the present study. More herbs and herbal 
formula should be tested using our comprehensive models of CYP2D6 for the better 
understanding of the interaction of herbal compounds with important drug metabolizing 
enzymes. The application should also be extended to other important CYPs such as 
CYP2C9 and 3A4. Molecular dynamics should be conducted to explore the 
time-dependent molecular events during ligand-CYP2D6 binding and substrate oxidation. 
5.5 Conclusions and Future Directions 
In conclusion, we present our findings upon construction and validation of 
comprehensive computational models of CYP2D6 with the hope that it provides further 
insights into the factors that determining the binding modes of substrates to CYP2D6 and 
thus allow us to accurately predict the potential of new and herbal compounds as 
CYP2D6 substrates and/or inhibitors. Screening of high-affinity ligands for CYP2D6 
from herbal formula using computational models is a useful approach to identify potential 
herb-drug interactions. Functional benchmarking studies are ongoing at our laboratory to 
validate our major findings from these computational studies on CYP2D6. 
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